

Title: SARS-CoV-2 infection fatality rates in India: systematic review, meta-analysis and model-based estimation

Authors:

Lauren Zimmermann^{1,2}, Subarna Bhattacharya³, Soumik Purkayastha¹, Ritoban Kundu⁴, Ritwik Bhaduri⁴, Parikshit Ghosh⁵, Bhramar Mukherjee^{1,2,6}

Affiliations:

¹ Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA

² Center for Precision Health Data Science, University of Michigan, Ann Arbor, MI

³ Department of Global Public Health, School of Public Health, University of Michigan, Ann Arbor, MI

⁴ Indian Statistical Institute, Kolkata, West Bengal, India

⁵ Delhi School of Economics, New Delhi, India

⁶ Department of Epidemiology, University of Michigan, Ann Arbor, MI

* Correspondence to:

Bhramar Mukherjee
Department of Biostatistics
University of Michigan School of Public Health
1415 Washington Heights
Ann Arbor, MI 48109.
bhramar@umich.edu

Abstract

Introduction

Fervorous investigation and dialogue surrounding the true number of SARS-CoV-2 related deaths and implied infection fatality rates in India have been ongoing throughout the pandemic, and especially pronounced during the nation's devastating second wave. We aim to synthesize the existing literature on the true SARS-CoV-2 excess deaths and infection fatality rates (IFR) in India, through a systematic search followed by viable meta-analysis. We then provide updated epidemiological model-based estimates of the wave 1, wave 2 and combined IFRs using an extension of the Susceptible-Exposed-Infected-Removed (SEIR) model, using data from April 1, 2020 to June 30, 2021.

Methods

Following PRISMA guidelines, the databases PubMed, Embase, Global Index Medicus, as well as BioRxiv, MedRxiv, and SSRN for preprints (accessed through iSearch), were searched on July 3, 2021 (with results verified through August 15, 2021). Altogether using a two-step approach, 4,765 initial citations were screened resulting in 37 citations included in the narrative review and 19 studies with 41 datapoints included in the quantitative synthesis. Using a random effects model with DerSimonian-Laird estimation, we meta-analyze IFR_1 which is defined as the ratio of the total number of observed reported deaths divided by the total number of estimated infections and IFR_2 (which accounts for death underreporting in the numerator of IFR_1). For the latter, we provide lower and upper bounds based on the available range of estimates of death undercounting, often arising from an excess death calculation. The primary focus is to estimate pooled nationwide estimates of IFRs with the secondary goal of estimating pooled regional and state-specific estimates for SARS-CoV-2 related IFRs in India. We also try to stratify our empirical results across the first and the second wave. In tandem, we present updated SEIR model estimates of IFRs for waves 1, 2, and combined across the waves with observed case and death count data from April 1, 2020 to June 30, 2021.

Results

For India countrywide, underreporting factors (URF) for cases (sourced from serosurveys) range from 14.3-29.1 in the four nationwide serosurveys; URFs for deaths (sourced from excess deaths reports) range from 4.4-11.9 with cumulative excess deaths ranging from 1.79-4.9 million (as of June 2021). Nationwide pooled IFR_1 and IFR_2 estimates for India are 0.097% (95% confidence interval [CI]: 0.067 – 0.140) and 0.365% (95% CI: 0.264 – 0.504) to 0.485% (95% CI: 0.344 – 0.685), respectively, again noting that IFR_2 changes as excess deaths estimates vary. Among the included studies in this meta-analysis, the IFR_1 generally appear to decrease over time from the earliest study end date to the latest study end date (from 4 June 2020 to 6 July 2021, IFR_1 changed from 0.199 to 0.055%), whereas a similar trend is not as readily evident for IFR_2 due to the wide variation in excess death estimates (from 4 June 2020 to 6 July 2021, IFR_2 ranged from (0.290-1.316) to (0.241-0.651) %).

Nationwide SEIR model-based combined estimates for IFR_1 and IFR_2 are 0.101% (95% CI: 0.097 – 0.116) and 0.367% (95% CI: 0.358 – 0.383), respectively, which largely

reconcile with the empirical findings and concur with the lower end of the excess death estimates. An advantage of such epidemiological models is the ability to produce daily estimates with updated data with the disadvantages being that these estimates are subject to numerous assumptions, arduousness of validation and not directly using the available excess death data. Whether one uses empirical data or model-based estimation, it is evident that IFR_2 is at least 3.6 times more than IFR_1 .

Conclusion

When incorporating case and death underreporting, the meta-analyzed cumulative infection fatality rate in India varies from 0.36%-0.48%, with a case underreporting factor ranging from 25-30 and a death underreporting factor ranging from 4-12. This implies, by June 30, 2021, India may have seen nearly 900 million infections and 1.7-4.9 million deaths when the reported numbers stood at 30.4 million cases and 412 thousand deaths (covid19india.org) with an observed case fatality rate (CFR) of 1.35%. We reiterate the need for timely and disaggregated infection and fatality data to examine the burden of the virus by age and other demographics. Large degrees of nationwide and state-specific death undercounting reinforce the call to improve death reporting within India.

MAIN TEXT

INTRODUCTION

The second wave of SARS-CoV-2 in India—a country broaching 1/5th of the world population, wrought a devastating toll of an astronomical 414 thousand daily reported infections and 4.5 thousand reported daily deaths from COVID-19 (1) at its peak in May of 2021, leading to a collapse of healthcare infrastructure (2). Concerns have been raised regarding the inadequacy of the healthcare systems of adjacent countries in this region (3), as well as tragically realized amidst recent surges of SARS-CoV-2 in some of these countries (4).

It is now well-known that only a fraction of SARS-CoV-2 infections are captured, stemming from a large degree of covert infections, access, willingness and availability of testing, and sometimes a desire to maintain public image (5) (6). Similarly, due to

incomplete and lagged reporting, lack of medical certification and misclassification of the cause of deaths, not all COVID-19 related deaths have been captured correctly (7) (8) (9). Infection fatality rates (IFR) are measured as the ratio of the total number of deaths to the total number of infections over a given period. Serological surveys, with rigorous sampling design and cogent analysis, can provide an estimate of the prevalence of antibodies (Ab) formed in response to a past natural infection, and thereby an estimate of the total number of infected cases in an unvaccinated study population, which forms the basis for the denominator of the IFR measure. With introduction of vaccines, seropositivity could arise both from vaccines or from past infections and thus such studies are less informative about the denominator in an IFR calculation. Excess deaths calculation using the death data released during the pandemic period can give us an idea on the number of COVID-19 deaths we failed to report or the extent of death underreporting (7) (9) (10). Compartmental epidemiological models, including extended versions of the susceptible-exposed-infected-removed (SEIR) model and renewal process models can also estimate the total number of latent infections and deaths by making stringent assumptions needed to identify certain key parameters (11) (12) (13).

From a global lens, several systematic reviews have examined this integral measure of SARS-CoV-2 mortality, the IFR, at various points of the pandemic. As of 16 June 2020, a systematic review and meta-analysis of 24 studies estimated a pooled **worldwide** IFR of 0.68% (95% CI: 0.53 – 0.82), while noting considerable heterogeneity among the included studies and being unable to adjust for age, comorbidities, and other demographic factors (limited by the availability of data) (14). Other efforts to systematically investigate the infection fatality rates of SARS-CoV-2 include a review and

meta-analysis of age-specific IFRs from 27 studies among OECD countries (as of 18 September 2020), which concluded that the IFR increases substantially with age estimating an age-specific IFR of 0.002% among children aged <10, 0.01% among younger adults aged ≥ 25 , 0.4% among adults aged ≥ 55 , 4.6% among adults aged ≥ 65 , and up to 15% among adults aged ≥ 85 (15). Limited to non-developing countries, this review estimated that 90% of the variation in IFR estimates is explained by the age make-up of the underlying populations (15). Regarding reconciling SARS-CoV-2 seroprevalence, a key ingredient to know IFR estimates, a systematic review and meta-analysis (as of 14 August 2020) of 47 studies (encompassing 23 countries worldwide) found a worldwide seroprevalence estimate of 3.38% (95% CI: 3.05-3.72) with a range of 0.37% (Malaysia) to 22.1% (Iran) among the included studies, and reported considerable overall heterogeneity among the included studies as well as regional variation in the effect size with 1.45% (95% CI: 0.95-1.84) for South America to 5.27% (95% CI: 3.97-6.57%) for Northern Europe (16). India was not examined in these multi-country systematic reviews of SARS-CoV-2 IFR and seroprevalence, and nor were any of its neighboring countries.

Concerning India and its neighboring countries (i.e., Bangladesh, Nepal, Pakistan, and Sri Lanka), certain features common in this region are distinct from the countries considered in the above reviews and thereby beckon a comprehensive investigation of the SARS-CoV-2 fatality within these countries. First, the age structures of these countries are relatively young in comparison to higher income countries (as of 2020, the estimated median age in years are the following: India 28.4, Bangladesh 27.6, Nepal 24.6(20), Pakistan 22.8, Sri Lanka 34.0 versus the United Kingdom 40.5, Italy 47.3,

Germany 45.7, and the United States 38.3 (17)). Considering this difference in the population age composition, a meta-analysis of SARS-CoV-2 infection fatality rates and seroprevalence would aid in discerning the values of these measures specific to South-East Asia. We note that, at the time of this report, no systematic review has examined the existent studies on IFRs within the region encompassing and surrounding India.

Here, we perform a systematic review of existent literature on SARS-CoV-2 infection fatality rates (IFRs) in India and India's neighboring countries of Bangladesh, Nepal, Pakistan, and Sri Lanka, as of 3 July 2021, with verification of search thoroughness extending to 15 August 2021. Due to the paucity of data and availability of relevant studies in the adjacent countries and considering the intensity of the latest SARS-CoV-2 outbreak in India as detailed above, we focused on India for the quantitative synthesis. Through a meta-analysis of SARS-CoV-2 IFR estimates, we examine the nationwide, regional, and state-specific estimates and heterogeneity over the course of the pandemic within India. As an alternative approach to empirical evidence synthesis and meta-analysis, we use an extended susceptible-exposed-infected-removed (SEIR) model to present updated estimates of SARS-CoV-2 infection fatality rates with data through June 30, 2021, as well as underreporting factors for cases and deaths, corresponding to the first and second waves, as well as cumulative, for COVID-19 in India. This paper concludes with a discussion of takeaways from the systematic review and meta-analysis, as well as from the updated model-based results. We highlight some immediate and future considerations regarding revising the death reporting system in India and why capturing deaths are important for the health and future of the living.

METHODS

Terminology and Definitions

Below we provide the definitions, with formulas as needed, of the various terms used throughout this systematic review and meta-analysis.

Seroprevalence survey (i.e., serosurvey) in the context of SARS-CoV-2 are large-scale studies aimed at estimating the true prevalence of SARS-CoV-2 (i.e., the cumulative percent infected over a period of time) within the target population utilizing serology testing for IgG or IgM antibody presence (18) scaled to the level of a geographic location (e.g., nationwide, statewide, citywide, or districtwide), a community, or a smaller group. Study designs of serosurveys commonly involve population-based sampling methods (e.g., multi-stage cluster sampling, probability proportionate to size, etc.) applied to obtain a randomly selected, representative sample.

Case Underreporting Factor (URF (C)) is defined as the estimated total cumulative infections divided by the reported (i.e., observed) cumulative cases at the indicated date.

$$URF (C) = \frac{\textit{Estimated Total Cumulative Infections}}{\textit{Reported Cumulative Cases}}$$

The numerator (estimated total cumulative infections) is estimated by the population of the target geographic region from which samples were selected, multiplied by the seroprevalence, as sourced from serosurveys. The population estimate is age-adjusted according to the age cut-off for the underlying study by multiplying the total population estimate of the study area by the proportion of the population in the age range included in the study sample.

Excess Deaths is defined as the absolute difference between the observed all-cause mortality in a specific time period and the expected all-cause mortality in the same period. When calculating excess deaths, the expected all-cause mortality is commonly projected using prior years of data, an average of prior years, or an alternative benchmark, as it largely depends on the availability and continuity of all-cause mortality data within the location of study.

$$\textit{Excess Deaths} = \textit{Observed All Cause Mortality} - \textit{Expected All Cause Mortality}$$

Death Underreporting Factor (URF (D)) is defined as the estimated total cumulative deaths divided by the reported (i.e., observed) cumulative deaths at the indicated date, as collected 14 days after the date indicated.

$$\textit{URF (D)} = \frac{\textit{Estimated Total Cumulative Deaths}}{\textit{Reported Cumulative Deaths}}$$

The numerator of the URF (D) (i.e., estimated total cumulative deaths) is the location and time period-specific excess deaths estimate (available at the time of this report), as sourced from media reports and studies on excess deaths. Using all-cause-mortality to calculate excess deaths over a long period has the limitation that the numerator often is not specific to COVID-19 disease. Some model-based studies have alternative ways of estimating this fraction using assumed values of COVID-19 fatality rates.

Case Fatality Rate (CFR) is defined as the reported (i.e., observed) cumulative deaths divided by the reported/observed cumulative cases. Reported cumulative deaths are routinely collected 14 days after the date indicated to allow for fatality delay between symptom onset and death. Whereas reported cumulative cases are collected on the date

indicated, as a conservative approach to capturing the cumulative infections up to the date indicated. Further details on the intuition behind the assumption of a 14-day fatality lag can be found in **Supplementary Appendix F**.

$$CFR = \frac{\textit{Reported Cumulative Deaths (at a 14 day lag)}}{\textit{Reported Cumulative Cases}}$$

Infection Fatality Rate₁ (IFR₁) is defined as the reported (i.e., observed) cumulative deaths (collected 14 days after the indicated date) divided by the estimated total cumulative infections. In other words, IFR₁ is an estimate of the true fatality rate for which the uncertainty in the denominator is adjusted but not the uncertainty in the numerator, namely, death undercounting is not accounted for.

$$IFR_1 = \frac{\textit{Reported Cumulative Deaths}}{\textit{Estimated Total Cumulative Infections}}$$

In our meta-analysis, for studies without precalculated IFR₁, the denominator (estimated total cumulative infections) is computed as the seroprevalence multiplied by the population estimate of the study location. Again, the population estimate is age-adjusted, according to the age inclusion criterion of the study design, by multiplying the population number by the percent of the population in the specified age range.

Infection Fatality Rate₂ (IFR₂) is defined as the estimated total cumulative deaths (14 days after the indicated date) divided by the estimated total cumulative infections. In other words, IFR₂ is an estimate of the true fatality rate for which both the uncertainty in the denominator and the uncertainty in the numerator (i.e., death undercounting) are adjusted.

$$IFR_2 = \frac{\textit{Estimated Total Cumulative Deaths (at a 14 day lag)}}{\textit{Estimated Total Cumulative Infections}}$$

For studies without precalculated IFR_2 , the denominator (estimated total cumulative infections) is the same as the denominator in IFR_1 . The numerator (estimated total cumulative infections) is computed as the reported (i.e., observed) cumulative deaths (collected 14 days after the indicated date) multiplied by the death underreporting factor, as either model-derived or sourced directly from media reports and studies on excess deaths.

Identification of Studies for Systematic Review and Meta-analysis

The present systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement and guidelines (19) (see **Supplementary Appendix A** for the completed PRISMA checklist). Two reviewers developed the search strategy with the expertise and guidance of information specialists from the University of Michigan Taubman Health Sciences Library. On July 3, 2020, we performed the search for relevant articles publicly disseminated from January 1, 2020 onwards and conducted in any language within the databases PubMed, Embase, World Health Organization's database Global Index Medicus, as well as BioRxiv, MedRxiv, and SSRN through isearch, an interface that houses SARS-CoV-2 related reports curated by the National Institute of Health (a complete search strategy, including search terms, Boolean operators, and applied filters, for each database is published in **Supplementary Appendix B**). Up until August 15, we verified that no relevant studies were missed by manually combing through studies referenced in media

reports, government press releases, and any additional preprints or reports published after July 3 and through August 15, 2021.

For the narrative review, eligible studies included a nationwide, regional (e.g., state, union territory, city, district, or slum designated area, etc.), or age/sex-specific measure of seroprevalence or infection fatality rate (IFR) for India or adjacent countries of Bangladesh, Nepal, Pakistan, and Sri Lanka. Consistent with a systematic review that examines international infection fatality rates of SARS-CoV-2 among OECD countries (i.e. non-developing countries) (15), studies were excluded in the full-text screening (a) if the studies examined narrower subpopulations of the location of interest (e.g., healthcare workers, HIV positive adults, or industrial workers, etc.), (b) if the studies recruited participants from certain facilities (e.g., blood donors, dialysis centers), (c) if the studies considered individuals at hospitals, urgent care centers, intensive care units (ICUs), or tertiary care centers, (d) if the studies performed active recruitment of subjects (i.e. participants volunteered), and (e) if the studies limited their cohort to asymptomatic or symptomatic individuals. These criteria are used to identify studies both with representative samples of the general population of interest and with measurements of the outcomes that reflect seropositivity of SARS-CoV-2 regardless of virus manifestation (or irrespective of clinical presentation and presence of symptoms).

For the meta-analysis of infection fatality rates (IFRs), studies were included if (in addition to meeting the eligibility criteria for inclusion to the qualitative review) (a) 95% confidence interval was available for either the seroprevalence and/or the precalculated IFR, when available, and (b) data on COVID-19 confirmed fatalities was available for the study location from covid19india.org (20) at the time of this review. Additionally, for studies that

do not provide a precalculated IFR₂ (i.e., do not provide an IFR estimate adjusted for death underreporting), a study was excluded from IFR₂ examination if no excess deaths or death underreporting factors were available (at the time of this review) for the location of interest (e.g., district or city) in media reports or excess deaths focused publications. Namely, this report utilizes excess deaths from three sources for the nationwide meta-analysis of IFR₂ (21) (22) (23) and the following sources for the regional and state-level IFR₂ analysis: for cities and districts Ahmedabad (22), Bangalore Rural District (22), Chennai (22) (24), Indore (22), Mumbai (25) (22) (26), Ujjain (22), and for states Delhi (27) (13) (22), Karnataka (28) (29), Tamil Nadu (22) (28). **Table A** below summarizes the sources used in nationwide excess deaths studies (21) (22) (30) (23), as well as in the Data Development Lab (31), an interactive open source data platform recently made available for India.

Table A. Summary of data sources for nationwide excess deaths for India, as of June 2021, used in key

Ref	Sources
Leffler et al., 2021 (21)	1. state-specific excess deaths estimates (see Table 3)
Guilmoto, 2021 (32)	1. Age and sex-specific deaths from Kerala sample (https://dashboard.kerala.gov.in/deaths.php) 2. Deaths of elected officials from Member of the Legislative Assembly sample (https://tcpd.ashoka.edu.in/lok-dhaba/) 3. Deaths of railway workers from the Indian Railways sample (https://indianrailways.gov.in/railwayboard/uploads/directorate/stat_econ/Annual-Reports-2019-2020/Year-Book-2019-20-English_Final_Web.pdf) 4. Deaths of schoolteachers from Karnataka sample (<i>Not available</i>)
Deshmukh et al., 2021 (22)	1. Civil Registration System (https://crsorgi.gov.in/about-us.html), 2. MoHFW facility-based reported deaths, 3. Cvoter India OmniBus telephone survey (https://teamcvoter.com/)
Ramachandran et al., 2021 (30)	1. Consumer Pyramids Household Survey (https://consumerpyramidsdx.cmie.com/)
Anand et al., 2021 (23)	1. Consumer Pyramids Household Survey (https://consumerpyramidsdx.cmie.com/), 2. Civil Registration System (https://crsorgi.gov.in/about-us.html)

Data Development Lab (devdatalab.org/covid) (31)	1. state-specific excess deaths estimates (see the mortality data documentation on the Data Development Lab website, devdatalab.org/covid)
--	--

Two-Step Screening and Data Abstraction

Citation titles and abstracts were screened independently by two reviewers for verifying the inclusion and exclusion criteria. For articles not satisfying the exclusion criterion, the full text was accessed, and the two screeners separately reviewed the methods and results sections of these studies for final inclusion into this systematic review and meta-analysis. The two reviewers subsequently extracted data from the included articles on the following items: (a) study design, location, and time period, as well as inclusion criteria, (b) sample size denoting the number of participants in the study, (c) descriptive statistics of the proportion of the study cohort male versus female and the mean age of the study cohort, (d) estimate of infection fatality ratio (IFR) or seroprevalence for SARS-CoV-2 and corresponding 95% confidence intervals, when available, (e) any statistical sensitivity tests performed.

Statistical Meta-analysis

A detailed description of the meta-analysis framework is presented in **Supplementary Appendix F**. To perform the meta-analyses presented herein, the R package *meta* (33) was utilized and the R package *metafor* (34) was employed to perform the included sensitivity analyses.

In preparation for the meta-analysis, we extract the IFR or seroprevalence estimates, as well as the provided 95% CI, from each study corresponding to the study's intended overall population. For seroprevalence studies without precalculated IFR₁, we collect data on (a) COVID-19 confirmed fatalities from covid19india.org (20) 14 days after the end date of the study period (as previously reasoned), (b) 2019 projected population estimates from the World Bank for India (35), 2019 projected population estimates from the 2011 census for states (36), and 2011 census population estimates for districts and cities (limited by available projections) (36), (c) 2011 census information on age demographics for the study location (37), and (d) underreporting factors, as derived or directly reported from media reports and studies on excess deaths for the nation, state, district, or city were collected nearest to the end date of when the study was conducted. With these collected data items, for studies without a precalculated fatality rate, we compute IFR₁ and IFR₂ following the definitions provided in the **Terminology and Definitions** section above. We note that for smaller regional denominations (e.g., cities or districts) for which data on excess deaths were unavailable, we use the statewide death underreporting factor (if available) in computing IFR₂.

For the meta-analysis itself, we estimate three versions of SARS-CoV-2 pooled IFRs—namely (a) IFR₁, (b) IFR₂ with lower limit of the reported estimates of URF (D), and (c) IFR₂ with higher limit of the reported estimates of URF (D)—for each sub-analysis. First, using a random effects model with inverse variance method and DerSimonian-Laird (DL) estimation, we estimate the nationwide SARS-CoV-2 pooled IFRs, as well as 95% confidence intervals, for India across all available national IFR datapoints (both precalculated and computed herein) included in this review. Next, a regional analysis of

IFRs is performed considering India partitioned into the following regions: North, Northeast, East, South, West, and Central. Regions with at least one available eligible study are examined. To compute the regional SARS-CoV-2 pooled IFRs, we first pool the IFR estimates from statewide, citywide, and districtwide studies associated with each state, using the same random effects estimation approach. Then, the regional SARS-CoV-2 pooled IFRs are approximated with the statewide pooled IFR estimates, using the analogous random effects model with the inverse variance approach and DL estimator.

In both the nationwide and regional analyses, **heterogeneity** is assessed using the I^2 statistic, where a I^2 of 50% to 90% denotes substantial heterogeneity and $I^2 \geq 75%$ (and up to 100%) indicates considerable heterogeneity among the included studies, as recommended by Cochrane guidelines (38). For the regional analysis, we interpret the I^2 with caution as we do expect there to be variation in the true effect size among the included studies, as these studies cover varying states and IFRs have been found to vary by state (13).

To assess **publication bias**, we produce a funnel plot to examine the distribution of p-values and 95% confidence intervals, as well as perform the Egger's and Begg's tests to formally test for funnel plot asymmetry. To assess the **risk of bias** in the seroprevalence estimates across the included studies, we utilized the Joanna Briggs Institute (JBI) approach (39) (40). Upon completing the series of questions for each study, the tool provides a rating of risk of bias (low/ moderate/ high) based on the sampling design and data collection methods. We answer each question according to the provided values ("Yes"/ "No"/ "Unclear"/ "Not applicable"). Remarks are included with respect to the IFR estimates within the returned strata of the risk of bias.

Model-based Estimation of Fatality Rates in India during Wave 1, Wave 2, and combined over waves from April 1, 2020 to June 30, 2021

The present study follows the same methodology as the previous versions (13). In brief, we employ a compartmental epidemiologic model, the extended susceptible-exposed-infected-removed (SEIR-*fansy*), to model the transmission dynamics of SARS-CoV-2. Accounting for the false negative rates of the SARS-CoV-2 antigen test type (e.g., RT-PCR and rapid antigen tests) observed in India, we include unascertained cases and deaths as a compartment. As depicted in **Supplementary Appendix K Figure S1**, the population is further divided into 10 disjoint compartments: S (Susceptible), E (Exposed), T (Tested), U (Untested), P (Tested Positive), F (Tested False Negative), RR (Reported Recovered), RU (Unreported Recovered), DR (Reported Deaths) and DU (Unreported Deaths). A full description of the methodological framework is available in **Supplementary Appendix K**. Nine differential equations form the basis for imitating the spread of SARS-CoV-2. Parameters and 95% credible intervals (CrI) are estimated using Bayesian techniques by performing Metropolis–Hastings algorithm-based random sampling from the posterior distribution with a Gaussian proposal density.

Considering the inherent differences between the first and second waves of the pandemic (e.g., the strain on the healthcare infrastructure and dearth of medical resources in wave 2), we examine the entailed epidemiological measures for wave 1 and wave 2 separately, with wave 1 as April 1 2020–January 31, 2021 and wave 2 as February 1, 2021–June 30, 2021 (latest until this report). The start date of wave 2 of February 1, 2021 is reasoned as two weeks before the national effective reproduction number crossed unity on February 14, 2021 to allow for time between virus exposure and symptom onset. Daily

infected cases, recovered cases, and deaths are collected from covid19india.org (20). We compute nationwide and state-wise fatality rates and case–as well as death–underreporting factors for both wave 1 and wave 2. Additionally, we estimate cumulative infected case and death counts across waves 1 and 2 adjusting for the respective underreporting factors. To obtain the combined number of cases across both waves, we multiply the wave-specific infections with the underreporting estimate and sum across the two waves. Similarly, to obtain the combined number of deaths across both waves, we compute the combined number of deaths by multiplying the wave-specific deaths with the underreporting estimate and sum across the two waves. Lastly, an overall infection fatality rate (IFR) for India as of 30 June 2021 is provided as the estimated cumulative number of deaths divided by the estimated cumulative number of infections.


RESULTS

Search Results and Included Studies

As shown in **Figure 1** below, the search resulted in a total of 5174 citations across the four search engines: PubMed (2940), Embase (1119), WHO Global Index Medicus (Southeast Asia Region: 5, Eastern Mediterranean Region: 2), and isearch (1078). After removing duplicate citations across databases, 4765 articles were screened in the initial level of title/abstract, and we reviewed 137 articles in the second level of full-text screening. Of these studies, 61 studies were excluded as no seroprevalence, nor infection fatality rate estimates were presented. Moreover, 18 studies were excluded as the cohort consisted of healthcare workers, 15 studies were excluded as the cohort consisted of patients from hospitals, urgent care units, or tertiary care centers, 5 studies were excluded

because the cohorts were limited to either asymptomatic (4 studies) or symptomatic (1 study) individuals, 4 studies were excluded as the cohort consisted of working individuals, 2 studies were excluded as the cohort consisted of blood donors, 2 studies were excluded as the cohort was sampled from testing centers, 1 study was excluded because the cohort consisted of members from elderly care centers, 1 study was excluded as the participants were actively recruited. Overall, across these subpopulations, 48 studies were collectively excluded for the reason of having narrow or non-representative samples, which in turn impedes generalizability to the broader target population within the location of study.

Figure 1. PRISMA flow diagram (41)



Qualitative Review

Locations of included articles

Of the 37 articles included in the narrative review, 2/5 countries originally in the search (namely, India and Pakistan) were present in these articles. In other words, no eligible

studies were available for Bangladesh, Nepal, nor Sri Lanka. The predominant country studied was India (35/37 included articles) with Pakistan being the other country (2/37 included articles). In the initial screening, nearly all citations were written in English with 1 citation written in French. In the full-text screening, all articles were written in English.

Study designs, populations, and objectives

As shown in **Supplementary Appendix C Table 1**, among the 37 included articles, 27/37 were serosurvey studies (25 serosurveys for India (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) and 2 serosurveys for Pakistan (67) (68)) and 10/37 were other study designs (69) (70) (71) (72) (73) (74) (13) (12) (75) (76), such as extended compartmental epidemiological model-based approaches.

The age distributions of the study populations reflect the younger populations in India and Pakistan with 6/11 studies (that reported the study age composition) having a mean age of ≤ 24 to < 40 years and 5/11 studies with a mean age of ≤ 40 to < 50 years (**Supplementary Appendix C Table 1**). Regarding the participation rates by gender, out of the 19 studies (that reported the study gender composition) 5 studies had a considerably larger proportion of male than female participants, whereas 3 studies had a heavier percentage of female than male participants (**Supplementary Appendix C Table 1**). The remaining 11/19 had a comparable percentage of male versus female participants.

A nationwide target population accounted for 10/37 studies, namely, 8 for India (59) (60) (61) (62) (74) (13) (12) (75) (76) and 1 for Pakistan (68). The predominant population of

interest was cities with 19/37 studies focusing on municipal target populations and with the following counts of studies per city: 6 Delhi–India (47) (48) (49) (50) (70) (71), 4 Mumbai–India (56) (57) (58) (73), 1 Ahmedabad–India (42), 2 Bhubaneswar–India (44) (45), 2 Chennai–India (46) (69), 1 Indore–India (55), 1 Pimpri-Chinchwad–India (63), 1 Ujjain–India (66), and 1 Karachi–Pakistan (67). The next highest population of interest was state and union territories with 6/37 studies focusing on statewide generalizations and the following counts of studies per state or union territory: 3 Karnataka–India (52) (53) (72), 1 Kashmir–India (54), 1 Puducherry–India (64), and 1 Tamil Nadu–India (65). The prevalence of SARS-CoV-2 in slum dwellings was considered in 8/37 studies with the following counts of studies per slum area: 3 slum sections within Mumbai–India (56) (57) (73), 1 slum sections within Matunga, Chembur West, and Dahisar wards in Mumbai–India (58), 1 Devarajeevana Halli (DJ Halli) slum in Bengaluru–India (51), 1 slum sections within Pimpri-Chinchwad–India (63) and 2 nationwide slum prevalence approximations from the 2nd and 3rd nationwide serosurveys for India (60) (61). Seroprevalence of SARS-CoV-2 within rural districts versus urban was examined in 9/37 included studies and with the following counts per area: 1 Bangalore Rural District (with subdistricts–otherwise referred to as taluks of Devanahalli, Doddaballapura, Hoskote, Nelamangala)–India (43), 1 Delhi–India (50), 1 Karnataka–India (52), 1 Kashmir–India (54), 1 Puducherry–India (64), 1 Tamil Nadu–India (65) and 3 nationwide–India (59) (60) (61).

SARS-CoV-2 surveillance measurements and levels of granularity

As presenting either an IFR or seroprevalence estimate was an inclusion criterion, all 37 included studies estimated one or both of these measures. The breakdown of measures examined was as follows: 8/37 studies presented only IFR estimates without estimating

seroprevalence, 15/37 studies presented only seroprevalence estimates without computing IFRs, and 14/37 studies reported both estimated seroprevalence and IFRs. Among the included studies, seroprevalence was estimated at the following levels: overall region, subregion (e.g., district/ward), type of residence (e.g., urban/rural/slum/non-slum), age, sex, age-sex, and for select comorbidities (e.g., diabetes and hypertension). In contrast, IFRs were estimated largely at the overall level with just 2 studies presenting age-sex stratified estimates (1 serosurvey for Tamil Nadu (65) and 1 other study design for Karnataka, Mumbai and Bihar migrants (72)).

Remarks on excluded articles

The prevailing reason for exclusion of studies in the full-text screening was that the article did not provide concurrent prevalence estimate nor an IFR (61/109). Of these 61 studies presenting other epidemiological measures, a large number examined CFRs. Additionally, a considerable number of studies (18/109) were excluded that examined the subpopulation of healthcare workers and with the following counts of healthcare worker studies per country: India (16) and Pakistan (2). The third notable exclusion criterion was studies that examined hospital, urgent care, or tertiary care centers (15/109), which resulted in the following counts of patient or hospitalized studies per country: India (11), Pakistan (2), Bangladesh (1), and Nepal (1). A complete list of studies excluded with reasonings is presented in the **Supplementary Appendix D**, as well as a summary table synthesizing the total number of studies excluded per eligibility criterion by country (see **Supplementary Appendix E**).

Quantitative Summary for India: Meta-analysis of Infection Fatality Rates (IFR)

Of the 37 eligible studies in the narrative review, 19 and 17 studies were included in the meta-analysis of IFR₁ and IFR₂, respectively. **Supplementary Appendix G** lists the studies that were not able to be included in the meta-analysis and each respective reason for exclusion. To summarize, the reasons for exclusion include: (a) did not provide a 95% confidence interval for the seroprevalence and/or IFR estimate, (b) fatality data were unavailable for the study location (e.g., city or select districts) from covid19india.org (20), (c) excess deaths data were unavailable at the state level for the study location in order to derive the death underreporting factor, (d) studies in Pakistan as previously discussed the meta-analysis focuses on India, and (e) studies that stratify by slum versus non-slum and do not provide an overall estimates are excluded, as individuals living in slum areas tend to be of low socioeconomic status relative to persons in non-slum areas.

Summary of Nationwide Underreporting of Infections

As shown in **Table 1** below, the breadth of case underreporting countrywide has remained high in wave 2 compared to wave 1, as is evidenced by the dip in case underreporting factors (URF) from 29.1 to 14.3 in the 1st to the 2nd nationwide serosurveys compared to the consistency in high case URFs from 25.7 to 24.9 in the 3rd and 4th nationwide serosurveys, respectively, in India (59) (60) (61) (62). Please note that the 4th serosurvey did include vaccinated individuals, but by June 30, only roughly 5% of the Indian population was fully vaccinated and under 20% were partially vaccinated, so the estimates reflect largely antibodies from past infections but are likely overestimates.

Table 1. Nationwide seroprevalence and case underreporting factors for India.

Serosurvey	Age Range	Age-adjusted		Estimated Number of Infections ³ (M)	Reported Infections ⁴	Underreporting Factor ⁵
		Population ¹ (M)	Seroprevalence ²			
May-Jun 2020	≥ 18 years	905	0.73%	7	226,719	29.1
Aug-Sep 2020	≥10 years	1,106	7.1%	79	5,485,624	14.3
Dec '20-Jan '21	≥10 years	1,106	24.1%	267	10,395,952	25.7
Jun-Jul 2021	≥6 years	1,132	67.6%	765	30,662,903	24.9

[1] Seroprevalence estimates in this table are as directly reported in the nationwide serosurvey.

[2] Age-adjusted Population is the 2019 population estimate for India of 1.366 billion from the World Bank (https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN&most_recent_year_desc=false), and further multiplied by the proportion of the population within the listed Age Range, as obtained the 2011 census age composition (https://censusindia.gov.in/vital_statistics/SRS_Report/9Chap%20%20-%202011.pdf).

[3] Estimated Number of Infections is computed as Seroprevalence multiplied by Age Adjusted Population.

[4] Reported Infections are obtained from covid19india.org (20) on the end date of each serosurvey.

[5] Underreporting Factor for cases is computed as Estimated Number of Infections divided by Reported Infections.

Key Findings

- ❖ **Estimated cumulative SARS-CoV-2 infections for India is 765 million, based on the 4th nationwide serosurvey (as of July 2021).**
- ❖ **Underreporting factor for SARS-CoV-2 infections ranges from 14.3-29.1, across the four nationwide serosurveys in India.**

Background on Nation and State Level Excess Deaths

As shown in **Table 2**, five recent studies have provided nationwide excess deaths estimates for India, as of June 2021 (21) (32) (22) (30) (23). Of the three studies that examine excess deaths in India broken out by waves 1 and 2 (21) (22) (23), excess deaths are generally found to be considerably higher in wave 2 than wave 1 with the exception of the Anand et al., 2021 study (23), where excess deaths decrease from 3.4 (wave 1) to 1.5 million (wave 2). We note that the time period of the second wave in this study (23) extends into wave 2, as the national effective reproductive number crossed unity on February 14, 2021 in India, which may in part explain the high excess deaths estimate comparable to the other two studies. The degree of nationwide death

underreporting has remained high from waves 1 to 2 with the Wave 1 URF (D) ranging from 3.8-19.6 and the Wave 2 URF (D) ranging from 4.0-11.2 (**Table 2**). Up to June 2021, the cumulative excess death estimates across waves 1 and 2 for India range from 1.79 million (21) to 4.9 million (23), suggesting a combined nationwide URF (D) of 4.4-11.9.

As shown below in **Table 3**, the statewide excess deaths available at the time of this report largely show a similar story of increased excess deaths in wave 2 relative to wave 1, corroborating the severe toll of the second wave of the pandemic on India. In parallel, the state-specific death URFs are consistently higher in wave 2 compared to wave 1 (**Table 3**), actualizing the widely discussed absence and deterioration of timely and accurate death reporting in wave 2 in various states in India. The exception to this assertion is Kerala where the wave-specific death URFs are not meaningful different and excess deaths have remained low or albeit negative (**Table 3**). In wave 1, the two states with the highest death URFs are Assam (14.1-19) and Andhra Pradesh (9.1-11.1), whereas the two states with the lowest death underreporting that in fact exhibited negative excess deaths compared to prior year(s) are Gujarat (-70 thousand deaths) and Uttar Pradesh (-37 thousand deaths). In wave 2, the two states with the largest death underreporting are Madhya Pradesh (23.8-42.4) and again Andhra Pradesh (24.6-36.2). The two states with the lowest death URFs in wave 2, where excess deaths were lower than the number of reported COVID-19 deaths, are Kerala and Delhi. It is important to recognize that the timing of the onset of the second wave differs by state and city, wherein **Table 3** the categorization of waves is based on the timing of the second wave nationwide in India.

Table 2. Nationwide excess deaths and death underreporting factors for India in waves 1, 2, and combined.

Ref/First Author	Wave 1 (Apr 2020-Jan 2021)				Wave 2 (Feb-Aug 2021)				Combined across Waves 1 and 2 (Apr 2020-Aug 2021)			
	Time Period	Excess Deaths (M)	COVID-19 Reported Deaths ¹	Under Reporting Factor ²	Time Period	Excess Deaths (M)	COVID-19 Reported Deaths ¹	Under Reporting Factor ²	Time Period	Excess Deaths (M)	COVID-19 Reported Deaths ¹	Under Reporting Factor ²
(21) Leffler	Jan-Dec 2020	Low: 736 th High: 1.04	151,954	Low: 4.8 High: 6.9	Jan-Jun 2021	Low: 1.06 High: 1.58	263,001	Low: 4.0 High: 6.0	Jan '20-Jun '21	Low: 1.79 High: 2.62	412,019	Low: 4.4 High: 6.4
(32) Guilmoto	-	-	-	-	-	-	-	-	Mar '20-May '21	Low: 2.16 High: 2.45	353,558	Low: 6.1 High: 6.9
(22) Deshmukh	Jun '20-Jan '21	Low: 595 th High: 658 th	155,769	Low: 3.8 High: 4.2	Apr-Jun 2021	Low: 2.51 High: 2.77	249,059	Low: 10.1 High: 11.2	Jun '20-Jun '21	Low: 3.11 High: 3.43	412,019	Low: 7.5 High: 8.3
(30) ³ Ramachandran	-	-	-	-	-	-	-	-	Jan '20-Jun '21	3.36	404,211	8.4
(23) Anand	Apr '20-Mar '21	3.4	173,153	19.6	Apr-Jun 2021	1.5	249,059	6	Apr '20-Jun '21	4.9	412,019	11.9

[1] COVID-19 Reported Deaths are obtained 14 days after the end date of the time period from *covid19india.org* (20), unless otherwise noted.

[2] Underreporting Factor is computed as Excess Deaths divided by COVID-19 Reported Deaths, unless otherwise noted.

[3] Underreporting Factor (URF), as well as COVID-19 Reported Deaths, are directly reported in this study. Hence, the URF in this table is the precalculated estimate provided.

Key Findings

- ❖ **Cumulative excess deaths for India countrywide range from 1.79-4.9 million deaths, and so the nationwide death underreporting factors (URF(D)) range from 4.4-11.9, based on nationwide excess deaths studies (as of June 30 2021).**
- ❖ **For Wave 1, the nationwide URF (D) ranges from 3.8-19.6 with 595 thousand-3.4 million estimated excess deaths. For Wave 2, the nationwide URF (D) ranges from 4.0-11.6 with 1.06-2.77 million estimated excess deaths.**

Table 3. Statewide excess deaths and death underreporting factors for India in waves 1, 2, and combined.

Region	State	Source	Within Wave 1 (Apr 2020-Jan 2021)				Within Wave 2 (Feb-Aug 2021)				Within Combined (Across Waves 1 and 2)			
			Time Period	Excess Deaths (000s)	COVID-19 Reported Deaths ^a	URF ^b	Time Period	Excess Deaths (000s)	COVID-19 Reported Deaths ^a	URF ^b	Time Period	Excess Deaths (000s)	COVID-19 Reported Deaths ^a	URF ^b
Central	Madhya Pradesh	(22) ^c	Jul-Dec 2020 (vs. 2018-19)	27	3,035	9.0	Mar-May 2021 (vs. 2018-19)	178	4,203	42.4	Jul '20- May '21	205	8,588	23.9
		(21)	Jan-Dec 2020	-28	3,740	N/A	Jan-May 2021	181	4,982	36.4	-	-	-	-
		(77) ^c	-	-	-	-	Jan-May 2021 (vs. 2018-19)	189	4,461	42.3	-	-	-	-
		(28) ^c	-	-	-	-	Mar-May 2021 (vs. 2018-19)	192	8,068	23.8	-	-	-	-
East	Bihar	(21)	Jan-Dec 2020	134	1,447	92.6	Jan-May 2021	126.3	8,108	-	-	-	-	-
	Odisha	(22) ^c	-	-	-	-	Jan-Jun 2021 (vs. 2015-19)	36	2,145	16.6	-	-	-	-
		(21)	-	-	-	-	Jan-Jun 2021	37	1,473	25.1	-	-	-	-
	West Bengal	(21)	Jan-Dec 2020	53	10,010	5.3	Jan-May 2021	49	7,262	6.8	-	-	-	-
North	Delhi	(21)	Apr-May 2020	-9	1,327	N/A	Apr-May 2021	12.5	13,812	N/A	-	-	-	-
		(27) ^c	-	-	-	-	Apr-May 2021	29	13,201	2.22	-	-	-	-
	Haryana	(22) ^c	Jul-Dec 2020 (vs. 2018-19)	15	2,669	5.5	Apr-May 2021 (vs. 2018-19)	46	5,148	9	Jul '20- May '21	61	9,032	6.8
		(21)	Jan-Dec 2020	11	2,972	3.7	Jan-May 2021	41	6,127	6.7	-	-	-	-
	Himachal Pradesh	(21)	Jan-Dec 2020	0.291	951	N/A	Jan-May 2021	3	2,460	1.2	-	-	-	-
	Punjab	(21)	Jan-Dec 2020	-11	5,473	N/A	Jan-Jun 2021	36	10,261	3.5	-	-	-	-
	Rajasthan	(21)	Jan-Dec 2020	6	2,744	2.2	Jan-May 2021	32	6,146	5.3	-	-	-	-
	Uttar Pradesh	(21)	Jan-Dec 2020	-37	8,543	N/A	Jan-Apr 2021	48	8,605	5.6	-	-	-	-
Northeast	Assam	(22) ^c	Jul-Oct 2020 (vs. 2018-19)	17	918	19.0	-	-	-	-	-	-	-	-
		(21)	Jan-Dec 2020	15	1,065	14.1	-	-	-	-	-	-	-	-
	Andhra Pradesh	(22) ^c	Jul-Oct 2020 (vs. 2018-19)	72	6,503	11.1	Apr-Jun 2021 (vs. 2018-19)	135	3,713	36.2	Jul '20- Jun '21	207	13,057	15.9
		(21)	Jan-Dec 2020	65	7,138	9.1	Jan-May 2021	120	4,891	24.6	-	-	-	-
	Karnataka	(21)	Jan-Dec 2020	12	12,155	1.0	Jan-Jun 2021	77	23,899	3.2	-	-	-	-
		(28) ^c	-	-	-	-	-	-	-	-	Jan '20- May '21	126	29,090	4.3

South		(29) ^c	-	-	-	-	-	-	-	(vs. '18-19)	168	29,090	5.8	
	Kerala	(22) ^c	Aug '20-Mar '21 (vs. 2018-19)	10	4548	2.1	Apr-May 2021 (vs. 2019)	9	4,194	2.1	Aug '20-May '21 (vs. '15-19)	19	11,343	1.7
		(21)	Jan-Dec 2020	-27	3,393	N/A	Jan-May 2021	6	8,270	N/A	-	-	-	-
	Tamil Nadu	(22) ^c	Jun-Nov 2020 (vs. 2018-19)	76	11,545	6.6	Mar-May 2021 (vs. 2018-19)	64	11,516	5.5	Jul '20-Jun '21	140	33,557	4.2
		(21)	Jan-Dec 2020	72	12,246	5.9	Jan-Jun 2021	157	21,435	7.3	-	-	-	-
	(28) ^c	-	-	-	-	-	-	-	-	Jan '20-May '21	155	35,087	4.4	
West	Gujarat	(22) ^c	-	-	-	Mar-May 2021 (vs. 2020)	37	5,423	6.9	-	-	-	-	
		(21)	Jan-Nov 2020	-70	4,182	N/A	Mar-May 2021	32	5,593	5.8	-	-	-	-
	(78) ^c	-	-	-	-	Mar-May 2021	65.9	4,218	15.6	-	-	-	-	
	Maharashtra	(28) ^c	-	-	-	-	-	-	-	Aug '20-May '21	213	75,877	2.8	

[a] COVID-19 Reported Deaths are obtained 14 days after the end date of the time period from *covid19india.org* (20), unless otherwise noted.

[b] Underreporting Factor is computed as Excess Deaths divided by COVID-19 Reported Deaths, unless otherwise noted.

[c] Underreporting Factor (URF), as well as COVID-19 Reported Deaths, are directly reported in this study. Hence, the URF in this table is the precalculated estimate provided.

Key Findings

- ❖ **Cumulative regional death underreporting factors (URF(D)) range from 1.7 (Kerala)-23.9 (Madhya Pradesh), across both waves.**
- ❖ **For Wave 1, the statewide excess deaths range from -70 thousand (Gujarat) to 134 thousand (Bihar). For Wave 2, the statewide excess deaths ranges from 3 thousand (Himachal Pradesh) to 192 thousand (Madhya Pradesh).**

Nationwide IFR₁ and IFR₂

Figure 2 presents the results of the nationwide meta-analysis of IFR₁ for India. Using a random effects approach with DL estimation, the estimated nationwide pooled SARS-CoV-2 IFR₁ for India is 0.097% (95% CI: 0.067 – 0.140). This suggests a nationwide SARS-CoV-2 fatality ratio for India of 97 deaths per 100,000 infections, when not accounting for underreporting of deaths. As seen in **Figure 2**, there is considerable variation in the time periods encompassed in the studies belying this overall estimate. The range of IFR₁ (from highest to lowest) among the included studies is 0.199% (4 June 2020) to 0.055% (6 July 2021).




Figure 2. Nationwide estimated pooled IFR₁ of SARS-CoV-2 for India.

Note: * = IFR₁ precalculated. ** = IFR₂ precalculated. *** = both IFR₁ and IFR₂ precalculated. For those with no stars, IFR₁ and IFR₂ as well as 95% CIs were computed.

Figure 3 shows the results of the nationwide meta-analysis of IFR₂ for India. Using a random effects approach with DL estimation, the estimated nationwide pooled SARS-CoV-2 IFR₂ for India ranges from 0.365% (95% CI: 0.264 – 0.504) to 0.485% (95% CI: 0.344 – 0.685), when applying the lower and higher ends of the uncertainty bracket for

death underreporting, respectively. This can be interpreted as a nationwide SARS-CoV-2 fatality ratio for India of 365-485 deaths per 100,000 infections, when further adjusting for underreporting of deaths.




Figure 3. Nationwide estimated pooled IFR₂ of SARS-CoV-2 for India, with lower and higher URF uncertainty.
 Note: * = IFR₁ precalculated. ** = IFR₂ precalculated. *** = both IFR₁ and IFR₂ precalculated. For those with no stars, IFR₁ and IFR₂ as well as 95% CIs were computed.

A detailed forest plot of the nationwide seroprevalences of SARS-CoV-2 in India, as well as the accompanying 95% confidence interval, underlying the computed nationwide IFRs, as directly reported in the included studies, can be found in **Supplementary Appendix H Figure 1**.

With respect to observed time trends from this meta-analysis, **Table 4** includes a comparison of the case fatality rate (CFR) to IFR₁ and IFR₂ in waves 1 versus combined across waves 1 and 2. Both the CFR (i.e., not accounting for case nor death

underreporting) and IFR₁ (i.e., not accounting for death underreporting) have decreased overtime. Specifically, the nationwide CFR has decreased from 5.56% in June 2020 to 1.36% in July 2021 (**Table 4**). The nationwide IFR₁ has also largely been decreasing over time from 0.199% (4 June 2020) to 0.055% (6 July 2021), based on estimates (both precalculated and computed) from included studies (**Table 4**). Whereas for IFR₂ (i.e., when adjusting for both case and death undercounting) this trend is not readily apparent. As a whole, IFR₂ has changed overtime between 0.290% (4 June 2020) to 0.241-0.651% (6 July 2021), oscillating between 0.241% (6 Jan 2021) to 0.916-1.316% (4 June 2020), as detailed in **Table 4**. The absence of this trend for IFR₂ reconciles with the large excess deaths estimates observed for wave 2 compared to wave 1 (**Table 2**) and, in particular, the increase in the nationwide death URFs of 3.8-4.2 (wave 1) to 10.1-11.2 (wave 2) (**Table 2**), as derived from the excess deaths estimated in Deshmukh et al., 2021 (22).

Table 4. Comparison of nationwide CFR to IFR₁ and IFR₂ from included studies for wave 1 and across waves.

Study, End Date	Reported Infections ^a	Reported Cases ^b	Wave 1 (Apr 2020-Jan 2021)			Across Waves 1 and 2 (Apr 2020-Aug 2021)		
			Case Fatality Rate (%)	IFR ₁ (%)	IFR ₂ (%)	Case Fatality Rate (%)	IFR ₁ (%)	IFR ₂ (%)
Campbell, 4 Jun '20**	12,605	226,719	5.560	0.199	0.290	-	-	-
Murhekar, 4 Jun '20	12,605	226,719	5.560	0.191	0.916-1.316	-	-	-
Murhekar, 20 Sep '20	102,715	5,485,624	1.872	0.131	0.627-0.902	-	-	-
Murhekar, 6 Jan '21	152,907	10,395,952	1.471	0.057	0.218-0.241	-	-	-
Purkayastha, 31 Jan '21***	155,769	10,758,629	1.448	0.129	0.461	-	-	-
Purkayastha, 15 May '21***	325,998	24,683,242	-	-	-	1.321	0.055	0.249
Murhekar, 6 Jul '21	418,511	30,662,903	-	-	-	1.365	0.055	0.241-0.651

Note: * = IFR₁ precalculated. ** = IFR₂ precalculated. *** = both IFR₁ and IFR₂ precalculated. For those with no stars, IFR₁ and IFR₂ as well as 95% CIs were computed.

[a] Reported Infections were collected on the study end date from covid19india.org (20).

[b] Reported Cases were collected 14 days after the study end date from covid19india.org (20).

Key Findings

- ❖ Nationwide pooled IFR₁ and IFR₂ estimates for India are 0.097% (95% confidence interval [CI]: 0.067 – 0.140) and 0.365% (95% CI: 0.264 – 0.504) to 0.485% (95% CI: 0.344 – 0.685), respectively, with IFR₂ lower and upper values reflecting the range of excess deaths available at the time of this study.
- ❖ Among the included studies in this meta-analysis, the IFR₁ largely decreases over time from the earliest to the latest study end date (i.e., from 4 June 2020 to 6 July 2021, IFR₁ ranged from 0.199 to 0.055%). In contrast, this trend is not as apparent for IFR₂ (from 4 June 2020 to 6 July 2021, IFR₂ changed from (0.290-1.316) to (0.241-0.651) %).

Regional and Statewide IFR₁ and IFR₂: Detailed estimates of regional pooled IFR₁ and IFR₂ of SARS-CoV-2 in India and 95% confidence intervals (CI), as well as the statewide pooled IFR₁ and IFR₂ estimates inputted for each region, are presented in **Figures 4 and 5**, respectively. Using the same random effects model with DerSimonian-Laird estimation as in the nationwide analysis, the regional pooled IFR₁ is estimated to be the following (as ordered from highest to lowest pooled effect size and reporting only regions with more than one state): East 0.136% (95% CI: 0.062 – 0.302), West 0.125% (95% CI: 0.052 – 0.303), North 0.109% (95% CI: 0.037 – 0.325), and South 0.062% (95% CI: 0.023 – 0.164) (**Figure 4**). Hence, East and West India have the largest estimated IFR₁ of 0.136% and 0.125%, respectively, suggesting estimated infection fatality rates (when not adjusting for underreporting) for SARS-CoV-2 of 136 deaths per 100,000 persons and 125 deaths per 100,000 persons in these regions, respectively. The estimate for the East is largely driven by the comparatively high statewide IFR₁ estimate for West Bengal of 0.322% (95% CI: 0.290 – 0.357), whereas the estimate for the West is driven by Maharashtra (0.244%) (**Figure 4**). The lowest IFR₁ estimate is for South India of 0.062

(95% CI: 0.023 – 0.164), backed by the Andhra Pradesh and Karnataka which have the lowest statewide pooled IFR₁ of 0.019% and 0.019%, respectively (**Figure 4**). Also considering regions with 1 state, pooled regional IFR₁ estimates range from 0.062 for South to 0.174% for Central.

We also find considerable heterogeneity exists even within each respective region in India. As examples, the statewide pooled IFR₁ varies in the North from 0.043% (Jammu and Kashmir) to 0.362% (Punjab), in the South from 0.019% (Andhra Pradesh and Karnataka, respectively) to 0.162% (Puducherry), and in the West from 0.051% (Goa) to 0.244% (Maharashtra).




Figure 4. Regional estimated pooled IFR₁ of SARS-CoV-2 for India.

Note: * = IFR₁ precalculated. ** = IFR₂ precalculated. *** = both IFR₁ and IFR₂ precalculated.

For those with no stars, IFR₁ and IFR₂ as well as 95% CIs were computed.

Using the same random effects model with DL estimation, the range of the regional pooled IFR₂ is estimated to be the following (as ordered from highest to lowest pooled effect size and considering only regions with >1 state): North 0.477% (95% CI: 0.250 – 0.911) to 0.477% (95% CI: 0.250 – 0.911), West 0.396% (95% CI: 0.294 – 0.534) to 0.399% (95% CI: 0.297 – 0.535), East 0.304% (95% CI: 0.153 – 0.605) to 0.304% (95% CI: 0.153 – 0.605), and South 0.191% (95% CI: 0.165 – 0.223) to 0.205% (95% CI: 0.175 – 0.241) (**Figure 5**). Hence, North and West India have the largest estimated IFR₂ of 0.477-0.477% and 0.396-0.399%, respectively, indicating estimated infection fatality rates (when adjusting for death underreporting) for SARS-CoV-2 of 477 deaths per 100,000 persons and 396-399 deaths per 100,000 persons in these regions, respectively. The Northern IFR₂ estimate is largely driven by the comparatively high statewide IFR₂ estimate for Punjab (1.010%) which has the second highest statewide pooled IFR₂ (after Madhya Pradesh at 1.061%) of all states encompassed among the included studies, whereas the estimate for the West is driven by Gujarat (0.607%) (**Figure 5**). The lowest IFR₂ estimate is again for South India of 0.191-0.205% (among regions with >1 state), backed by Karnataka and Kerala which have the lowest statewide pooled IFR₂ of 0.067-0.083% and 0.144%, respectively (**Figure 5**). In sum, when considering regions with 1 state, pooled regional IFR₂ estimates range from 0.168% for Northeast to 1.061% for Central.




Figure 5. Regional estimated pooled IFR₂ of SARS-CoV-2 for India, with lower and higher URF uncertainty.

Note: State-specific IFRs in this forest plot are pooled estimates across included studies encompassed in each state.

A detailed forest plot of the state, city and district-specific seroprevalences of SARS-CoV-2 in India, as well as the accompanying 95% confidence interval, belying the computed regional and statewide IFRs, as directly reported in the included studies, can be found in **Supplementary Appendix H Figure 1**.

Key Findings

- ❖ **Regional pooled IFR₁ estimates within India range from a low of 0.062% in the South to a high of 0.136% in the East. Regional pooled IFR₂ estimates range from [0.191 – 0.205%] in the South to [0.477%] in the North.**
- ❖ **Considerable within region heterogeneity is also observed, as pooled state specific IFR₁ and IFR₂ estimates are evidenced to vary within regions.**

We present a funnel plot of the standard error of the effect sizes of the included studies in **Figure 6** as a standard method for examining publication bias. Although the results show asymmetry, in the context of seroprevalence proportions from serosurveys, which comprise the bulk of the study designs, this does not necessarily indicate the presence of publication bias (79). Instead, we suspect that the asymmetry is due to heterogeneity in the actual effect sizes of the prevalence of SARS-CoV-2 among the populations captured by the included studies. A detailed assessment of publication bias is presented in **Supplemental Appendix J**. The results of the Joanna Briggs Institute (JBI) assessment for risk of bias within each included study can be found in **Supplemental Appendix I**.




Figure 6. Funnel plot for examination of publication bias across included studies.

Data files and code used to produce the above results are available on GitHub at the following repository: https://github.com/lzimmermann4/india_c19_ifrs.

Updated Model-based estimates of Wave 1 and Wave 2 Fatalities

Since wave 1 is defined analogously as in the latest report (13) and the underlying data are the same, the wave 1 estimates presented herein are unchanged. Briefly, when adjusting the denominator by the estimated cases underreporting factor of 11.11 (95% CrI 10.71 – 11.47), the nationwide IFR₁ estimate (defined as observed cumulative deaths/estimated total cumulative infections) for wave 1 is 0.129% (95% CrI 0.125 – 0.134). When further adjusting the numerator by the estimated death underreporting factor of 3.56 (95% CrI 3.48 – 3.64), we obtain a nationwide IFR₂ estimate (i.e., estimated cumulative total deaths/estimated cumulative total infections) for wave 1 of 0.461% (95%

CrI 0.455 – 0.468). The wave 1 IFR₂ estimate is largely congruent to the estimated effect sizes from the latest nationwide serosurvey in India (59) in that it falls within the bounds of the computed IFR₂ herein for the 4th nationwide serosurvey of 0.241-0.651%, when applying a death underreporting factor range of 4.4 (1.79 million excess deaths (21)) to 11.9 (4.9 million excess deaths (23)).

Since wave 2 data extend to June 30, 2021, using the same compartmental epidemiological model we estimate case and death underreporting factors of 13.3 (95% CrI 11.4 – 14.6) and 3.46 (95% CrI 3.13 – 3.69), respectively. As such, the nationwide IFR₁ estimate for wave 2 is 0.095% (95% CrI 0.086 – 0.109), which is slightly higher than the previously reported estimate of 0.032% (95% CrI 0.029% – 0.035%) as of May 15, 2021 (i.e. near the peak of wave 2 in India) (13). The nationwide IFR₂ estimate for wave 1 is 0.326% (95% CrI 0.316 – 0.342), which is higher than our latest reported estimate of 0.183% (95% CrI 0.180 – 0.186) as of May 15, 2021 (13). The current estimates of the IFR for wave 2 have increased in magnitude in comparison to than past estimates due to having a time period that better reflects the trajectory of the second wave and data that encompass both the ascent and descent of cases and deaths. Moreover, the updated underreporting factors for cases and deaths are half the size of previous underreporting factors for wave 2 (i.e. 26.73 (95% CrI 24.26 – 28.81) and 5.77 (95% CrI 5.34 – 6.15), respectively, as of May 15) (13) and have largely converged in magnitude to the underreporting factors for wave 1.

Figure 6 contains the case and death underreporting factors and estimated number of infections and deaths for waves 1 and 2, respectively, for India. State-level estimates of IFR₁ and IFR₂ for waves 1 and 2 are reported in **Supplementary Appendix N Figure 2**,

which shows the between state variation in these measures for wave 1 and wave 2, respectively, for the 20 states with high cases-deaths within India.




Figure 6. Comparison of observed and estimated case and death counts and corresponding underreporting factors from wave 1, wave 2 and both combined.

Key Findings

- ❖ For Wave 1, nationwide SEIR model-based estimated total cumulative deaths is 551 thousand and the estimated total cumulative infections is 119.6 million, whereas for Wave 2 the former is 852 thousand and the latter is 262 million, with data from April 1, 2020-June 30, 2021.
- ❖ For Wave 1, nationwide model-based IFR_1 and IFR_2 estimates are 0.129% (95% CrI 0.125 – 0.134) and 0.461% (95% CrI 0.455 – 0.468), respectively. For Wave 2, nationwide model-based IFR_1 and IFR_2 estimates are 0.095% (95% CrI 0.086 – 0.109) and 0.326% (95% CrI 0.316 – 0.342), respectively.

Combined estimates across the waves

As shown in **Figures 6** above, the total cases (reported and unreported) is estimated to be 381.6 million and the total deaths (reported and unreported) to be 1.4 million, across waves 1 and 2 for India. Subsequently, the combined infection fatality rate (IFR) across both waves is estimated to be 0.101% for IFR₁, and 0.367% for IFR₂ (as previously defined). State-level case and death underreporting factors for India are included in **Supplementary Appendix N Tables 1-3 and Figure 3**.

We also include a state and country level comparison of the estimated case underreporting factors across both waves to the estimated case under counting factors presented by ICSM in the 4th nationwide seroprevalence survey (as of May 31, 2021) for India (59) (see **Supplementary Appendix N Table 4**). Briefly, the estimated case underreporting factors presented herein are lower at large than the case undercounting factors announced for the 4th nationwide seroprevalence survey (59), with the exceptions of Andhra Pradesh, Chhattisgarh, Jammu and Kashmir, and Kerala where the case underreporting factors that we estimate are larger, as well as Maharashtra where the case underreporting factor is the same. As such, we present estimated case underreporting factors that are conservative with respect to the recent nationwide serosurvey under counting estimates. The true extent of the magnitude of infections absent in reported case counts is wagered to lie somewhere in between.

Key Findings

- ❖ **As of 30th June 2021, nationwide URF (C) and URF (D) are estimated to be 12.5 and 3.5, respectively by the SEIR model.**
- ❖ **Nationwide SEIR model-based estimated total cumulative infections is 381.6 million and estimated total cumulative deaths is 1.4 million (as of 30th June 2021), whereas reported deaths were 412 thousand and cases were at 30.4 million.**
- ❖ **Nationwide model-based cumulative IFR₁ and IFR₂ estimates are 0.101% (95% CI: 0.097 – 0.116) and 0.367% (95% CI: 0.358 – 0.383), respectively.**
- ❖ **The magnitude of these model-based estimates largely reconcile with the empirical findings. Across empirical data and model-based estimation, IFR₂ is nearly 3.6 times the size of IFR₁.**

DISCUSSION AND CONCLUSIONS

Neighboring Countries: Despite there being insufficient data and sparse eligible studies in the neighboring countries, a brief snapshot into the SARS-CoV-2 situation within each country shows that the case fatality rate (unadjusted for underreporting) in neighboring countries is at par with India, if not higher. In **Table 5**, we provide a comparison of nationwide CFRs, as of 31 July 2021, within each of the countries included in this review (i.e., India, Bangladesh, Nepal, Pakistan, and Sri Lanka). Of these five countries, Pakistan stands out as having the highest CFR at 2.37% with 1.02 million cumulative reported infections and 24 thousand cumulative reported deaths (31 July 2021). Whereas India in fact has the lowest CFR of these 5 countries at 1.36%, but less surprisingly given its large population has the highest reported death and confirmed infection toll of 430 thousand and 31.6 million (31 July 2021), respectively. We recognize and caution that the CFR is an imperfect measure of the true SARS-CoV-2 fatality rate and that levels of

underreporting of deaths and cases vary by country (8). In sum, **Table 5** also presents a CFR across the countries included in this systematic review which is 1.42% to summarize the observed mortality rate in this region. The CFR among the neighboring countries alone is 1.96% which indicates that the SARS-CoV-2 observed mortality rate of the neighboring countries appears to be similar to that of India, if not slightly higher (whilst cautioning the fog of undercounting).

Table 5. Comparison of nationwide CFRs among countries in review, as of July 2021.

Country (Population) ^a	As of July 31, 2021		
	Reported Deaths ^b	Reported Cases ^c	Case Fatality Rate (%)
Pakistan (216 million)	24,266	1,024,861	2.37
Bangladesh (163 million)	23,988	1,249,484	1.92
Sri Lanka (21 million)	5,878	308,812	1.90
Nepal (28 million)	10,259	695,389	1.48
India (1.36 billion)	430,732	31,613,993	1.36
<i>Region excluding India (430 million)</i>	<i>64,391</i>	<i>3,278,546</i>	<i>1.96</i>
<i>Region including India (1.796 billion)</i>	<i>495,123</i>	<i>34,892,539</i>	<i>1.42</i>

Note: Case Fatality Rates (CFR) are computed as the Reported Deaths divided by Reported Cases. Regional CFRs are unweighted.

[a] Population estimates are projected for the year 2019 from World Bank

(<https://data.worldbank.org/indicator/SP.POP.TOTL?locations=BD-NP-PK-LK-IN>) (80).

[b] Reported Deaths were collected cumulatively 14 days after the date July 31, 2021 (i.e. August 14, 2021) from Worldometer COVID-19 Data (<https://www.worldometers.info/coronavirus/>) (81).

[c] Reported Cases were collected cumulatively for the date July 31, 2021 from Worldometer COVID-19 Data (<https://www.worldometers.info/coronavirus/>) (81).

Summary on fatality rates in India: For India, there were enough eligible studies to perform a meta-analysis of infection fatality rates. A key result of the meta-analysis concerning the nationwide IFR estimates for India is that both the CFR (i.e., not accounting for infection nor death underreporting) and IFR₁ (i.e., not accounting for death underreporting) have decreased over time, whereas IFR₂ appears to have remained same or even increased in some studies over time. In other words, when failing to take into account case and/or death underreporting (i.e., CFR and IFR₁), the SARS-CoV-2

mortality rate falsely appears to be decreasing. However, when correctly adjusting for both underreporting of infections and deaths (i.e., IFR₂), we do not observe that less deaths are resulting from the same number of infections through wave 2 compared to wave 1. This aligns with the catastrophic collapse of the healthcare system observed at large in India during the second wave of the pandemic (2). In sum, use of either the CFR or IFR₁ (not accounting for death underreporting) alone may be deceptively misleading, and IFR₂ should also be utilized in public health programming and policy decision making.

The narrative review of general population SARS-CoV-2 infection fatality rate or seroprevalence studies brought forth some trends concerning virus spread and fatality. In India, dense urban areas and slum dwellings have been found to have markedly higher prevalence rates in comparison to non-slum or rural locations (e.g., 58.4% (95% CI: 56.8–59.9) among slums versus 17.3% (95% CI: 16.0–18.7) for Mumbai (58) among non-slums, and 57.9% (95% CI: 53.4–62.3) among a slum in Bengaluru (51)). Trends in the infection fatality rates (IFRs) are less obvious among the albeit limited number of slum population-focused seroprevalence studies in this region. A study in Mumbai found the IFR of SARS-CoV-2 in slums to be one-third the size of that of non-slums (i.e. 0.076% among slums versus 0.263% among non-slums (58)). Similarly, another study on a slum in Bengaluru estimated the IFR to be 2.94 deaths per 10,000 infections (or 0.029%) (51).

When estimating regional and statewide IFR estimates for India, the latest available studies for certain regions was during the outset of the pandemic (e.g., Central India with both input studies around August 2020). Such variation in study time periods highlights the need for updated seroprevalence studies in select regions. The findings from this regional meta-analysis also underscore the geographical differences in data

collection/research spread across India. A large number of the included studies in this systematic review and meta-analysis were in the South and North, with substantially less coverage in the Central and Northeast regions. Moreover, no eligible serosurveys were available for the region Northeast India (which includes the following states: Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Sikkim and Tripura). This leads us to the limitations of the meta-analysis presented herein.

Limitations of Meta-analysis: We were not able to incorporate Bangladesh, Nepal, Pakistan, nor Sri Lanka in the meta-analysis presented in this paper as no eligible studies were available for these countries (aside from Pakistan, which had 2 included seroprevalence surveys), as previously discussed in the **Results** section. There were insufficient age- as well as sex-disaggregated IFRs for India (and for the neighboring countries) to examine heterogeneity in IFR estimates by either demographic. Furthermore, although age and sex-disaggregated seroprevalence estimates were extracted from the included studies, disaggregated deaths and cases by these demographics are not available for India nor for its states, cities, nor districts, at the time of this review. Additionally, there were insufficient data on excess deaths for select states (e.g., Jammu and Kashmir and Puducherry) that precluded our ability to compute IFR₂ for studies encompassed in these states and, as such, we were unable to include these studies in the meta-analysis for the regional IFR₂. Additionally, we caution that several of the included studies in the quantitative synthesis are in the process of being peer-reviewed, and so multiple underlying datapoints have not yet been verified.

Lastly, we note that global studies that examine India along with multiple other countries (as part of a country level global analysis) but do not explicitly refer to India in the

title/abstract would not be captured by our published search strategy. Therefore, a limitation of the meta-analysis is that these IFR estimates for India from global studies are not comprehensively reflected in the empirical results of IFRs and similarly in the excess deaths synthesis. For example, a recent study by Rahmandad et al. (2021) (82) that **appears** (exact estimates are not reported) to estimate for India a ratio of estimated to reported deaths on the log scale in the ballpark of 1.2-1.5 (i.e. 3.3-4.4 when exponentiated) and an IFR near 0.4-0.5% for India (as of 22 December 2020), as part of a global analysis of 92 nations, was not captured (no explicit reference to India in title/abstract). Hence, this is an example of model-based estimates not reflected in the empirical findings evidenced in this report.

Recommendations moving forward: Based on the empirical and model-based findings evidenced in this report, we provide some high-level recommendations, primarily, as it concerns India. To reiterate, investigations aimed at estimating the true extent of COVID-19 attributed deaths in India have relied on a myriad of data sources (**Table A**). Such data sources do not come without their challenges (e.g., non-response bias and selection bias), and often lead to considerable variation in the ultimate results. For example, Ramachandran and Malani (2021) provide a higher estimate of excess deaths for India of 5.21 million (compared to their 3.36 million excess deaths estimate) for January 2020 to June 2021, when further considering households that do not respond consecutively (30). Given that no current all-cause mortality data exist for India at the time of this report with the latest release in 2010-2013, linking data sources in this manner is a common alternative. We encourage the release of timely and disaggregated data on SARS-CoV-2 cases and deaths, as are needed to assess stratified effects by age-sex-geography(5).

Despite geographic heterogeneity, quality of case and death reporting remains of great concern for India and continues to mask the true fatality rate as well as impede ongoing epidemiological investigations. In the absence of all-cause and disaggregated COVID-19 mortality data, tools (e.g., a personal digital health identifier) (5) and fortified vital surveillance methods (e.g., monitoring inactive bank accounts) and practices (e.g., increased community engagement) (5) are needed to facilitate and validate the use of the previously mentioned data sources and others. Strengthening the nationwide vital surveillance system in these ways would enable timely and pointed interventions from public health and government officials to ultimately prevent further overload of healthcare systems and loss of life. To put the excess deaths synthesis into context, the range of death underreporting factor for India of 4.4-11.9 (based on 1.79-11.9 million excess deaths from (21) and (23), respectively) falls toward the higher end of the global death undercounting factor of 3.3 (95% CI: 2.1-4) estimated by the Economist (as of May 2021) (83). This indicates that the extent of death underreporting, as it pertains to SARS-CoV-2 remains particularly acute for India as compared to that of globally.

Why death matters? From an economic perspective, why is it necessary to do these mortality calculations? Death matters because life matters – prolonging life is a goal, not merely a means to generate economic value. The widely used human development index (HDI) of the World Bank takes a multi-dimensional approach to measuring welfare. Material wellbeing (GDP) is only one of its three components; the others involve knowledge (literacy rate) and life (life expectancy at birth).

Nevertheless, for the purpose of cost-benefit analysis and economic evaluation of public health measures, it is useful to be able to assign a monetary value to every life lost or

saved. Measuring the value of a life by lost earnings or productivity is deeply flawed – it would, for example, have the absurd implication that the lives of non-working individuals have no value at all. The most commonly used approach to estimating the value of a statistical life (VSL) adopts the revealed preference or willingness-to-pay (WTP) principle. Hedonic wage regressions estimate the compensating differential (84) in market wages for jobs that involve a higher probability of fatal accidents – a measure of how much income the average worker is willing to sacrifice in order to reduce mortality risk. Sacrificed earnings are then aggregated over the lifetime using present discounted values and scaled up to a probability of 1 to arrive at VSL.

There are several estimates of VSL from developed countries¹ but studies on developing countries including India are few and far between. For our purposes, we will use Majumder and Madheswaran (2018) (85) who estimate VSL for the average male industrial worker in India to be INR 44.69 million (US \$0.61 million at current exchange rates)². This may introduce upward as well as downward biases into our calculations. For example, people dying of COVID-19 are, on average, older than the industrial workforce, which implies the mortality cost presented below is an overestimate. On the other hand, wages are only one part of a worker's economic contribution. A proper accounting of the social value of a life must also account for profits, rents and consumers' surplus generated

¹ The paucity of data in poorer countries has prompted some economists to adopt the benefit transfer method (BMT) – VSL estimates from richer countries are taken off-the-shelf and linearly scaled down to produce an estimate for poorer countries using the per capita GDP ratio. As Majumder and Madheswaran (2018) (85) note, this is likely to generate a significant underestimate since available data suggest the income elasticity of the demand for safety is considerably less than one, i.e., the poor are willing to pay a much higher proportion of their incomes to increase the chance of staying alive, in similar spirit to Engel's Law for food.

² Other estimates of VSL in India are as follows: INR 14 - 19 million (86), INR 6.4 - 15 million (87), INR 14.8 – 15.4 million (88), INR 10.28 million (89).

by the economic activity of that individual, as well as non-pecuniary benefits conferred on relatives, friends and acquaintances. These are not reflected in private WTP and are therefore a source of underestimating VSL. The calculations presented below are ballpark figures that will reflect reality closely if the above-mentioned biases largely cancel each other out.

Table 6 below monetizes the death toll of COVID-19 in India till June 2021. Based on reported death figures alone, the economic cost of Covid-induced mortality comes to around 9% of India's annual GDP. If we use the model-based estimates or the lower end of the range of excess death estimates, we incur a notional cost of 30-40% of annual GDP. Note that the official decline in India's GDP in the fiscal year 2020-21 is 7.7%, which is a gross underestimate of the true loss once the value of lives is taken into account. By various estimates, the fiscal outlay of the government in its financial rescue package was about 1% of GDP. This is a very small fraction of what is at stake in this pandemic. Total healthcare spending in 2018 by the central and state governments taken together was only 1.28% of GDP, which again illustrates the serious under-investment in mitigating health shocks like COVID-19.

Table 6. Summary of economic cost estimates attributed to SARS-CoV-2 death toll in India, as of June 2021.

Approach	Deaths (millions)	Economic Cost (Rs trillions) ^a	Economic Cost (% GDP) ^b
Reported ¹	0.412	18.4	9.05%
Estimated (meta-analysis) ²	low: 1.79	low: 79.9	low: 39.30%
	high: 4.9	high: 218.9	high: 107.60%
Estimated (model-based) ³	1.4	62.7	30.79%

[1] Reported deaths were collected 14 days after the date June 30, 2021 from *covid19india.org* (20).

[2] The range of excess death estimates from the review of excess deaths literature is 1.79 (Leffler et al., 2021 (21)) to 4.9 million deaths (Anand et al. 2021 (23)).

[3] Estimated (model-based) Deaths are cumulative through June 30, 2021, as presented in **Figure 6**.

[a] Economic Cost is the economic cost in trillions of Indian rupees of the nationwide SARS-CoV-2 death burden in India, under each death quantification approach. This economic cost estimate is calculated as Deaths (in millions) multiplied by 44.69 million rupees, the assumed estimated value of each life lost (85).

[b] Economic Cost (% GDP) is as calculated as the absolute Economic Cost (Rs trillions) divided by 203.5 trillion rupees, which is India's nominal GDP in 2019-20, as sourced from (90) and multiplied by 100 to express as a percentage.

Other than national estimates of mortality and IFR, there is considerable value to measuring infections and deaths across gender, caste, income levels, regions, etc. These can be useful guides for policymakers, telling them where scarce healthcare resources and aid should be concentrated. The within-country heterogeneity in both the epidemiological and economic impact of the disease has been noted in studies from all parts of the world. Unfortunately, absence of disaggregated data has tied the hands of researchers in India. Nevertheless, our meta-analysis uncovers substantial regional variations in IFR₂, from a low of 0.191 – 0.205% in the South to a high of 0.477% in the North. These differences are plausibly created by socio-economic factors (like differences in quality of governance and healthcare) rather than biological ones and provide policymakers the information necessary for welfare arbitrage and efficient resource allocation.

In closing, premature mortality is not only an indicator of health but also of economic cost and productivity, as discussed above and as has been evidenced for other health conditions in India (91). Furthermore, unforeseen death within a family or community may disturb the livelihood and income generation structure, thereby pervading to the broader welfare of impacted individuals, although reverse causation is present (92). Aside from the health lens, premature mortality and infectious disease mortality's consequences for economic stability and ensuing welfare policy further support the need for continued attention to assessing the mortality burden of COVID-19 within India.

REFERENCES

1. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect. Dis.* **20**, 533–534 (2020).
2. J. Gettleman, S. Yasir, H. Kumar, S. Raj, A. Loke, As Covid-19 Devastates India, Deaths Go Undercounted. *N. Y. Times* (2021), (available at <https://www.nytimes.com/2021/04/24/world/asia/india-coronavirus-deaths.html>).
3. A. Khalid, S. Ali, COVID-19 and its Challenges for the Healthcare System in Pakistan. *Asian Bioeth. Rev.* **12**, 1–14 (2020).
4. Nepal: “Struggling to breathe”: The second wave of Covid-19 in Nepal. *Amnesty Int.*, (available at <https://www.amnesty.org/en/wp-content/uploads/2021/07/ASA3142292021ENGLISH.pdf>).
5. L. V. Zimmermann, M. Salvatore, G. R. Babu, B. Mukherjee, Estimating COVID-19–Related Mortality in India: An Epidemiological Challenge With Insufficient Data. *Am. J. Public Health.* **111**, S59–S62 (2021).
6. A. Pan, L. Liu, C. Wang, H. Guo, X. Hao, Q. Wang, J. Huang, N. He, H. Yu, X. Lin, S. Wei, T. Wu, Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA.* **323**, 1915–1923 (2020).
7. A. Karlinsky, D. Kobak, Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. *eLife.* **10**, e69336 (2021).
8. SCORE Dashboard, (available at <https://www.who.int/data/data-collection-tools/score/dashboard>).
9. The true death toll of COVID-19: estimating global excess mortality, (available at <https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality>).
10. Excess Deaths Associated with COVID-19 (2021), (available at https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm).
11. S. Purkayastha, R. Bhattacharyya, R. Bhaduri, R. Kundu, X. Gu, M. Salvatore, D. Ray, S. Mishra, B. Mukherjee, A comparison of five epidemiological models for transmission of SARS-CoV-2 in India. *BMC Infect. Dis.* **21**, 533 (2021).
12. H. Campbell, P. Gustafson, *medRxiv*, in press, doi:10.1101/2021.05.12.21256975.
13. S. Purkayastha, R. Kundu, R. Bhaduri, D. Barker, M. Kleinsasser, D. Ray, B. Mukherjee, Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India. *BMC Res. Notes.* **14**, 262 (2021).
14. G. Meyerowitz-Katz, L. Merone, A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. *Int. J. Infect. Dis.* **101**, 138–148 (2020).

15. A. T. Levin, W. P. Hanage, N. Owusu-Boaitey, K. B. Cochran, S. P. Walsh, G. Meyerowitz-Katz, Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur. J. Epidemiol.* **35**, 1123–1138 (2020).
16. A. Rostami, M. Sepidarkish, M. M. G. Leeftang, S. M. Riahi, M. Nourollahpour Shiadeh, S. Esfandyari, A. H. Mokdad, P. J. Hotez, R. B. Gasser, SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. *Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.* **27**, 331–340 (2021).
17. World Population Prospects - Population Division - United Nations, (available at <https://population.un.org/wpp/>).
18. L. J. Carter, L. V. Garner, J. W. Smoot, Y. Li, Q. Zhou, C. J. Saveson, J. M. Sasso, A. C. Gregg, D. J. Soares, T. R. Beskid, S. R. Jervy, C. Liu, Assay Techniques and Test Development for COVID-19 Diagnosis. *ACS Cent. Sci.* **6**, 591–605 (2020).
19. D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, T. P. Group, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Med.* **6**, e1000097 (2009).
20. Coronavirus in India: Latest Map and Case Count, (available at <https://www.covid19india.org>).
21. C. T. Leffler, J. D. L. V, E. Yang, “Preliminary Analysis of Excess Mortality in India During the Covid-19 Pandemic (Update August 4, 2021)” (2021), p. 2021.08.04.21261604, , doi:10.1101/2021.08.04.21261604.
22. Y. Deshmukh, W. Suraweera, C. Tumbe, A. Bhowmick, S. Sharma, P. Novosad, S. H. Fu, L. Newcombe, H. Gelband, P. Brown, P. Jha, *medRxiv*, in press, doi:10.1101/2021.07.20.21260872.
23. Three New Estimates of India’s All-Cause Excess Mortality during the COVID-19 Pandemic. *Cent. Glob. Dev.*, (available at <https://cgdev.org/publication/three-new-estimates-indias-all-cause-excess-mortality-during-covid-19-pandemic>).
24. R. S, Interpreting deaths in Chennai. *The Hindu* (2021), (available at <https://www.thehindu.com/opinion/op-ed/interpreting-deaths-in-chennai/article34645264.ece>).
25. VitalStatisticsReport - MyBMC - Welcome to BMC’s Website, (available at https://portal.mcg.gov.in/irj/portal/anonymous/qlvitalstatsreport?guest_user=english).
26. Mumbai Had 13k “Excess” Deaths in March-July. How Does Its COVID Story Change? - The Wire Science, (available at <https://science.thewire.in/the-sciences/covid-19-mumbai-all-cause-mortality-data-ifr-bmc-seroprevalence-survey/>).
27. I. T. B. B. Delhi/G, hinagar June 23, 2021UPDATED: June 23, 2021 22:10 Ist, Excess deaths challenge India’s official Covid toll. *India Today*, (available at <https://www.indiatoday.in/coronavirus-outbreak/story/excess-deaths-challenge-india-official-covid-toll-1818564-2021-06-23>).

28. S. Ramani, Excess deaths in Maharashtra were at least 3 times the official COVID toll. *The Hindu* (2021), (available at <https://www.thehindu.com/news/national/excess-deaths-in-maharashtra-were-at-least-3-times-the-official-covid-toll/article35708965.ece>).
29. S. S. Srivatsa, S. Ramani, Karnataka's excess deaths nearly 6 times official COVID-19 toll. *The Hindu* (2021), (available at <https://www.thehindu.com/news/national/excess-deaths-in-karnataka-nearly-six-times-official-covid-19-tally/article34870624.ece>).
30. S. Ramachandran, A. Malani, *medRxiv*, in press, doi:10.1101/2021.07.20.21260577.
31. Development Data Lab, (available at <https://www.devdata.org/covid>).
32. C. Z. Guilhoto, "Estimating the death toll of the Covid-19 pandemic in India" (2021), p. 2021.06.29.21257965, , doi:10.1101/2021.06.29.21257965.
33. S. Balduzzi, G. Rücker, G. Schwarzer, How to perform a meta-analysis with R: a practical tutorial. *Evid. Based Ment. Health.* **22**, 153–160 (2019).
34. W. Viechtbauer, Conducting Meta-Analyses in R with the metafor Package. *J. Stat. Softw.* **36**, 1–48 (2010).
35. Population, total - India | Data, (available at <https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN>).
36. Census 2011 India, (available at <https://www.census2011.co.in/>).
37. Census of India: Age Structure And Marital Status, (available at https://censusindia.gov.in/census_and_you/age_structure_and_marital_status.aspx).
38. Cochrane Handbook for Systematic Reviews of Interventions, (available at <https://training.cochrane.org/handbook>).
39. Z. Munn, S. Moola, K. Lisy, D. Riitano, C. Tufanaru, Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *JBI Evid. Implement.* **13**, 147–153 (2015).
40. S. Moola, Z. Munn, C. Tufanaru, E. Aromataris, K. Sears, R. Sfetec, M. Currie, K. Lisy, R. Qureshi, P. Mattis, P.-F. Mu, in *JBI Manual for Evidence Synthesis*, E. Aromataris, Z. Munn, Eds. (JBI, 2020); <https://wiki.jbi.global/display/MANUAL/Chapter+7%3A+Systematic+reviews+of+etiology+and+risk>).
41. M. J. Page, J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hróbjartsson, M. M. Lalu, T. Li, E. W. Loder, E. Mayo-Wilson, S. McDonald, L. A. McGuinness, L. A. Stewart, J. Thomas, A. C. Tricco, V. A. Welch, P. Whiting, D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst. Rev.* **10**, 89 (2021).

42. O. Prakash, B. Solanki, J. K. Sheth, M. Kadam, S. Vyas, Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases. *Indian J. Public Health*. **65**, 5–10 (2021).
43. L. R. Inbaraj, C. E. George, S. Chandrasingh, Seroprevalence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study. *PloS One*. **16**, e0249247 (2021).
44. J. S. Kshatri, D. Bhattacharya, S. Kanungo, S. Giri, S. K. Palo, D. Parai, J. Turuk, A. Mansingh, H. R. Choudhary, M. Pattnaik, G. C. Dash, P. Mohanty, N. Mishra, D. M. Satapathy, S. K. Sahoo, S. Pati, Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India. *Sci. Rep.* **11**, 10551 (2021).
45. J. S. Kshatri, D. Bhattacharya, I. Praharaj, A. Mansingh, D. Parai, S. Kanungo, S. K. Palo, S. Giri, M. Pattnaik, S. R. Barik, G. C. Dash, H. R. Choudhary, J. Turuk, N. N. Mandal, S. Pati, Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys. *Epidemiol. Infect.* **149**, e139 (2021).
46. S. Selvaraju, M. S. Kumar, J. W. V. Thangaraj, T. Bhatnagar, V. Saravanakumar, C. P. G. Kumar, K. Sekar, E. Ilayaperumal, R. Sabarinathan, M. Jagadeesan, M. S. Hemalatha, M. V. Murhekar, Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India. *Emerg. Infect. Dis.* **27**, 586–589 (2021).
47. A look at serological surveys conducted in Delhi. *Hindustan Times* (2021), (available at <https://www.hindustantimes.com/cities/delhi-news/a-look-at-serological-surveys-conducted-in-delhi-101612270983224.html>).
48. N. Sharma, P. Sharma, S. Basu, S. Saxena, R. Chawla, K. Dushyant, N. Mundeja, Z. S. Marak, S. Singh, G. K. Singh, R. Rustagi, *medRxiv*, in press, doi:10.1101/2020.12.13.20248123.
49. N. M. Babu, Percentage of people with antibodies high, shows Delhi serological survey. *The Hindu* (2020), (available at <https://www.thehindu.com/news/cities/Delhi/percentage-of-people-with-antibodies-high/article32156162.ece>).
50. P. Misra, S. Kant, R. Guleria, S. K. Raj, W. U. S. study team of Aiiims, *medRxiv*, in press, doi:10.1101/2021.06.15.21258880.
51. C. E. George, L. R. Inbaraj, S. Chandrasingh, L. P. de Witte, High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond? *Epidemiol. Infect.* **149**, e39 (2021).
52. M. Mohanan, A. Malani, K. Krishnan, A. Acharya, *medRxiv*, in press, doi:10.1101/2020.11.02.20224782.
53. G. R. Babu, R. Sundaresan, S. Athreya, J. Akhtar, P. K. Pandey, P. S. Maroor, M. R. Padma, R. Laliitha, M. Shariff, L. Krishnappa, C. N. Manjunath, M. K. Sudarshan, G. Gururaj, T. S. Ranganath, K. D. E. Vasanth, P. Banandur, D. Ravi, S. Shiju, E. Lobo, A. Satapathy, L. Alahari, P. Dinesh, V. Thakar, A. Desai, A. Rangaiah, A. Munivenkatappa, K. S, S. G. Basawarajappa, H. G. Sreedhara, S. Kc, A. K. B, N. Umar, M. Ba, R. Vasanthapuram, The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the

general population: Results from a statewide sentinel-based population survey in Karnataka, India. *Int. J. Infect. Dis.* **108**, 27–36 (2021).

54. S. M. S. Khan, M. A. Qurieshi, I. Haq, S. Majid, J. Ahmad, T. Ayub, A. B. Fazili, A. A. Bhat, A. M. Ganai, Y. Jan, R.-R. Kaul, Z. A. Khan, M. A. Masoodi, B. Mushtaq, F. Nazir, M. Nazir, M. W. Raja, M. Rasool, A. Asma, M. Aziz, S. Ayoub, A. A. Bhat, I. N. Chowdri, S. Ismail, M. F. Kawoosa, M. A. Khan, M. S. Khan, R. Kousar, A. A. Lone, S. Nabi, M. Obaid, T. B. Qazi, I. Sabah, I. A. Sumji, “Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case” (SSRN Scholarly Paper ID 3820632, Social Science Research Network, Rochester, NY, 2021), , doi:10.2139/ssrn.3820632.
55. S. Sakalle, S. Saroshe, H. Shukla, A. Mutha, A. Vaze, A. Arora, A. Athotra, S. Ramaswamy, A. Jain, M. Dhuria, A. D. Patil, A. Rai, S. Garg, S. K. Jain, J. Bindal, S. K. Singh, Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020. *J. Fam. Med. Prim. Care.* **10**, 1479–1484 (2021).
56. Tata Institute of Fundamental Research, SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2, (available at https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf).
57. S. Reporter, Third sero survey: antibodies in 36.30% samples in Mumbai. *The Hindu* (2021), (available at <https://www.thehindu.com/news/cities/mumbai/third-sero-survey-antibodies-in-3630-samples-in-mumbai/article34404107.ece>).
58. A. Malani, D. Shah, G. Kang, G. N. Lobo, J. Shastri, M. Mohanan, R. Jain, S. Agrawal, S. Juneja, S. Imad, U. Kolthur-Seetharam, Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. *Lancet Glob. Health.* **9**, e110–e111 (2021).
59. PIB’S BULLETIN ON COVID-19, (available at <https://pib.gov.in/pib.gov.in/Pressreleaseshare.aspx?PRID=1740000>).
60. M. V. Murhekar, T. Bhatnagar, J. W. V. Thangaraj, V. Saravanakumar, M. S. Kumar, S. Selvaraju, K. Rade, C. P. G. Kumar, R. Sabarinathan, A. Turuk, S. Asthana, R. Balachandar, S. D. Bangar, A. K. Bansal, V. Chopra, D. Das, A. K. Deb, K. R. Devi, V. Dhikav, G. R. Dwivedi, S. M. S. Khan, M. S. Kumar, A. Laxmaiah, M. Madhukar, A. Mahapatra, C. Rangaraju, J. Turuk, R. Yadav, R. Andhalkar, K. Arunraj, D. K. Bharadwaj, P. Bharti, D. Bhattacharya, J. Bhat, A. S. Chahal, D. Chakraborty, A. Chaudhury, H. Deval, S. Dhatrak, R. Dayal, D. Elantamilan, P. Giridharan, I. Haq, R. K. Hudda, B. Jagjeevan, A. Kalliath, S. Kanungo, N. N. Krishnan, J. S. Kshatri, A. Kumar, N. Kumar, V. G. V. Kumar, G. G. J. N. Lakshmi, G. Mehta, N. K. Mishra, A. Mitra, K. Nagbhushanam, A. Nimmathota, A. R. Nirmala, A. K. Pandey, G. V. Prasad, M. A. Qurieshi, S. D. Reddy, A. Robinson, S. Sahay, R. Saxena, K. Sekar, V. K. Shukla, H. B. Singh, P. K. Singh, P. Singh, R. Singh, N. Srinivasan, D. S. Varma, A. Viramgami, V. C. Wilson, S. Yadav, S. Yadav, K. Zaman, A. Chakrabarti, A. Das, R. S. Dhaliwal, S. Dutta, R. Kant, A. M. Khan, K. Narain, S. Narasimhaiah, C. Padmapriyadarshini, K. Pandey, S. Pati, S. Patil, H. Rajkumar, T. Ramarao, Y. K. Sharma, S. Singh, S. Panda, D. C. S. Reddy, B. Bhargava, T. Anand, G. R. Babu, H. Chauhan, T. Dikid, R. R. Gangakhedkar, S. Kant, S. Kulkarni, J. P. Muliylil, R. M. Pandey, S. Sarkar, N. Shah, A. Shrivastava, S. K. Singh, S. Zodpe, A. Hindupur, P. R.

- Asish, M. Chellakumar, D. Chokkalingam, S. Dasgupta, M. M. E. Gowtham, A. Jose, K. Kalaiyarasi, N. N. Karthik, T. Karunakaran, G. Kiruthika, H. Dinesh Kumar, S. Sarath Kumar, M. P. Sarath Kumar, E. Michaelraj, J. Pradhan, E. B. Arun Prasath, D. Gladys Angelin Rachel, S. Rani, A. Rozario, R. Sivakumar, P. Gnana Soundari, K. Sujeetha, A. Vinod, SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021. *Int. J. Infect. Dis.* **108**, 145–155 (2021).
61. M. V. Murhekar, T. Bhatnagar, S. Selvaraju, V. Saravanakumar, J. W. V. Thangaraj, N. Shah, M. S. Kumar, K. Rade, R. Sabarinathan, S. Asthana, R. Balachandar, S. D. Bangar, A. K. Bansal, J. Bhat, V. Chopra, D. Das, A. K. Deb, K. R. Devi, G. R. Dwivedi, S. M. S. Khan, C. P. G. Kumar, M. S. Kumar, A. Laxmaiah, M. Madhukar, A. Mahapatra, S. S. Mohanty, C. Rangaraju, A. Turuk, D. K. Baradwaj, A. S. Chahal, F. Debnath, I. Haq, A. Kalliath, S. Kanungo, J. S. Kshatri, G. G. J. N. Lakshmi, A. Mitra, A. R. Nirmala, G. V. Prasad, M. A. Qurieshi, S. Sahay, R. K. Sangwan, K. Sekar, V. K. Shukla, P. K. Singh, P. Singh, R. Singh, D. S. Varma, A. Viramgami, S. Panda, D. C. S. Reddy, B. Bhargava, R. Andhalkar, A. Chaudhury, H. Deval, S. Dhattrak, R. R. Gupta, E. Ilayaperumal, B. Jagjeevan, R. C. Jha, K. Kiran, N. N. Krishnan, A. Kumar, V. V. Kumar, K. Nagbhusanam, A. Nimmathota, A. K. Pandey, H. S. Pawar, K. S. Rathore, A. Robinson, H. B. Singh, V. C. Wilson, A. Yadav, R. Yadav, T. Karunakaran, J. Pradhan, T. Sivakumar, A. Jose, K. Kalaiyarasi, S. Dasgupta, R. Anusha, T. Anand, G. R. Babu, H. Chauhan, T. Dikid, R. R. Gangakhedkar, S. Kant, S. Kulkarni, J. P. Muliylil, R. M. Pandey, S. Sarkar, A. Shrivastava, S. K. Singh, S. Zodpey, A. Das, P. Das, S. Dutta, R. Kant, K. Narain, S. Narasimhaiah, S. Pati, S. Patil, H. Rajkumar, T. Ramarao, K. Sarkar, S. Singh, G. S. Toteja, K. Zaman, SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. *Lancet Glob. Health.* **9**, e257–e266 (2021).
62. M. V. Murhekar, T. Bhatnagar, S. Selvaraju, K. Rade, V. Saravanakumar, J. W. V. Thangaraj, M. S. Kumar, N. Shah, R. Sabarinathan, A. Turuk, P. K. Anand, S. Asthana, R. Balachandar, S. D. Bangar, A. K. Bansal, J. Bhat, D. Chakraborty, C. Rangaraju, V. Chopra, D. Das, A. K. Deb, K. R. Devi, G. R. Dwivedi, S. M. S. Khan, I. Haq, M. S. Kumar, A. Laxmaiah, Madhuka, A. Mahapatra, A. Mitra, A. R. Nirmala, A. Pagdhune, M. A. Qurieshi, T. Ramarao, S. Sahay, Y. K. Sharma, M. B. Shrinivasa, V. K. Shukla, P. K. Singh, A. Viramgami, V. C. Wilson, R. Yadav, C. G. Kumar, H. E. Luke, U. D. Ranganathan, S. Babu, K. Sekar, P. D. Yadav, G. N. Sapkal, A. Das, P. Das, S. Dutta, R. Hemalatha, A. Kumar, K. Narain, S. Narasimhaiah, S. Panda, S. Pati, S. Patil, K. Sarkar, S. Singh, R. Kant, S. Tripathy, G. S. Toteja, G. R. Babu, S. Kant, J. P. Muliylil, R. M. Pandey, S. Sarkar, S. K. Singh, S. Zodpey, R. R. Gangakhedkar, D. S. Reddy, B. Bhargava, Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. *Indian J. Med. Res.* **152**, 48 (2020).
63. A. Banerjee, B. Gaikwad, A. Desale, S. L. Jadhav, J. Bhawalkar, P. Salve, V. Dange, C. Raut, H. Rathod, K. Srivastava, “SARS-CoV-2 Seroprevalence Study in Pimpri-Chinchwad, Maharashtra, India Coinciding with Falling Trend – Do the Results Suggest Imminent Herd Immunity?” (SSRN Scholarly Paper ID 3729394, Social Science Research Network, Rochester, NY, 2020), , doi:10.2139/ssrn.3729394.
64. S. S. Kar, S. Sarkar, S. Murali, R. Dhodapkar, N. M. Joseph, R. Aggarwal, Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020. *Emerg. Infect. Dis.* **27**, 666–669 (2021).

65. A. Malani, S. Ramachandran, V. Tandel, R. Parasa, S. Imad, S. Sudharshini, V. Prakash, Y. Yogananth, S. Raju, T. S. Selvavinayagam, *medRxiv*, in press, doi:10.1101/2021.02.03.21250949.
66. A. Joshi, P. Shankar, A. Chatterjee, J. Singh, A. Pakhare, K. Yadav, A. Shrivastava, A. K. Maurya, R. S. Nagi, D. Biswas, A. M. Kokane, S. Singh, Heterogeneous patterns of COVID-19 transmission in an Urban set up – sero-epidemiological survey data from Ujjain, Madhya Pradesh (a central Indian city). *Data Brief.* **37**, 107169 (2021).
67. M. I. Nisar, N. Ansari, F. Khalid, M. Amin, H. Shahbaz, A. Hotwani, N. Rehman, S. Pugh, U. Mehmood, A. Rizvi, A. Memon, Z. Ahmed, A. Ahmed, J. Iqbal, A. F. Saleem, U. B. Aamir, D. B. Larremore, B. Fosdick, F. Jehan, Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.* **106**, 176–182 (2021).
68. M. Haq, A. Rehman, J. Ahmad, U. Zafar, S. Ahmed, M. A. Khan, A. Naveed, H. Rajab, F. Muhammad, W. Naushad, M. Aman, H. U. Rehman, S. Ahmad, S. Anwar, N. U. Haq, SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand? *Infection*, 1–6 (2021).
69. Estimates of COVID-19 infection fatality rate in Chennai - Mathematics, (available at <https://maths.mdx.ac.uk/research/modelling-the-covid-19-pandemic/chennaiifrestimates/>).
70. R. Bhattacharyya, R. Kundu, R. Bhaduri, D. Ray, L. J. Beesley, M. Salvatore, B. Mukherjee, Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates. *Sci. Rep.* **11**, 9748 (2021).
71. D. K. Hazra, B. S. Pujari, S. M. Shekatkar, F. Mozaffar, S. Sinha, V. Guttal, P. Chaudhuri, G. I. Menon, *medRxiv*, in press, doi:10.1101/2021.06.02.21258203.
72. R. Cai, P. Novosad, V. Tandel, S. Asher, A. Malani, Representative Estimates of COVID-19 Infection Fatality Rates from Three Locations in India. *medRxiv* (2021), doi:10.1101/2021.01.05.21249264.
73. M. Banaji, *medRxiv*, in press, doi:10.1101/2021.04.08.21255101.
74. G.-A.-U. G.- Öffentlichkeitsarbeit, COVID-19 - Georg-August-Universität Göttingen, (available at <https://www.uni-goettingen.de/en/606540.html>).
75. R. Bhaduri, R. Kundu, S. Purkayastha, M. Kleinsasser, L. J. Beesley, B. Mukherjee, *medRxiv*, in press, doi:10.1101/2020.09.24.20200238.
76. S. Goli, K. S. James, *medRxiv*, in press, doi:10.1101/2020.04.09.20059014.
77. Rukmini S, Madhya Pradesh saw nearly three times more deaths than normal after second wave of Covid-19 struck. *Scroll.in*, (available at <https://scroll.in/article/996772/madhya-pradesh-saw-nearly-three-times-more-deaths-than-normal-after-second-wave-of-covid-19-struck>).

78. 61k Covid deaths not counted in Gujarat: Report. *Hindustan Times* (2021), (available at <https://www.hindustantimes.com/india-news/61k-covid-deaths-not-counted-in-gujarat-report-101621027267608.html>).
79. N. Wang, *How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial* (2018).
80. Population, total - Bangladesh, Nepal, Pakistan, Sri Lanka, India | Data, (available at <https://data.worldbank.org/indicator/SP.POP.TOTL?locations=BD-NP-PK-LK-IN>).
81. COVID Live Update: 213,646,658 Cases and 4,459,162 Deaths from the Coronavirus - Worldometer, (available at <https://www.worldometers.info/coronavirus/>).
82. H. Rahmandad, T. Y. Lim, J. Sterman, Behavioral dynamics of COVID-19: estimating underreporting, multiple waves, and adherence fatigue across 92 nations. *Syst. Dyn. Rev.* **37**, 5–31 (2021).
83. The pandemic's true deaths toll. *The Economist* (2021), (available at <https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates>).
84. R. Thaler, S. Rosen, in *Household Production and Consumption* (NBER, 1976; <https://www.nber.org/books-and-chapters/household-production-and-consumption/value-saving-life-evidence-labor-market>), pp. 265–302.
85. A. Majumder, S. Madheswaran, Value of Statistical Life in India: A Hedonic Wage Approach, 24.
86. Shanmugam, K R., The Value of Life: Estimates from Indian Labour Market, (available at <https://www.proquest.com/openview/ef7bca1b0c4a3687f5795066574b5919/1?pq-origsite=gscholar&cbl=1819379>).
87. N. B. Simon, M. L. Cropper, A. Alberini, S. Arora, “Valuing mortality reductions in India: a study of compensating wage differentials,” *Policy Research Working Paper Series* (2078, The World Bank, 1999), (available at <https://ideas.repec.org/p/wbk/wbrwps/2078.html>).
88. by S. Madheswaran, “Measuring the value of life and limb: Estimating compensating wage differentials among workers in Chennai and Mumbai,” *Working papers* (27, The South Asian Network for Development and Environmental Economics), (available at <https://ideas.repec.org/p/snd/wpaper/27.html>).
89. K. Shanmugam, S. Madheswaran, in *Environmental Valuation: In South Asia* (2011), pp. 412–443.
90. National Accounts Data | MOSPI, (available at <https://mospi.gov.in/web/mospi/download-tables-data/-/reports/view/templateOne/16701?q=TBDCAT>).
91. A. Pearce, L. Sharp, P. Hanly, A. Barchuk, F. Bray, M. de Camargo Cancela, P. Gupta, F. Meheus, Y.-L. Qiao, F. Sitas, S.-M. Wang, I. Soerjomataram, Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS): A population-based comparison. *Cancer Epidemiol.* **53**, 27–34 (2018).

92. N. Saikia, F. Ram, Determinants of Adult Mortality in India. *Asian Popul. Stud.* **6**, 153–171 (2010).

Acknowledgments:

The authors thank the librarians from the University of Michigan Taubman Health Sciences Library for their instruction on developing the search strategy for this rapid review.

Funding: The research was sponsored by funding from the University of Michigan School of Public Health and Center for Precision Health Data Science.

Author Contributions:

Conceptualization: LZ, BM

Methodology: LZ, BM

Investigation: LZ, SB, SP, RK, RB, PG, BM

Supervision: BM

Writing – original draft: LZ, BM

Writing – review & editing: LZ, SB, SP, RK, RB, PG, BM

Competing interests: Authors have no competing interests

medRxiv preprint doi: <https://doi.org/10.1101/2021.09.08.21263296>; this version posted September 14, 2021. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](#) .

***Supplementary material: SARS-CoV-2 infection fatality rates in India:
systematic review, meta-analysis and model-based estimation***

Authors:

Lauren Zimmermann^{1,2}, Subarna Bhattacharya³, Soumik Purkayastha¹, Ritoban Kundu⁴,
Ritwik Bhaduri⁴, Parikshit Ghosh⁵, Bhramar Mukherjee^{1,2,6}

Affiliations:

¹ Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA

² Center for Precision Health Data Science, University of Michigan, Ann Arbor, MI

³ Department of Global Public Health, School of Public Health, University of Michigan, Ann Arbor, MI

⁴ Indian Statistical Institute, Kolkata, West Bengal, India

⁵ Delhi School of Economics, New Delhi, India

⁶ Department of Epidemiology, University of Michigan, Ann Arbor, MI

(*) Corresponding author (Email: bhramar@umich.edu).

Supplementary Appendices

- A. PRISMA checklist
- B. Systematic review search procedure
- C. Summary of included articles
- D. List of excluded articles
- E. Summary of excluded articles
- F. Meta-analysis methodology
- G. Summary of excluded articles from the quantitative summary
- H. Supplementary meta-analysis and summary of seroprevalence estimates within India
- I. Risk of bias assessment across included articles
- J. Assessment of publication bias
- K. SEIR-*fansy* model framework
- L. Data source and model-based results

Appendix A. PRISMA checklist [1]

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Title Page
ABSTRACT			
Abstract	2	Background: Provide an explicit statement of the main objective(s) or question(s) the review addresses. Methods: Specify the inclusion and exclusion criteria for the review. Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched. Specify the methods used to assess risk of bias in the included studies. Specify the methods used to present and synthesise results. Results: Give the total number of included studies and participants and summarise relevant characteristics of studies. Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured). Discussion: Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision). Provide a general interpretation of the results and important implications. Other: Specify the primary source of funding for the review. Provide the register name and registration number.	Title Page
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	3-6
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	6
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	11-12
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	10-11, App B
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	App B
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	13, App B
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	13, App B
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	7-10, 13
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	7-10, 13
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation	15

Section and Topic	Item #	Checklist item	Location where item is reported
		tools used in the process.	
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	14, App F
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	App F, App G
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	14, App F, App G
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	13-15, App F
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	13-15, App F
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	13-15
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	15
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	15
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	10, 15
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	17-19
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	22, App D, App E, App G
Study characteristics	17	Cite each included study and present its characteristics.	19-22
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	App I
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	20, App C
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	37, App I
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	29-37
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	33-36
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	37-38, App H
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	37, App J
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	37, App J
DISCUSSION			

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Section and Topic	Item #	Checklist item	Location where item is reported
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	42-45
	23b	Discuss any limitations of the evidence included in the review.	45-46
	23c	Discuss any limitations of the review processes used.	45-46
	23d	Discuss implications of the results for practice, policy, and future research.	46-50
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	NA
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	NA
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Title Page
Competing interests	26	Declare any competing interests of review authors.	Title Page
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	38, App C

NA = not applicable.

Appendix B. Systematic review search procedure

To conduct the present systematic review, we systematically collected publications and preprints concerning infection fatality rates (IFRs) from SARS-CoV-2 in India and neighboring countries of Bangladesh, Nepal, Pakistan, and Sri Lanka. To identify relevant papers, we searched four databases: PubMed, Embase, Global Index Medicus, and isearch for preprints (encompassing bioRxiv, medRxiv, and SSRN). The search was conducted on July 3, 2021 and, as such, the results reflect published studies and preprints available from January 1, 2020 to July 3, 2021. Results were further verified through August 15, 2021 through reviewing media reports, government press releases, and manual search of preprints and publications. Data were extracted from the online search engines into the reference manager Zotero, deduplicated, and imported into Excel for screening.

The title/abstract screening, the full-text screening, and data abstraction were independently performed by two screeners to verify which studies met inclusion and exclusion criteria and to verify data collected. When the two screeners disagreed on the marking for a citation, the screeners reached a consensus on whether to advance the citation to the next level of screening. Below we publish the full search strategies for each database.

PubMed (National Library of Medicine)

Date searched: 7/3/2021

Number of results: 2,940

Date filter: January 1, 2020 to [blank]

Other filters applied: None

1.

covid-19[tw] OR COVID19[tw] OR SARS-CoV-2[tw] OR SARS-CoV2[tw] OR severe acute respiratory syndrome coronavirus 2[tw] OR 2019-nCoV[tw] OR 2019nCoV[tw] OR coronavirus[tw] OR coronavirus[mh] OR covid-19[mh]

2.

india[text word] OR india[mesh] OR indian[text word] OR pakistan[text word] OR pakistani[text word] OR pakistan[mesh] OR bangladesh[text word] OR bangladeshi[text word] OR bangladesh[mesh] OR nepal[text word] OR nepal[mesh] OR "sri lanka"[text word] OR "sri lankan"[text word] OR "sri lanka"[mesh]

3.

IFR[text word] OR infection*[text word] OR CFR[text word] OR case*[text word] OR transmission*[text word] OR mortalit*[text word] OR mortality[mesh] OR fatalit*[text word] OR lethalit*[text word] OR death*[text word] OR burden[text word] OR underreporting[text word] OR "under-reporting"[text word] OR seroprevalence[text word] OR serosurvey[text word] OR serology[text word] OR serology[mesh] OR seroconversion[text word] OR seroconversion[mesh] OR "serosurveillance"[text word] OR Seroepidemiologic studies[mesh] OR seroepid*[text word] OR seropositiv*[text word] OR antibod*[text word] OR

antibodies[mesh] OR surveillance[text word] OR SIR[text word] OR SEIR[text word] OR “susceptible-exposed-infected-removed”[text word] OR “susceptible-infected-removed”[text word]

(1 AND 2 AND 3)

Embase (Elsevier)

Date searched: 7/3/2021

Number of results: 1,119

Date filter: 2020 to 2021

Other filters applied: Embase only and not Medline (as Medline is included in PubMed)

1.

covid-19:ti,ab,kw OR COVID19:ti,ab,kw OR SARS-CoV-2:ti,ab,kw OR SARS-CoV2:ti,ab,kw OR "severe acute respiratory syndrome coronavirus 2":ti,ab,kw OR 2019-nCoV:ti,ab,kw OR 2019nCoV:ti,ab,kw OR coronavirus:ti,ab,kw OR 'Coronavirinae'/exp OR 'coronavirus disease 2019'/exp

2.

india:ti,ab,kw OR 'india'/exp OR indian:ti,ab,kw OR pakistan:ti,ab,kw OR pakistani:ti,ab,kw OR 'pakistan'/exp OR bangladesh:ti,ab,kw OR bangladeshi:ti,ab,kw OR 'bangladesh'/de OR nepal:ti,ab,kw OR 'nepal'/de OR "sri lanka":ti,ab,kw OR "sri lankan":ti,ab,kw OR 'sri lanka'/de

3.

IFR:ti,ab,kw OR infection*:ti,ab,kw OR CFR:ti,ab,kw OR case*:ti,ab,kw OR transmission*:ti,ab,kw OR mortalit*:ti,ab,kw OR 'mortality'/exp OR fatalit*:ti,ab,kw OR lethalit*:ti,ab,kw OR death*:ti,ab,kw OR burden:ti,ab,kw OR underreporting:ti,ab,kw OR under-reporting:ti,ab,kw OR seroprevalence:ti,ab,kw OR serosurv*:ti,ab,kw OR serology:ti,ab,kw OR 'serology'/exp OR seroconversion:ti,ab,kw OR 'seroconversion'/de OR 'Seroepidemiology'/exp OR seroepid*:ti,ab,kw OR seropositiv*:ti,ab,kw OR antibod*:ti,ab,kw OR 'antibody'/exp OR surveillance:ti,ab,kw OR SIR:ti,ab,kw OR SEIR:ti,ab,kw OR susceptible-exposed-infected-removed:ti,ab,kw OR susceptible-infected-removed:ti,ab,kw

(1 AND 2 AND 3)

isearch (National Library of Medicine)

Date searched: 7/3/2021

Number of results: 1,078

Date filter: January 1, 2020 to [blank]

Other filters applied: filtered to facets bioRxiv, medRxiv, SSRN; searched through title and abstract.

Note: Since isearch is curated to include COVID-19 related studies only, we translated the PubMed concept blocks 2 and 3.

(india OR indian OR pakistan OR pakistani OR bangladesh OR bangladeshi OR nepal OR "sri lanka" OR "sri lankan") AND (IFR OR infection* OR CFR OR case* OR transmission* OR mortalit* OR fatalit* OR lethalit* OR death* OR burden OR underreporting OR "under-reporting" OR seroprevalence OR serosurvey OR serology OR seroconversion OR "serosurveillance" OR seroepid* OR seropositiv* OR antibod* OR surveillance OR SIR OR SEIR OR "susceptible-exposed-infected-removed" OR "susceptible-infected-removed")

Global Index Medicus–SEAR & EMR (World Health Organization)

Note: We searched in IMSEAR (Index Medicus for the South-East Asia Region) for India, Bangladesh, Nepal, and Sri Lanka, and we searched in IMEMR (Index Medicus for the Eastern Mediterranean Region) for Pakistan.

For IMSEAR:

Date searched: 7/3/2021

Number of results: 35

Date filter: 2020 to [blank]

Other filters applied: Index filtered to "IMSEAR (South-East Asia)"; searched through title, abstract, subject.

(tw:(covid-19) OR tw:(COVID19) OR tw:(SARS-CoV-2) OR tw:(SARS-CoV2) OR tw:(“severe acute respiratory syndrome coronavirus 2”) OR tw:(2019-nCoV) OR tw:(2019nCoV) OR tw:(coronavirus)) AND (tw:(india) OR tw:(indian) OR tw:(bangladesh) OR tw:(bangladeshi) OR tw:(nepal) OR tw:(“sri lanka”) OR tw:(“sri lankan”)) AND (tw:(IFR) OR tw:(infection*) OR tw:(CFR) OR tw:(case*) OR tw:(transmission*) OR tw:(mortalit*) OR tw:(fatalit*) OR tw:(lethalit*) OR tw:(death*) OR tw:(burden) OR tw:(underreporting) OR tw:(“under-reporting”) OR tw:(seroprevalence) OR tw:(serosurvey) OR tw:(serology) OR tw:(seroconversion) OR tw:(“serosurveillance”) OR tw:(seroepid*) OR tw:(seropositiv*) OR tw:(antibod*) OR tw:(surveillance) OR tw:(SIR) OR tw:(SEIR) OR tw:(“susceptible-exposed-infected-removed”) OR tw:(“susceptible-infected-removed”))

For IMEMR:

Date searched: 7/3/2021

Number of results: 2

Date filter: 2020 to [blank]

Other filters applied: Index filtered to "IMEMR (Eastern Mediterranean)"; searched through title, abstract, subject.

(tw:(covid-19) OR tw:(COVID19) OR tw:(SARS-CoV-2) OR tw:(SARS-CoV2) OR tw:(“severe acute respiratory syndrome coronavirus 2”) OR tw:(2019-nCoV) OR tw:(2019nCoV) OR tw:(coronavirus)) AND (tw:(pakistan) OR tw:(pakistani)) AND (tw:(IFR) OR tw:(infection*) OR tw:(CFR) OR tw:(case*) OR tw:(transmission*) OR tw:(mortalit*) OR tw:(fatalit*) OR tw:(lethalit*) OR tw:(death*) OR tw:(burden) OR tw:(underreporting) OR tw:(“under-reporting”) OR tw:(seroprevalence) OR tw:(serosurvey) OR tw:(serology) OR tw:(seroconversion) OR tw:(“serosurveillance”) OR tw:(seroepid*) OR tw:(seropositiv*) OR tw:(antibod*) OR tw:(surveillance) OR tw:(SIR) OR tw:(SEIR) OR tw:(“susceptible-exposed-infected-removed”) OR tw:(“susceptible-infected-removed”))

Appendix C. Summary of included articles

Table 1. Summary of data abstraction from included studies.

Location	Study Design	Time Period	Age Criteria	Sample Size	Descriptive Statistics	IFR Estimate (95% CI): ^a	Prevalence Estimate % (95% CI): ^a	Reference
IND–Ahmedabad, Gujarat	cross-sectional serosurvey	Aug 2020	none	N=3973 non-response rate: N/A	48.1% female and 51.8% male mean age: 37.5 (± 15.9) years	N/A	Overall: 31.92 (30.48–33.38) Age 0–9: 34.69 (21.67–49.64) Age 10–19: 31.66 (27.18–36.51) Age 20–29: 26.63 (23.98–29.47) Age 30–39: 31.98 (29.04–35.08) Age 40–49: 32.58 (29.23–36.12) Age 50–59: 35.55 (31.34–39.99) Age 60–69: 36.10 (30.98–41.56) Age 70–79: 44.72 (35.75–53.94) Age 80–89: 40.91 (20.71–63.65) Age 90–99: 0.00	Prakash, 2021 [2]
IND–Bangalore Rural District of Karnataka	cross-sectional serosurvey	2–22 Oct 2020	age≥18	N=509 non-response rate: N/A	47.7% female and 52.3% male mean age: 47.0 (± 16.4) years	0.13% (i.e. 12.8 deaths per 10,000 cases)	<i>Adjusting for test sensitivity and specificity</i> Overall: 6.1 (4.02–8.17) <i>Unadjusted</i> Overall: 12.4 (9.6–15.6)	Inbaraj, 2021 [3]

							Female: 12.0 (8.8–17.6) Male: 12.0 (8.4–16.6) Age ≤20: 5.6 (0.1–27.3) Age 21–40: 13.6 (8.9–19.5) Age 41–60: 12.5 (8.3–17.8) Age >60: 11.3 (6.0–18.9)	
IND– Bhubaneswar, Berhampur, Rourkela cities of Odisha ¹	cross-sectional serosurvey	Aug 2020	age≥18	N=4146 non-response rate: 27.6% for females 12.4% for males	mean age: 44.2 (± 14.2) years	N/A	<i>Across Three Cities</i> Overall: 20.30 (19.0– 21.56) Female: 22.79 (20.73– 24.96) Male: 18.81 (17.33– 20.37) Age <20: 17.09 (10.76– 25.15) Age 20–29: 18.75 (15.68–22.13) Age 30–39: 21.83 (19.16–24.69) Age 40–49: 19.68 (17.29–22.25) Age 50–59: 18.50 (15.89–21.34) Age ≥60: 23.21 (20.14– 26.52)	Kshatri, 2021a [4]
IND– Bhubaneswar, Odisha ¹	serial cross- sectional serosurvey	Jul, Aug, Sept 2020	age≥18	N=3693 non-response rate: 18.33% (across the three rounds)	mean age: 43.1 (± 13.9) years	N/A	<i>Round 1 Round 2 Round 3</i> Overall: 1.58 (0.88–2.58) 5.23 (4.09–6.57) 48.61 (45.96–51.26)	Kshatri, 2021b [5]

							Female: 1.29 (0.27–3.72) 5.37 (3.44–7.95) 50.12 (45.24–54.99) Male: 1.67 (0.87–2.90) 5.16 (3.80–6.83) 47.96 (44.79–51.14) Age 18–29: 1.61 (0.33– 4.64) 5.80 (3.35–9.24) 42.74 (36.31–49.34) Age 30–39: 0.56 (0.01– 3.07) 7.72 (4.96–11.36) 54.02 (48.30–59.65) Age 40–49: 1.30 (0.27– 3.76) 2.57 (1.12–5.01) 51.71 (46.75–56.63) Age 50–59: 2.82 (0.92– 6.47) 3.49 (1.61–6.52) 49.12 (43.15–55.10) Age ≥60: 1.68 (0.35– 4.82) 7.39 (3.99–12.30) 38.18 (30.73–46.05)	
IND–Chennai, Tamil Nadu	cross-sectional serosurvey	7–14 Jul 2020	age≥10	N=12,405 non-response rate: N/A (17.7% not available,13.5% refusal rate)	52.7% female, 47% male, 0.3% transgender mean age: 41.1 (± 17.3) years	N/A	<i>Weighted and test performance adjusted</i> Overall: 18.4 (14.8–22.6) Female: 20.3 (16.4–25.0) Male: 16.3 (12.9–20.3) Transgender: 2.4 (0.0– 27.3) Age 10–19: 18.6 (14.4– 23.7) Age 20–29: 20.8 (16.5– 25.9)	Selvaraju, 2021 [6]

							Age 30–39: 18.2 (14.3–22.8) Age 40–49: 19.3 (15.2–24.2) Age 50–59: 20.1 (15.8–25.2) Age ≥60: 13.1 (9.9–17.1)	
IND–Chennai, Tamil Nadu	analysis of seroprevalence & mortality data	Jul, Oct, Nov 2020	age≥10 (Jul), age≥18 (Oct), age≥18 (Nov)	N=12,405 (Jul), N= (Oct), N=26,135 (Nov) non-response rate: N/A	N/A	<i>Adjusting for death undercounting</i> range: 0.27-0.33% (Jul), 0.30-0.28% (Oct), 0.22-0.25% (Nov) <i>Not adjusting for death undercounting</i> range: 0.16-0.20% (Jul), 0.16-0.16% (Oct), 0.13-0.13% (Nov)	N/A	Banaji, 2021 [7]
IND–Delhi ²	cross-sectional serosurvey	15-23 January 2021	age≥5	N=28,000 non-response rate: N/A	N/A	N/A	Overall: 56.1%	<i>Other</i> ^b [8]
IND–Delhi	repeated cross-sectional serosurvey	1–7 Aug, 1–7 Sep, 15–21 Oct 2020	age≥5	N=15,046 (Aug); N=17409 (Sep) N=15015 (Oct) non-response rate: 10%	52.5% female and 47.4% male mean age: N/A	Aug: 0.77% (0.75–0.79) to 0.79% (0.76–0.81) Sep: 0.98% (0.95–1.01) to 1.03% (1.00–1.06) Oct: 1.27% (1.24–1.31) to 1.34% (1.31–1.38)	<i>Round 1 Round 2 Round 3</i> Overall: 28.39 (27.65–29.14) 24.08 (23.43–24.74) 24.71 (24.01–25.42)	Sharma, 2020 [9]
IND–Delhi ²	cross-sectional serosurvey	27 Jun–10 July 2020	age≥5	N=21,387 non-response rate: N/A	N/A	N/A	Overall: 22.86%	<i>Other</i> ^c [10]
IND–Delhi ²	compartmental epidemiologic model	As of 23 Jan 2021	none	N/A	N/A	<i>Adjusting for death undercounting</i> range: 0.4-0.5%	N/A	Bhattacharyya, 2021 [11]

IND–Delhi, Mumbai, Pune, Bengaluru, Chennai ²	compartmental epidemiologic model	1 Mar 2020–15 Feb 2021	none	N/A	N/A	Bengaluru: 0.05% Chennai: 0.052% Delhi: 0.1% Mumbai: 0.15% Pune: 0.17%	N/A	Hazra, 2021 [12]
IND–Delhi urban, Delhi rural, Bhubaneswar rural, Agartala rural, and Gorakhpur rural	prospective serosurvey	15 Mar–10 Jun 2021	age≥2	N=4509 non-response rate: N/A	mean age: N/A (median age was 11 for Delhi urban, 12 for Delhi rural, 11 for Bhubaneswar, 13 for Gorakhpur, 14 years for Agartala)	N/A	Overall: 65.9 (64.6–67.4) Age <18: 59.0 (55.4–62.6) Age ≥18: 67.3 (65.8–68.8) <i>Rural</i> Overall: 62.2 (60.7–63.9) Age <18: 55.9 (52.0–59.9) Age ≥18: 63.5 (61.8–65.3) <i>Urban</i> Overall: 79.1 (76.5–81.6) Age <18: 78.3 Age ≥18: 79.2	Misra, 2021 [13]
IND–Devarajeevana Halli slum in Bengaluru, Karnataka ¹	cross-sectional serosurvey	Sep 2020	age≥18	N=499 non-response rate: N/A	74.3% female and 25.7% male mean age: 39.7 (± 14.5) years	2.94 per 10,000 cases	<i>Slum</i> Overall: 57.9 (53.4–62.3) Age ≤20: 52.8 (35.5–69.6) Age 21–40: 57.9 (51.5–64.0) Age 41–60: 59.9 (52.0–67.4) Age >60: 54.8 (38.7–70.2)	George, 2021 [14]
IND–Karnataka	cross-sectional serosurvey	15 Jun–29 Aug 2020	none	N=1408 non-response rate: 34.5%	N/A	N/A	Overall: 46.7 (43.3–50.0) Rural: 44.1 (40.0–48.2) Urban: 53.8 (48.4–59.2)	Mohanan, 2020 [15]

IND–Karnataka	cross-sectional serosurvey	3–16 Sep 2020	age≥18	N=16,416 non-response rate: <i>N/A</i>	48.7% female and 51.2% male mean age: <i>N/A</i>	0.05%	Overall: 27.7 (26.1–29.3) Female: 21.9 (19.9–23.8) Male: 29.8 (27.7–31.8) Age 18–29: 19 (16.8–21.3) Age 30–39: 25.7 (22.7–28.7) Age 40–49: 29.3 (25.6–33) Age 50–59: 33.3 (28.9–37.7) Age ≥60: 31.6 (28.1–35)	Babu, 2021 [16]
IND–Karnataka, Mumbai, and among (male) Bihar migrants	matching serosurvey to administrative data	15 Jun–29 Aug 2020 (Karn.) 29 June–19 July 2020 (Mumbai) 4 May–21 July 2020 (Bihar)	age≥10	N=1196 (Karn.) N=6904 (Mumb.) N=4362 (Bihar)	35% female and 65% male mean age: <i>N/A</i>	<i>Karnataka</i> Male age 10-49: 0.009% (0.007, 0.010) Male age 50-89: 0.120% (0.090, 0.150) Female age 10-49: 0.004% (0.004, 0.005) Female age 50-89: 0.056% (0.043, 0.069) <i>Mumbai</i> Male age 10-49: 0.033% (0.032, 0.034) Male age 50-89: 0.530% (0.516, 0.544) Female age 10-49: 0.016% (0.016, 0.017) Female age 50-89: 0.285% (0.277, 0.293)	<i>N/A</i>	Cai, 2021 [17]
IND–Kashmir	cross-sectional serosurvey	17 Oct–4 Nov 2020	age≥18	N=6230 non-response rate: <i>N/A</i>	49.8% female and 50.2% male mean age: <i>N/A</i>	342.1 (320.2–366.0) deaths per million cases	<i>Weighted and adjusted for test performance</i> Overall: 36.7 (34.3–39.2) Female: 37.6 (34.3–41.1) Male: 35.9 (33.3–38.7)	Khan, 2021 [18]

							Age 18–29: 33.5 (29.8–37.4) Age 30–49: 36.1 (33.3–39.1) Age 50–69: 42.3 (38.6–46.0) Age ≥70: 45.1 (37.6–52.8) Urban: 40.0 (36.1–43.9) Rural: 35.3 (32.2–38.5)	
IND–Indore, Madhya Pradesh	cross-sectional serosurvey	11–23 Aug 2020	age≥1	N=7103 non-response rate: <i>N/A</i>	48.1% female and 51.8% male mean age: <i>N/A</i>	1 death per 579 cases	Overall: 7.75 (7.14–8.36) Female: 7.57 (6.70–8.44) Male: 7.91 (7.06–8.76) Age <18: 7.26 (6.24–8.28) Age ≥18: 7.97 (7.21–8.74) Age 18–45: 7.11 (6.22–8.01) Age 45–60: 10.04 (8.28–11.80) Age >60: 8.40 (5.87–10.92)	Sakalle, 2021 [19]
IND–Mumbai, Maharashtra ²	cross-sectional serosurvey	Mar 2021	<i>N/A</i>	N=10,197 non-response rate: <i>N/A</i>	<i>N/A</i>	<i>N/A</i>	Overall: 36.3% Female: 37.12% Male: 35.02% Non-slum: 28.5% Slum: 41.6%	<i>Other</i> ^d [19]
IND–Mumbai, Maharashtra	cross-sectional serosurvey	Aug 2020 (last half)	age≥12	N=5200 non-response rate: <i>N/A</i>	44.6% female and 55.3% male mean age: <i>N/A</i>	<i>N/A</i>	<i>Non-slum</i> Overall: 17.1% (15.5–18.7) Age 12–24: 18.5% (13.5–23.4)	<i>Other</i> ^e [21]

							Age 25–40: 16.6% (13.7–19.5) Age 41–60: 18.6% (16.1–21.0) Age >60: 13.2% (9.6–16.7) <i>Slum</i> Overall: 45.3% (43.5–44.6) Age 12–24: 40.8% (37.0–44.6) Age 25–40: 42.4% (39.5–45.3) Age 41–60: 50.3% (47.3–53.3) Age >60: 48.2% (41.7–54.7)	
IND–Mumbai, Maharashtra	cross-sectional serosurvey	29 Jun–19 Jul 2020	age≥12	N=6904 non-response rate: <i>N/A</i>	44.6% female and 55.3% male mean age: <i>N/A</i>	Overall: 0.12% Slum: 0.076% Non-slum: 0.263%	<i>Non-slum</i> Overall: 17.3 (16.0–18.7) Matunga: 19.2 (17.0–21.4) Chembur West: 17.9 (15.6–20.3) Dahisar: 12.8 (10.2–15.4) <i>Slum</i> Overall: 58.4 (56.8–59.9) Matunga: 61.7 (59.6–63.8) Chembur West: 59.4 (57.0–61.8) Dahisar: 54.9 (50.7–59.1)	Malani, 2020 [22]

IND–Mumbai, Maharashtra	analysis of seroprevalence & mortality data	29 Jun–19 Jul 2020	age≥12	N=6904 non-response rate: <i>N/A</i>	44.6% female and 55.3% male mean age: <i>N/A</i>	<i>Adjusting for death undercounting</i> Overall: 0.23% (0.15–0.33) <i>Not adjusting for death undercounting</i> Slum: 0.084% (0.068–0.10) Non-slum: 0.29% (0.22–0.38)	<i>N/A</i>	Banaji, 2021 [23]
IND–nationwide	Fourth cross-sectional survey	14 June–6 July 2021	age≥6	N=28,975 non-response rate: <i>N/A</i>	<i>N/A</i>	<i>N/A</i>	Overall: 67.6% (66.4–68.7) Female: 69.2% (67.9–70.5) Male: 65.8% (64.4–67.1) Age 6–9: 57.2% (55.0–59.4) Age 10–17: 61.6% (59.8–63.3) Age 18–44: 66.7% (65.3–68.0) Age 45–60: 77.6% (76.1–79.0) Age >60: 76.7% (74.6–78.7) Rural: 66.7% (65.4–68.1) Urban: 69.6% (67.5–71.7)	<i>Other</i> ^f [24]
IND–nationwide	Third cross-sectional survey	18 Dec 2020–6 Jan 2021	age≥10	N=28,598 non-response rate: <i>N/A</i>	51.6% female and 48.4% male mean age: 38.2 (± 16.4) years	<i>N/A</i>	Overall: 24.1 (23.0–25.3) Female: 24.9 (23.7–26.3) Male: 23.2 (22.1–24.5) Age 10–17: 27.2 (24.9–29.4) Age 18–44: 22.2 (21.1–23.4)	Murhekar, 2021 [25]

							Age 45–60: 26.7 (25.2–28.2) Age >60: 26.3 (24.3–28.3) Rural: 21.4 (20.3–22.6) Urban non-slum: 29.5 (27.0–32.1) Urban slum: 34.7 (31.2–38.5)	
IND–nationwide	Second cross-sectional survey	18 Aug–20 Sep 2020	age≥10	N=29,082 non-response rate: 17%	48.8% female and 51.2% male mean age: 37.0 (± 16.4) years	0.09–0.11% 9.43 (8.41–10.73) to 10.65 (9.50–12.12) deaths per 10,000 cases	Overall: 6.6 (5.8–7.4) Female: 6.5 (5.7–7.3) Male: 6.7 (5.9–7.5) Age 10–17: 5.4 (4.5–6.4) Age 18–44: 6.9 (6.1–7.7) Age 45–60: 6.5 (5.7–7.5) Age >60: 6.2 (5.2–7.3) Rural: 5.2 (4.6–6.0) Urban non-slum: 9.0 (7.1–11.3) Urban slum: 16.9 (12.9–21.7) <i>Randomly generated sample</i> Overall: 7.1 (6.2–8.2)	Murhekar, 2021 [26]
IND–nationwide	First cross-sectional survey	11 May–4 Jun 2020	age≥18	N=28,000 non-response rate: N/A (86.9–95.9% across strata)	51.5% female and 48.4% male mean age: 45.3 (± 15.2) years	11.72 (7.21–19.19) to 15.04 (9.26–24.62) deaths per 10,000 cases	Overall: 0.73 (0.34–1.13)	Murhekar, 2020 [27]
IND–nationwide	analysis of seroprevalence	31 Mar 2020	none	N/A	N/A	0.41%	N/A	Bommer, 2020 [27]

	& mortality data							
IND– nationwide	compartmental epidemiologic model	Wave 1 1 Apr 2020-31 Jan 2021	none	N/A	N/A	IFR1 IFR2 Wave 1 India: 0.129% (0.125–0.134) 0.461% (0.455–0.468) Maharashtra: 0.460 (0.444-0.480) 0.968 (0.955-0.985) Punjab: 0.362 (0.331-0.397) 1.010 (0.991-1.031) West Bengal: 0.322 (0.289-0.357) 0.675 (0.665-0.686) Gujarat: 0.284 (0.267-0.302) 0.592 (0.579-0.606) Tamil Nadu: 0.226 (0.210-0.243) 0.514 (0.504-0.523) Karnataka: 0.207 (0.199-0.216) 0.505 (0.499-0.511) Rajasthan: 0.168 (0.153-0.186) 0.428 (0.415-0.443) Madhya Pradesh: 0.163 (0.154-0.173) 0.328 (0.319-0.338) Haryana: 0.148 (0.131-0.172) 0.428 (0.411-0.453) Odisha: 0.137 (0.117-0.160) 0.351 (0.333-0.367)	N/A	Purkayastha, 2021 [29]
IND– Andhra Pradesh, Assam, Bihar, Delhi, Goa, Gujarat, Haryana, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttarakhand, West Bengal		Wave 2 1 Feb-15 May 2021						

Jharkhand: 0.122 (0.094-0.156) | 0.238 (0.226-0.252)

Telangana: 0.099 (0.065-0.165) | 0.261 (0.250-0.273)

Bihar: 0.086 (0.073-0.103) | 0.204 (0.191-0.219)

Uttarakhand: 0.078 (0.062-0.104) | 0.404 (0.390-0.426)

Assam: 0.069 (0.060-0.081) | 0.168 (0.160-0.177)

Kerala: 0.061 (0.057-0.067) | 0.144 (0.140-0.148)

Delhi: 0.060 (0.060-0.061) | 0.380 (0.377-0.383)

Goa: 0.051 (0.049-0.053) | 0.320 (0.311-0.329)

Andhra Pradesh: 0.019 (0.019-0.019) | 0.168 (0.167-0.170)

Wave 2

India, wave 2: 0.032 (0.029-0.035) | 0.183 (0.180-0.186)

India, across waves 1 and 2: 0.06 | 0.24

Goa: 0.102 (0.101-0.103) | 0.393 (0.382-0.405)

Delhi: 0.081 (0.080-0.081) | 0.298 (0.295-0.301)

Punjab: 0.049 (0.045-0.056) | 0.397 (0.390-0.404)

Assam: 0.047 (0.037-0.065) | 0.221 (0.209-0.240)

Maharashtra: 0.047 (0.046-0.049) | 0.209 (0.207-0.211)
Uttarakhand: 0.045 (0.044-0.048) | 0.387 (0.381-0.393)
Uttar Pradesh: 0.026 (0.023-0.030) | 0.166 (0.163-0.170)
Rajasthan: 0.024 (0.019-0.029) | 0.173 (0.168-0.179)
Karnataka: 0.022 (0.022-0.023) | 0.201 (0.199-0.203)
West Bengal: 0.022 (0.019-0.026) | 0.105 (0.102-0.109)
Tamil Nadu: 0.021 (0.020-0.022) | 0.131 (0.130-0.133)
Gujarat: 0.020 (0.017-0.023) | 0.188 (0.185-0.192)
Haryana: 0.019 (0.019-0.020) | 0.159 (0.157-0.161)
Jharkhand: 0.017 (0.016-0.018) | 0.311 (0.308-0.314)
Madhya Pradesh: 0.015 (0.013-0.016) | 0.132 (0.130-0.134)
Andhra Pradesh: 0.013 (0.012-0.014) | 0.093 (0.091-0.095)
Kerala: 0.012 (0.012-0.012) | 0.056 (0.055-0.056)

						Telangana: 0.011 (0.009-0.013) 0.110 (0.108-0.113) Bihar: 0.005 (0.005-0.006) 0.103 (0.102-0.105) Odisha: 0.002 (0.002-0.002) 0.028 (0.028-0.029)		
IND–nationwide IND–Delhi	Bayesian model with seroprevalence & mortality data	11 May –4 Jun 2020 (overall India) 1–7 August 2020 (Delhi)	age≥18 for overall India age≥5 for Delhi	28,000 (India) (Delhi); non-response rate: N/A (India); 10% (Delhi)	51.5% female and 48.4% male (India) and 52.5% female and 47.4% male (Delhi); mean age: 45.3 (SD 15.2) years (India); N/A (Delhi)	<i>Adjusting for death undercounting:</i> For overall India: 0.29% (0.06–0.58) For Delhi: 0.17% (0.07–0.40)	<i>For overall India</i> 0.7% (0.4–1.1) <i>For Delhi</i> 28.4% (27.6–29.1)	Campbell, 2021 [30]
IND–nationwide IND–Delhi, Maharashtra ²	compartmental epidemiologic model	As of 1 Sep 2020	none	N/A	N/A	<i>Adjusting for death undercounting</i> India: 0.91% Delhi: 0.91% Maharashtra: 1.24%	N/A	Bhaduri, 2020 [31]
IND–Pimpri-Chinchwad, Maharashtra ¹	cross-sectional survey	7–17 Oct 2020	age≥12	N=5000 non-response rate: 10%	N/A	0.17%	Overall: 34.04 (31.3–36.8) Female: 36.6 (33.7–39.5) Male: 31.0 (28.0–34.1) Age 12–17: 37.6 (31.2–44.0) Age 18–30: 31.9 (28.8–35.0) Age 31–50: 33.8 (30.3–37.3) Age 51–65: 38.2 (33.6–42.9)	Banerjee, 2020 [32]

							Age >65: 30.6 (24.4–36.8) Slum: 40.9 (37.0–44.7) Tenement: 41.2 (37.7–44.8) Housing: 29.8 (25.8–33.8)	
IND– nationwide IND– Andhra Pradesh, Delhi, Gujarat, Haryana, Jammu & Kashmir, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh	analysis of IFRs, fatality and testing data	Through 8 Apr 2020	none	N/A	N/A	<i>Adjusting for death undercounting</i> India: Andhra Pradesh: Delhi: 0.396% Gujarat: 0.437% Haryana: 0.394% Jammu & Kashmir: 0.358% Karnataka: 0.440% Kerala: 0.579% Madhya Pradesh: 0.364% Maharashtra: 0.435% Rajasthan: 0.358% Tamil Nadu: 0.524% Telangana: 0.432% Uttar Pradesh: 0.335%	N/A	Goli, 2020 [33]
IND– Puducherry	serial three-phase cross-sectional serosurvey	11–16 Aug, 10–16 Sep, 12–16 Oct 2020	age≥18	N=2667 (869 in Phase 1, 898 in Phase 2, 900 in Phase 3) non-response rate: 2.2%	mean age: N/A (median age in mid-40's)	<i>Phase 1 Phase 2 Phase 3</i> 73.4 deaths per 100,000 infected persons 75.8 deaths per 100,000 infected persons 106.1 deaths per 100,000 infected persons	<i>Phase 1 Phase 2 Phase 3</i> Overall: 4.9 (3.5–6.4) 20.7 (18.0–23.3) 34.5 (31.5–37.7) Female: 6.3 (4.0–8.6) 20.0 (16.3–23.6) 37.2 (33.1–41.6) Male: 3.6 (1.9–5.4) 21.4 (17.6–25.2) 31.0 (26.7–35.6)	Kar, 2021 [34]

							Age 18–29: 4.7 (1.5–7.8) 20.0 (13.9–26.1) 32.2 (25.8–39.3) Age 30–44: 4.4 (2.1–6.7) 20.9 (16.2–25.7) 36.5 (30.8–42.6) Age 45–59: 5.4 (2.5–8.2) 23.6 (18.5–28.7) 39.0 (33.2–45.0) Age ≥60: 5.6 (2.0–9.1) 16.7 (11.4–22.1) 28.7 (23.0–35.1) Rural: 3.1 (1.0–5.2) 20.8 (16.0–25.7) 31.6 (26.3–37.4) Urban: 5.7 (3.9–7.5) 20.7 (17.5–23.8) 35.8 (32.1–39.7)	
IND–Tamil Nadu	cross-sectional survey	19 Oct–30 Nov 2020	age≥18	N=26,135 non-response rate: <i>N/A</i>	61% female and 39% male mean age: <i>N/A</i>	Female age 18–29: 0.002% Female age 30–39: 0.006% Female age 40–49: 0.019% Female age 50–59: 0.060% Female age 60–69: 0.143% Female age ≥70: 0.266% Male age 18–29: 0.003% Male age 30–39: 0.015% Male age 40–49: 0.045% Male age 50–59: 0.164% Male age 60–69: 0.380% Male age ≥70: 0.923%	Overall: 31.6 (30.4–32.8) Female: 32.1 (31.1–33.0) Male: 30.4 (29.6–31.2) Age 18–29: 31.1 (30.3–31.8) Age 30–39: 32.0 (31.2–32.7) Age 40–49: 33.3 (32.5–34.0) Age 50–59: 33.2 (32.4–33.9) Age 60–69: 28.4 (27.7–29.1) Age ≥70: 25.2 (24.5–25.8)	Malani, 2021 [35]

							Rural: 25.1 (24.2–26.1) Urban: 36.7 (35.7–37.7)	
IND–Ujjain, Madhya Pradesh	cross-sectional survey	24 Aug–5 Sep 2020	age≥1	N=4883 non-response rate: <i>N/A</i>	56.3% female and 43.7% male mean age: <i>N/A</i>	<i>N/A</i>	Overall: 13.9 (10.4–18.0) Female: 11.7 Male: 16.5 Age <15: 9.5 Age 15–30: 12.2 Age 30–45: 17.1 Age 45–60: 16.7 Age >60: 10.8	Joshi, 2021 [36]
PAK–District East and District Malir in Karachi ³	serial three-round cross-sectional serosurvey	15–25 Apr, 25 Jun–11 Jul, 17–22 Aug 2020	none	N=3005 non-response rate: <i>N/A</i> (refusal rates for DE; 44%, 42%, 8% for DM)	mean age: 25.9–27.1 for District East and 24.32–28.5 for District Malir	<i>Phase 1 Phase 2 Phase 3</i> 1.66% 0.37% 0.26%	<i>Phase 1 Phase 2 Phase 3</i> <i>District East</i> Overall: 0.4 (0.0–1.3) 15.1 (9.4–21.7) 21.5 (15.6–28) <i>District Malir</i> Overall: 0.2 (0.0–0.7) 8.7 (5.1–13.1) 12.8 (8.3–17.7)	Nisar, 2021 [37]
PAK–Khyber Pakhtunkhwa Sindh, Punjab ³	cross-sectional serosurvey	15–31 Jul 2020	none	N=15,390 non-response rate: <i>N/A</i>	20.2% female and 79.8% male mean age: 35.2 (± 13.2) years	<i>N/A</i>	<i>Across provinces</i> Overall: 42.4 (41.5–43.14) Female: 40.5 (38.7–42.2) Male: 42.8 (41.9–43.7) Age ≤20: 36.7 (34.2–39.1) Age 21–40: 42.3 (41.3–43.3) Age 41–60: 44.3 (42.7–45.9)	Haq, 2021 [38]

Age >60: 44.6 (40.7–
48.5)
Khyber Pakhtunkhwa
Overall: 42.2 (41.2–44.0)
Sindh
Overall: 31.8 (29.6–34.1)

Punjab
Overall: 44.5 (43.5–45.6)

Note: Entries are in alphabetical order by location of study and in descending order by study start date. N/A = Not Available. Studies highlighted in grey have been included in the quantitative analysis.

¹ No reported death or case counts are available for the city or slum from *covid19india.org*, at the time of this review.

² No 95% confidence intervals (CI) or 95% credible intervals were provided in the underlying study for either IFR or seroprevalence estimate.

³ Location of the study is outside of India and the meta-analysis focuses on India.

^a The 95% confidence intervals (CI) or 95% credible intervals presented in this table are directly reported from each underlying study, if provided.

^b Data from media reports. (Hindustan Times 2021: Available at: <https://www.hindustantimes.com/cities/delhi-news/a-look-at-serological-surveys-conducted-in-delhi101612270983224.html>)

^c Data from media reports. (The Hindu. Published online July 22, 2020. Available at: <https://www.thehindu.com/news/cities/Delhi/percentage-of-people-with-antibodies-high/article32156162.ece>)

^d Data collected from technical report. (Available at: https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf)

^e Data from media reports. (The Hindu. Published on April 25, 2021. Available at: <https://www.thehindu.com/news/cities/mumbai/third-sero-survey-antibodies-in-3630-samples-in-mumbai/article34404107.ece>)

^f Data from media reports. (Press Information Bureau, National Media Center. Briefing on COVID-19. Published on July 20, 2021)

Appendix D. List of excluded articles

Table 1. List of excluded articles from qualitative review and reason for exclusion.

First Author, Ref	Location (Country–Location)	Reason for Exclusion
Ahamad, [39]	Bangladesh	Provides no relevant seroprevalence or IFR
Ahamad, [40]	Bangladesh	Provides no relevant seroprevalence or IFR
Al-Bari, [41]	Bangladesh	Provides no relevant seroprevalence or IFR
Barnwal, [42]	Bangladesh	Provides no relevant seroprevalence or IFR
Dey, [43]	Bangladesh	Provides no relevant seroprevalence or IFR
Hasan, [44]	Bangladesh	Active recruitment of participants
Islam, [45]	Bangladesh	Provides no relevant seroprevalence or IFR
Islam, [46]	Bangladesh	Provides no relevant seroprevalence or IFR
Khan, [47]	Bangladesh	Provides no relevant seroprevalence or IFR
Mukaddes, [48]	Bangladesh	Provides no relevant seroprevalence or IFR
Rahman, [49]	Bangladesh	Provides no relevant seroprevalence or IFR
Siam, [50]	Bangladesh	Provides no relevant seroprevalence or IFR
Russell, [51]	Bangladesh and others	Provides forecasted estimates
Rana, [52]	Bangladesh–Southern Bangladesh	Focuses on asymptomatic individuals
Adapa, [53]	India	Provides no relevant seroprevalence or IFR
Adapa, [54]	India	Provides no relevant seroprevalence or IFR
Al Arydah, [55]	India	Provides no relevant seroprevalence or IFR
Asirvatham, [56]	India	Provides no relevant seroprevalence or IFR
Cai, [57]	India	Previous version
Chatterjee, [58]	India	Provides no relevant seroprevalence or IFR
Chatterjee, [59]	India	Provides forecasted estimates
Frost, [60]	India	Provides forecasted estimates
Gonzalez, [61]	India	Provides no relevant seroprevalence or IFR
Gupta, [62]	India	Focuses on tested individuals
Gupta, [63]	India	Provides no relevant seroprevalence or IFR
Jahan, [64]	India	Provides no relevant seroprevalence or IFR
Kumar, [65]	India	Provides no relevant seroprevalence or IFR
Kumar, [66]	India	Provides no relevant seroprevalence or IFR
Menon, [67]	India	Provides no relevant seroprevalence or IFR
Mohanty, [68]	India	Provides no relevant seroprevalence or IFR
Mukhopadhyay, [69]	India	Provides no relevant seroprevalence or IFR
Naushin, [70]	India	Focuses on laboratory workers
Neve, [71]	India	Provides forecasted estimates
Parai, [72]	India	Focuses on healthcare workers
Radha, [73]	India	Provides no relevant seroprevalence or IFR
Ranjan, [74]	India	Provides no relevant seroprevalence or IFR

Jayesh, [75]	India	Provides no relevant seroprevalence or IFR
Singh, [76]	India	Focuses on high contact workers
Srivastav, [77]	India	Provides no relevant seroprevalence or IFR
Tamrakar, [78]	India	Provides no relevant seroprevalence or IFR
Unnikrishnan, [79]	India	Provides no relevant seroprevalence or IFR
Venkatesan, [80]	India	Conducted at a hospital/healthcare clinic/ICU
Wang, [81]	India	Provides forecasted estimates
Yadav, [82]	India	Focuses on patient cohort
Ansari, [83]	India	Provides no relevant seroprevalence or IFR
Abraham, [84]	India	Provides no relevant seroprevalence or IFR
Giri, [85]	India and hotspot regions	Provides no relevant seroprevalence or IFR
Shah, [86]	India and others	Provides no relevant seroprevalence or IFR
Wong, [87]	India and others	Examines pediatric participants
Zaveri, [88]	India and others	Provides no relevant seroprevalence or IFR
Bhattacharyya, [89]	India and states	Previous version
Chauhan, [90]	India and states	Provides no relevant seroprevalence or IFR
Meghana, [91]	India and states	Provides forecasted estimates
Mukherjee, [92]	India and states	Previous version
Purkayastha, [93]	India and states	Previous version
Patel, [94]	India, Bangladesh, and Pakistan	Provides no relevant seroprevalence or IFR
Velumani, [95]	India—12 cities across India	Focuses on tested individuals
Gupta, [96]	India—52 districts and 20 states across India	Focuses on SARI patient cohort
Prakash, [97]	India—Ahmedabad, Gujarat	Focuses on healthcare workers
Mahto, [98]	India—Bihar	Focuses on healthcare workers
Malani, [99]	India—Bihar	Focuses on working individuals
Madhusudan, [100]	India—Chennai, Tamil Nadu	Focuses on healthcare workers
Pons Salort, [101]	India—Delhi	Provides forecasted estimates
Siddiqui, [102]	India—Delhi	Conducted at a hospital/healthcare clinic/ICU
Thiruvengadam, [103]	India—Delhi	Focuses on patient cohort
Kaushal, [104]	India—Dharavi Slum in Mumbai, Maharashtra	Provides no relevant seroprevalence or IFR
Mishra, [105]	India—Eastern India	Focuses on healthcare workers
Kataria, [106]	India—Gurugram, Haryana	Focuses on healthcare workers
Ranjan, [107]	India—Karnataka	Provides no relevant seroprevalence or IFR
Khan, [108]	India—Kashmir	Focuses on healthcare workers
Kumar, [109]	India—Kerala	Focuses on healthcare workers
Kaur, [110]	India—Majha, Punjab	Focuses on patient cohort
Goenka, [111]	India—metropolitan city	Focuses on healthcare workers
Kumar, [112]	India—Mumbai, Maharashtra	Focuses on healthcare workers

Mahajan, [113]	India–Mumbai, Maharashtra	Focuses on healthcare workers
Mahajan, [114]	India–Mumbai, Maharashtra	Focuses on healthcare workers
Singhal, [115]	India–Mumbai, Maharashtra	Focuses on healthcare workers
Tanna, [116]	India–Nagpur, Maharashtra	Focuses on patient cohort
Sharma, [117]	India–New Delhi	Focuses on healthcare workers
Gupta, [118]	India–Northern India	Focuses on healthcare workers
Khan, [119, p. 2]	India–District Srinagar	Focuses on patient cohort
Satpati, [120]	India–Paschim Medinipur, West Bengal	Focuses on asymptomatic individuals
Mahto, [121]	India–Patna, Bihar	Focuses on healthcare workers
Bogam, [122]	India–Pune, Maharashtra	Provides no relevant seroprevalence or IFR
Ghose, [123]	India–Pune, Maharashtra	Focuses on asymptomatic individuals and high incidence sub-wards
Monteiro, [124]	India–Pune, Maharashtra	Provides no relevant seroprevalence or IFR
Sharma, [125]	India–Punjab	Provides no relevant seroprevalence or IFR
Vignesh, [126]	India–Tamil Nadu	Provides no relevant seroprevalence or IFR
Laxminarayan, [127]	India–Tamil Nadu and Andhra Pradesh	Provides no relevant seroprevalence or IFR
Panchamia, [128]	India–three states in Western India	Focuses on elderly homes
Suresh, [129]	India–Uttar Pradesh	Conducted at a hospital/healthcare clinic/ICU
Banerjee, [130]	India–West Bengal	Conducted at a hospital/healthcare clinic/ICU
Basnet, [131]	Nepal	Provides no relevant seroprevalence or IFR
Dhimal, [132]	Nepal	Provides no relevant seroprevalence or IFR
Pathak, [133]	Nepal	Provides no relevant seroprevalence or IFR
Sharma, [134]	Nepal	Conducted at a hospital/healthcare clinic/ICU
Abbas, [135]	Pakistan	Focuses on healthcare workers
Chaudhry, [136]	Pakistan	Provides no relevant seroprevalence or IFR
Din, [137, p. 19]	Pakistan	Provides no relevant seroprevalence or IFR
Peter, [138]	Pakistan	Provides forecasted estimates
Waqar, [139]	Pakistan	Focuses on symptomatic individuals
Zaidi, [140]	Pakistan	Focuses on working individuals
Naiyar, [141]	Pakistan–Gujrat, Punjab	Conducted at a hospital/healthcare clinic/ICU
Younas, [142]	Pakistan–Karachi, Sindh	Conducted among blood donors
Ali, [143]	Pakistan–Khyber Pakhtunkhwa	Focuses on patient cohort
Haq, [144]	Pakistan–Khyber Pakhtunkhwa	Focuses on healthcare workers
Javed, [145]	Pakistan–multiple cities across Pakistan	Focuses on working individuals
Nisar, [146, p. 2]	Pakistan–Peshawar	Conducted among blood donors
Jeewandara, [147]	Sri Lanka–Colombo, Western Province	Focuses on asymptomatic individuals

Appendix E. Summary of excluded articles

Table 1. Summary of excluded articles by country, type of study, and reason

Exclusion Reason ^a	Type of Study	Number of Excluded Studies				
		India	Bangladesh	Nepal	Pakistan	Sri Lanka
Hospital, urgent or tertiary care	Serosurvey	6	--	--	2	--
	Other	6	--	1	--	--
Healthcare workers	Serosurvey	16	--	--	2	--
	Other	--	--	--	--	--
Workers ^b	Serosurvey	1	--	--	2	--
	Other	1	--	--	--	--
Asymptomatic or Symptomatic	Serosurvey	2	1	--	1	1
	Other	--	--	--	--	--
Blood donors	Serosurvey	--	--	--	2	--
	Other	--	--	--	--	--
Testing center	Serosurvey	1	--	--	--	--
	Other	1	--	--	--	--
Active recruitment	Serosurvey	--	--	--	--	--
	Other	--	1	--	--	--
Elderly care persons	Serosurvey	--	--	--	--	--
	Other	1	--	--	--	--
No relevant measures	Serosurvey	--	--	--	--	--
	Other	43	13	3	4	--
Total Excluded Studies^c:		78	15	4	13	1

(a) Studies excluded in the full-text screening are included in this table.

(b) Study population is limited to one or more working occupations (e.g., industrial workers, street vendors, industrial workers and street vendors, etc.).

(c) The summation of *Total Excluded Studies* across countries does not equal 109 studies because there are studies that examine multiple of the focus countries (e.g., India and Bangladesh, etc.). Phrased otherwise, the column counts in this table are not mutually exclusive.

Appendix F. Meta-analysis methodology

The aims of the meta-analysis are two-fold (1) estimate a nationwide IFR₁ and IFR₂ with lower and upper bounds based on nationwide excess deaths, and (2) estimate regional IFR₁ and IFR₂ with lower and upper bounds based on state/city/district-specific excess deaths.

Data collection and preparation

A description of the data collection and preparation of the datafile for the meta-analysis is provided in the ***Methods*** section. Here we elaborate on aspects that require further explanation and clarification.

For included studies with a pre-calculated infection fatality rate, the IFR₁ and/or IFR₂, along with the 95% confidence interval, are directly extracted from the included study. For studies that provide a pre-calculated IFR₁ but no IFR₂ (i.e., do not further account for death underreporting), we compute the IFR₂ through multiplying the numerator of the pre-calculated IFR₁ by the appropriate range of excess deaths estimates. For studies that report a pre-calculated IFR₂ but no IFR₁ (i.e., do not provide preliminary infection fatality estimate without accounting for death reporting), we compute the IFR₁, using the seroprevalence estimate quoted within the included study and following the same steps described below to compute IFR₁.

For studies without a pre-calculated IFR₁ and/or IFR₂, IFR₁ and/or IFR₂ is computed, as given in the below formulas

$$IFR_1 = \frac{\textit{Reported Cumulative Deaths}}{\textit{Estimated Total Cumulative Infections}} \quad (a)$$

$$IFR_2 = \frac{\textit{Estimated Total Cumulative Deaths}}{\textit{Estimated Total Cumulative Infections}} \quad (b)$$

where

Estimated Total Cumulative Infections = Seroprevalence * Age Adjusted Population

and

Estimated Total Cumulative Deaths = Reported Cumulative Deaths * Death Underreporting Factor.

For the denominator in formulas (a) and (b), the seroprevalence estimate corresponding to the general study population, as well as the 95% confidence interval, are directly extracted from the included study. We retrieved seroprevalence estimates that were adjusted (within the serosurvey design) for the test performance and weighted to be representative of the study's general population (typically, for the demographics age and sex, among others, such as rural versus urban), if available. For studies that did not both weight and account for test

performance, we extracted the solely weighted or solely test performance adjusted seroprevalence estimate, as provided. For studies that did not report either a weighted or a test performance adjusted seroprevalence estimate, we retrieved the provided crude seroprevalence estimates. The age-adjusted population estimate is calculated as the 2019 projected population estimate on the 2011 census website multiplied by the proportion of the population above the age-cutoff of the included study (e.g., proportion of the population of Karnataka aged ≥ 18 years), as obtained from the age composition for the study area from the 2011 census. As noted in the **Results** section, for select cities and districts, no 2019 projected population estimate was available and as such we use the 2011 census population estimates for the following cities and districts: Ahmedabad, Chennai, Bangalore Rural District, Indore, Ujjain. We note that this may lead to an overestimation of IFR_1 nor IFR_2 from these studies, and in turn slightly inflated pooled estimates for the regions containing these study locations.

For the numerator in formulas (a) and (b), COVID-19 reported cumulative deaths are sourced from covid19india.org and collected 14 days after the study end date to account for delay in death from SARS-CoV-2 symptom onset. In practice, reported (i.e., observed) deaths for the target population are obtained some specified number of days after the end date of the serological study that varies between studies (e.g., from 2 days [35] to 21 days [14] [18], among others). Levin et al., 2021 [148] perform a simulation-based sensitivity analysis to derive an appropriate fatality delay, and propose and adopt in their systematic review of age-specific infection fatality rates a fatality delay of 4 weeks after the midpoint of the serosurvey. As previously discussed, reported deaths were not available for select cities or districts in covid19india.org and so we were not able to compute IFR_1 nor IFR_2 for the cities or districts-level studies Berhampur, Bhubaneswar, Pimpri-Chinchwad, Rourkela and Devarajeevana Halli slum in Bengaluru, and thereby were not able to include these studies in the quantitative meta-analysis (as listed in **Appendix G**).

For the numerator in formula (b), the death under reporting factor is either directly extracted from media reports and excess deaths studies available at the time of this report (as are listed in the **Methods** section) or calculated using excess cumulative deaths estimates provided within these sources. For the latter, URF (D) is computed as the provided excess deaths estimate divided by the COVID-19 reported deaths 14 days after the end date of the study end date, as previously reasoned. As previously noted, excess deaths were not available for the following states at the time of this study and so we were unable to compute IFR_2 , as well as include in the regional analysis, the following states and corresponding studies: Jammu and Kashmir (ref) and Puducherry (ref).

Being that the infection fatality rate (IFR) measure is understood to be a rate and that upon inspection its distribution was heavily right skewed, a log transformation is applied to the sampling data to approximate a normal distribution.

For the 95% confidence interval for IFR_1 , first we obtain the standard error for seroprevalence from the directly provided 95% confidence interval from each included study as

$$se_{sero} = \frac{Upper-Lower}{1.96*2} = \frac{Upper-Lower}{3.92} \quad (c)$$

Now that we have the standard error for seroprevalence, the standard error for the log of IFR_1 can be obtained as IFR_1 relies on *Seroprevalence* as detailed in formula (a) above. First, notice that

$$\log(IFR_1) = \log \left\{ \frac{Reported\ Deaths}{Total\ Cumulative\ Infections} \right\}$$

By rules of logarithmic operations, it follows that

$$= \log(Reported\ Deaths) - \log(Total\ Cumulative\ Infections)$$

By the definition in formula (a) and assuming *Reported Deaths* do not contribute to variability and are thereby fixed, it follows that

$$= C - \log(n * \hat{p}_{sero})$$

where n is the study sample size and \hat{p}_{sero} is the seroprevalence estimate from the included study.

By rules of logarithmic operations, we have that

$$= C - \log(n) - \log(\hat{p}_{sero})$$

Assuming n does not contribute to variability and fixing at some constant

$$= C^* - \log(\hat{p}_{sero})$$

Therefore, $\log(IFR_1) = C^* - \log(\hat{p}_{sero})$. Let us consider the variance of $\log(IFR_1)$.

Substituting in for $\log(IFR_1)$ from above, we have

$$Var(\log IFR_1) = Var(\log \hat{p}_{sero})$$

From the Taylor Series expansion, it follows that

$$Var(\log \hat{p}_{sero}) \approx \frac{1}{\hat{p}_{sero}^2} Var(\hat{p}_{sero})$$

Then, the standard error for the log of IFR_1 is given by

$$se_{IFR_1} \approx \frac{1}{\hat{p}_{sero}} * se_{sero}$$

where se_{sero} is defined as in formula (c) above and \hat{p}_{sero} is the directly provided seroprevalence estimate.

Then, letting $\hat{\theta}$ denote the estimate of $\log IFR_1$, the asymptotic approximate 95% confidence interval for $\log IFR_1$ is as follows:

$$(\hat{\theta} - 1.96 * se_{IFR_1}, \hat{\theta} + 1.96 * se_{IFR_1})$$

The resulting confidence intervals are then exponentiated to back-transform from the logarithmic scale.

For the 95% confidence interval for IFR_2 , as the upper and lower bounds of the 95% confidence interval for the associated $URF (D)$ are often not available (i.e., the range of uncertainty associated with excess deaths estimates is not consistently available), the asymptotic approximate 95% confidence interval for IFR_2 is obtained by multiplying the 95% confidence interval for IFR_1 by the associated $URF (D)$.

Meta-analysis framework

A random effects model is used with the DerSimonian-Laird (DL) estimator for τ^2 (also denoted as tau^2), the variance of the true effect sizes. The DL estimator, $\widehat{\tau}_{DL}^2$, is given by

$$\widehat{\tau}_{DL}^2 = \max \left\{ 0, \frac{Q_w - (k - 1)}{\left[\sum_i w_i - \left(\frac{\sum_i w_i^2}{\sum_i w_i} \right) \right]} \right\} \quad (e)$$

where Q_w denotes the appropriate test statistic with $k-1$ denoting the degrees of freedom and w_i denotes the sampling weight for the i^{th} included study datapoint.

The inverse variance approach is then used to obtain the pooled estimates (nationwide, regional, and state-specific within India). This means that the weighting in the random effects model is the inverse of the sampling variance, as follows

$$w_i^{\{DL\}} = \frac{1}{se_i^2 + \widehat{\tau}_{DL}^2} \quad (f)$$

where i denotes the i^{th} included study datapoint, se_i^2 is the standard error from the i^{th} included study estimate, and $\widehat{\tau}_{DL}^2$ is the DL estimated random effects variance component, as defined in (e) above.

Using a random effects model with inverse variance method and DL estimator, the estimate for the pooled effect size is then given as follows:

$$\hat{\theta} = \frac{\sum_i \hat{\theta}_i w_i^{\{DL\}}}{\sum_i w_i^{\{DL\}}} \quad (e)$$

As previously mentioned, a log transformation is applied to the sampling data to approximate a normal distribution. In other words, we log transform both IFR₁ and IFR₂ in the meta-analysis and appropriately back-transform the resulting point estimates and standard errors by exponentiating the log-transformed values. Hence, $\hat{\theta}$ in (e) above in this context is $\hat{\theta}'_{IFR_1} = \log(\hat{\theta}_{IFR_1})$ and, similarly, $\hat{\theta}'_{IFR_2} = \log(\hat{\theta}_{IFR_2})$.

Then, to estimate the nationwide pooled infection fatality rates (IFR₁ and IFR₂) for India, countrywide IFR estimates (pre-calculated or computed) among included studies (as verified through August 15, 2021) are pooled, as provided in (e) above using the random effects framework detailed. The nationwide pooled infection fatality estimate includes the computed IFRs from each of the four nationwide seroprevalence surveys conducted consecutively for India, as stratifying by time periods (i.e., the nationwide first and second waves of SARS-CoV-2 in India) is of particular interest.

To estimate the regional pooled infection fatality rates (IFR₁ and IFR₂) in India, IFR estimates (pre-calculated or computed) from included studies within a state are pooled, as provided in (e) above with the same random effects approach outlined. Then, the regional IFR is estimated as the pooled IFR across pooled state level IFRs, as provided in (e) except where i now denotes the i^{th} state. Since the regional analysis does not involve stratifying by waves (and thereby time points), for serial (or repeated) serosurveys for which multiple seroprevalence estimates are provided for a given study location at various time points, the most recent estimate is considered and included in the regional analysis.

Using the *meta* package in R, pooled effect sizes are estimated, as well as 95% confidence intervals, following the methodological framework above.

Appendix G. Summary of excluded articles from quantitative summary

Table 1. Summary of excluded articles from quantitative summary and reason for exclusion.

Reference	Location (Country–Location)	Reason for Exclusion
Kshatri, 2021a [4]	India–Bhubaneswar	No fatality data available
Kshatri, 2021b [5]	India–Bhubaneswar, Berhampur, Rourkela cities of Odisha	No fatality data available
Banaji, 2021 [7]	India–Chennai, Tamil Nadu	Provides no 95% confidence intervals
Bhattacharyya, 2021 [11]	India–Delhi	Provides no 95% confidence intervals
<i>Other</i> [8]	India–Delhi	Provides no 95% confidence intervals
<i>Other</i> [10]	India–Delhi	Provides no 95% confidence intervals
Hazra, 2021 [12]	India–Delhi, Mumbai, Pune, Bengaluru, Chennai	Provides no 95% confidence intervals
Misra, 2021 [13]	India–Delhi urban, Delhi rural, Bhubaneswar rural, Agartala rural, and Gorakhpur rural	No fatality data available
George, 2021 [14]	India–Devarajeevana Halli slum in Bengaluru, Karnataka	Provides seroprevalence in slum
<i>Other</i> [19]	India–Mumbai, Maharashtra	Provides no 95% confidence intervals
<i>Other</i> [21]	India–Mumbai, Maharashtra	Provides seroprevalence in slum and non-slum
Malani, 2020 [22]	India–Mumbai, Maharashtra	Provides seroprevalence in slum and non-slum
Bommer, 2020 [27]	India–nationwide	Provides no 95% confidence intervals
Bhaduri, 2020 [31]	India–nationwide, Delhi, Maharashtra	Provides no 95% confidence intervals
Banerjee, 2020 [32]	India–Pimpri-Chinchwad, Maharashtra	No fatality data available
Goli, 2020 [33]	India–nationwide, Andhra Pradesh, Delhi, Gujarat, Haryana, Jammu & Kashmir, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh	Provides no 95% confidence intervals
Nisar, 2021 [37]	Pakistan–District East and District Malir in Karachi	Focuses on location outside of India
Haq, 2021 [38]	Pakistan–Khyber Pakhtunkhwa Sindh, Punjab	Focuses on location outside of India

Appendix H. Summary of seroprevalence estimates within India

Below is a forest plot with the seroprevalence estimates used to compute IFR_1 and in turn IFR_2 (except for studies for which IFR_2 was pre-calculated) in the meta-analysis of nationwide and regional IFRs.




Figure 1. Forest plot of SARS-CoV-2 seroprevalence estimates for India utilized in meta-analysis of IFR_1 and IFR_2 .

Appendix I. Risk of bias assessment across included articles

See supplementary file *Supplementary_RiskofBias.xlsx* for results from the risk of bias assessment among the included studies in the meta-analysis, using the Joanna Briggs Institute (JBI) tool. Responses to each question in the JBI approach, as well as the cumulative score and rank of risk of bias, are detailed for each of the 19 studies (i.e. 15 serosurvey studies and 4 other study designs).

Appendix J. Assessment of publication bias

To formally test for funnel plot asymmetry, the Egger's test (i.e., linear regression) is performed with a resulting p-value of 0.0501. Seeing as the significance level of the funnel plot intercept in the Egger's test nearly meets the benchmark of 0.05, we further conduct the Begg's test (i.e., rank correlation test) and with a p-value<0.0001, conclude that the funnel plot is asymmetric. As discussed within the ***Results*** section, despite the results of these diagnostic tests, we do not suspect that publication bias is the driving factor behind the observed asymmetry. Firstly, this is because the bulk of the included studies are seroprevalence studies, which are inherently large studies with rigorous study designs, thereby tending toward high precision (i.e., low standard errors). Secondly, there may be heterogeneity in the true effect size between the included studies for reasons such as geographic variation that may be attributing to the largely horizontal dispersion of the standard errors in ***Figure 6*** (the funnel plot) in the ***Results*** section, and funnel plots assume a single true effect size.

Appendix K. SEIR-fansy model framework

(Note: Explanation below is unchanged from Supplementary Materials in previous submission¹.)

Introduction


Here we are using the SEIR-fansy model^{1,2} and software package³ which uses a compartmental model accounting for false negative rates and preferential diagnostic testing for SARS-CoV-2 infections. The SEIR-fansy model can be represented by the compartmental model in Figure S1.

1. Purkayastha S, Kundu R, Bhaduri R, Barker D, Kleinsasser M, Debashree R, Mukherjee B. Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India. *BMC Res Notes*. **14**, 262 (2021). doi:10.1186/s13104-021-05652-2.

2. Bhaduri R, Kundu R, Purkayastha S, Kleinsasser M, Beesley LJ, Mukherjee B. Extending the Susceptible-Exposed-Infected-Removed (SEIR) model to handle the high false negative rate and symptom-based administration of Covid-19 diagnostic tests: SEIR-fansy. medRxiv [Preprint]. 2020 Sep 25:2020.09.24.20200238. doi: 10.1101/2020.09.24.20200238. PMID: 32995829; PMCID: PMC7523173.

3. Ritwik Bhaduri, Ritoban Kundu, Soumik Purkayastha, Lauren Beesley and Bhramar Mukherjee (2020). SEIRfansy: Extended Susceptible-Exposed-Infected-Recovery Model. R package version 1.1.0. <https://CRAN.R-project.org/package=SEIRfansy>

Figure S1: Schematic diagram for the SEIR-fansy model with imperfect testing and misclassification.



Mathematical framework

The following differential equations summarize the transmission dynamics being modeled.

$$\frac{\partial S}{\partial t} = -\beta \frac{S(t)}{N} (\alpha_p P(t) + \alpha_u U(t) + F(t)) + \lambda N - \mu S(t)$$

$$\frac{\partial E}{\partial t} = \beta \frac{S(t)}{N} (\alpha_p P(t) + \alpha_u U(t) + F(t)) - \frac{E(t)}{D_e} - \mu E(t)$$

$$\frac{\partial U}{\partial t} = (1 - r) \frac{E(t)}{D_e} - \frac{U(t)}{\beta_1 D_r} - \delta_1 \mu_c U(t) - \mu U(t)$$

$$\frac{\partial P}{\partial t} = (1 - f)r \frac{E(t)}{D_e} - \frac{P(t)}{D_r} - \mu_c P(t) - \mu P(t)$$

$$\frac{\partial F}{\partial t} = fr \frac{E(t)}{D_e} - \frac{\beta_2 F(t)}{D_r} - \frac{\mu_c F(t)}{\delta_2} - \mu F(t)$$

$$\frac{\partial RU}{\partial t} = \frac{U(t)}{\beta_1 D_r} + \frac{\beta_2 F(t)}{D_r} - \mu RU(t)$$

$$\frac{\partial RR}{\partial t} = \frac{P(t)}{D_r} - \mu RR(t)$$

$$\frac{\partial DU}{\partial t} = \delta_1 \mu_c U(t) + \frac{\mu_c F(t)}{\delta_2},$$

$$\frac{\partial DR}{\partial t} = \mu_c P(t)$$

Using the Next Generation Matrix Method (28), we have calculated the basic reproduction number

$$R_0 = \frac{\beta S_0}{\mu D_e + 1} \left(\frac{\alpha_U(1-r)}{\frac{1}{\beta_1 D_r} + \delta_1 \mu_c + \mu} + \frac{\alpha_P r(1-f)}{\frac{1}{D_r} + \mu_c + \mu} + \frac{rf}{\frac{\beta_2}{D_r} + \frac{\mu_c}{\delta_2} + \mu} \right)$$

where $S_0 = \lambda/\mu = 1$ since we have assumed that natural birth and death rates are equal within this short period of time. In this setting, both β and r are time-varying parameters which are estimated using the Metropolis-Hastings MCMC method. To estimate the parameters, we at first need to solve the differential equations, which is difficult to perform in this continuous-time setting. It is also worth noting that we do not require the values of the variables for each time point. Instead, we only need their values at discrete time steps, i.e., for each day. Thus, we approximate the above set of differential equations by a set of recurrence relations. For any compartment X , the instantaneous rate of change with respect to time t (given by $\frac{\partial X}{\partial t}$) is approximated by the difference between the counts of that compartment on the $(t + 1)^{th}$ day and the t^{th} day, that is $X(t + 1) - X(t)$. Starting with an initial value for each of the compartments on the Day 1 and using the discrete-time recurrence relations, we can then obtain the solutions of interest. Some examples of these discrete-time recurrence relations are presented below.

$$\begin{aligned}
 E(t+1) - E(t) &= \beta \frac{S(t)}{N} (\alpha_P P(t) + \alpha_U U(t) + F(t)) - \frac{E(t)}{D_e} - \mu E(t), \\
 U(t+1) - U(t) &= \frac{(1-r)E(t)}{D_e} - \frac{U(t)}{\beta_1 D_r} - \delta_1 \mu_c U(t) - \mu U(t), \\
 P(t+1) - P(t) &= \frac{r(1-f)E(t)}{D_e} - \frac{P(t)}{D_r} - \mu_c P(t) - \mu P(t), \\
 F(t+1) - F(t) &= \frac{rfE(t)}{D_e} - \frac{\beta_2 F(t)}{D_r} - \frac{\mu_c F(t)}{\delta_2} - \mu F(t).
 \end{aligned}$$

The rest of the differential equations can each be similarly approximated by a discrete-time recurrence relation.

Likelihood assumptions and estimation

We use Bayesian estimation techniques and Markov chain Monte Carlo (MCMC) methods (namely, Metropolis-Hastings method with Gaussian proposal distribution) for estimating the parameters. First, we approximated the above set of differential equations using a discrete time approximation using daily differences. So, after we started with an initial value for each of the compartments on the day 1, using the discrete time recurrence relations we can find the counts for each of the compartments on the next days. To proceed with the MCMC-based estimation, we specify the likelihood explicitly. We assume (conditional on the parameters) the number of new confirmed cases on day t depend only on the number of exposed individuals on the previous day. Specifically, we use multinomial modeling to incorporate the data on recovered and deceased cases as well. The joint conditional distribution is

$$\begin{aligned}
 &P[P_{new}(t), R_{new}(t), D_{new}(t) | E(t-1), P(t-1)] \\
 &= P[P_{new}(t) | E(t-1), P(t-1)] \cdot P[R_{new}(t), D_{new}(t) | E(t-1), P(t-1)] \\
 &= P[P_{new}(t) | E(t-1)] \cdot P[R_{new}(t), D_{new}(t) | P(t-1)]
 \end{aligned}$$

A multinomial distribution-like structure is then defined,

$$\begin{aligned}
 P_{new}(t) | E(t-1) &\sim \text{Bin} \left(E(t-1), \frac{r(1-f)}{D_e} \right) \\
 R_{new}(t), D_{new}(t) | P(t-1) &\sim \text{Mult} \left(P(t-1), \left(\frac{1}{D_r}, \mu_c, 1 - \frac{1}{D_r} - \mu_c \right) \right)
 \end{aligned}$$

Note: the expected values of $E(t-1)$ and $P(t-1)$ are obtained by solving the discrete time differential equations as described earlier.

Prior assumptions and MCMC

For the parameter r , we assume a $U(0,1)$ prior, while for β , we assume an improper non-informative flat prior with the set of positive real numbers as support. After specifying the likelihood and the prior distributions of the parameters, we draw samples from the posterior distribution of the parameters using the Metropolis-Hastings algorithm with a Gaussian proposal distribution. We run the algorithm for 200,000 iterations with a burn-in period of 100,000. Finally, the mean of the parameters in each of the iterations are obtained as the final estimates of β and r for the different time periods. To obtain confidence intervals of various estimates we predict the number of individuals in each compartment given a set of parameters which are drawn using MCMC. This is done for 100,000 iterations. Using these values, we obtain the 95% Bayesian Credible Intervals of the estimates (such as infection fatality rates and underreporting factors)

Estimation of parameters of interest

Our main parameters of interest here are Underreporting factors for cases and deaths and Infection Fatality rate. Underreporting factors (URF) for cases and deaths are defined as follows:

$$URF_{case} = \frac{\text{Estimated Total Cumulative Infections}}{\text{Observed Cumulative Cases}}$$

$$URF_{death} = \frac{\text{Estimated Total Cumulative Deaths}}{\text{Observed Cumulative Deaths}}$$

Here, total cumulative cases refers to all Cumulative cases including both reported and unreported cases. Similarly total cumulative deaths includes both reported and unreported deaths. Since we are unable to observe unreported cases or deaths we estimate total cumulative cases and deaths as follows:

1. Total Cumulative cases at time $t = P(t)+U(t)+F(t)+RR(t)+RU(t)+DR(t)+DU(t)$
2. Total Cumulative deaths at time $t = DR(t)+DU(t)$

To estimate the true fatality rate of COVID-19, we calculate 2 different infection fatality rates IFR1 and IFR2 as defined in formulas (a) and (b) respectively, in ***Supplementary Appendix F***.

We also calculate the Case fatality rate as defined in the ***Methods*** section.

Now *Cumulative Deaths* follows a $Bin(\text{Observed cumulative cases}, CFR_{true})$ distribution, with the estimate of CFR_{true} given by CFR, making CFR is a binomial proportion. Let $\hat{p} = CFR$ and $n = \text{Observed Cumulative Cases}$. So the asymptotic approximate 95% confidence interval is given by

$$(\hat{p} - 1.96\sqrt{\frac{\hat{p}(1-\hat{p})}{n}}, \hat{p} + 1.96\sqrt{\frac{\hat{p}(1-\hat{p})}{n}}).$$

The estimates of infection fatality rates and underreporting factors are based on Bayesian credible intervals constructed from the exact posterior draws, as described before.

Appendix L. Data source and model-based results

The data has been sourced from covid19india.org. We used daily case-recovery-death count data from April 1, 2020 to January 31, 2021 for wave 1 and from February 1, 2021 – June 30, 2021 for wave 2. The predicted number of reported and total cases and deaths for January 31, 2021 (wave 1) and June 30 (for wave 2 and waves 1 and 2 combined) are shown in Tables S1, S2, and S3 respectively.

The mean estimates and the 95% CrI's of underreporting factors for cases and deaths on January 31, 2021 are shown in ***Figure S2***. Relevant wave 2 values are presented in ***Figure S3***.

Table 11: Summary of the different metrics for the states and the nation for wave 1, on 31st

January 2021

<i>Place</i>	<i>Reported Cases (Observed)</i>	<i>Reported Cases (Predicted)</i>	<i>Total (reported + unreported) Cases (Predicted)</i>	<i>Reported Deaths (Observed)</i>	<i>Reported Deaths (Predicted)</i>	<i>Total (reported + unreported) Deaths (Predicted)</i>	<i>Cases per million</i>	<i>Deaths per million</i>
Andaman and Nicobar	4990	4971	420209	62	62	1027	13111.53	162.91
Andhra Pradesh	887836	882030	38244770	7153	7125	64317	17908.19	144.28
Arunachal Pradesh	16828	16367	1177129	56	54	773	12161.36	40.47
Assam	217039	206824	1576369	1087	1050	2650	6955.14	34.83
Bihar	260719	265325	1752581	1501	1515	3566	2504.52	14.42
Chandigarh	20925	21064	370319	334	330	1456	19825.67	316.45
Chhattisgarh	305367	306365	3958345	3701	3573	12372	11953.99	144.88
Dadra and Nagar Haveli	3377	3353	322500	2	2	38	5765.12	3.41
Delhi	635096	634237	17949712	10853	10771	68212	37830.49	646.48
Goa	53409	53536	1516370	768	763	4854	36618	526.55
Gujarat	261539	239728	1546257	4386	3937	9160	4327.27	72.57
Haryana	267897	255093	2212182	3018	2849	7763	10567.32	119.05
Jammu and Kashmir	124506	120675	11786372	1936	1861	35906	10149.64	157.82
Jharkhand	118667	108448	1142000	1072	973	2982	3597.26	32.5
Karnataka	939387	931828	7298441	12224	12112	31189	15375.77	200.08
Kerala	929179	973432	6109388	3744	3821	8781	27814.68	112.08
Ladakh	9720	9875	195168	130	131	627	35474.45	474.45
Madhya Pradesh	255112	246254	2593075	3811	3617	11092	3512.64	52.47
Maharashtra	2026399	1939901	11106302	51081	48974	107479	18032.58	454.56
Manipur	29068	28426	787087	371	359	2239	11308.79	144.34
Meghalaya	13716	12742	496017	146	135	1126	4623.02	49.21
Mizoram	4372	4488	237273	9	9	98	3984.67	8.2
Nagaland	12057	11586	315789	82	83	506	6094	41.45
Odisha	335072	322600	1630327	1959	1882	3873	7982.8	46.67
Punjab	173276	176267	1553488	5615	5670	15692	6245.68	202.39
Rajasthan	317491	295702	1696333	2766	2552	5569	4631.63	40.35
Sikkim	6104	6136	177128	133	135	877	9997.1	217.83
Tamil Nadu	838340	842658	5966633	12356	12378	30119	11619.88	171.26
Telangana	293959	287679	1625763	1599	1560	3426	8397.95	45.68
Tripura	33347	32051	801142	388	374	2131	9076.69	105.61
Uttar Pradesh	600299	584173	3838576	8658	8418	19731	3004.31	43.33
Uttarakhand	96129	94366	2147503	1644	1609	8655	9530.66	162.99
West Bengal	569998	548980	3171287	10173	9735	21392	6244.77	111.45
India	10758629	10512888	119510413	154428	149478	550380	8022.84	115.16

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table T2: Summary of the different metrics for the states and the nation for wave 2, on 30th June 2021

<i>Place</i>	<i>Reported Cases (Observed)</i>	<i>Reported Cases (Predicted)</i>	<i>Total (reported + unreported) Cases (Predicted)</i>	<i>Reported Deaths (Observed)</i>	<i>Reported Deaths (Predicted)</i>	<i>Total (reported + unreported) Deaths (Predicted)</i>	<i>Cases per million</i>	<i>Deaths per million</i>
Andaman and Nicobar	2475	2538	22006	66	63	178	6503.21	173.42
Andhra Pradesh	1005454	1052130	24433883	5590	5404	30424	20280.61	112.75
Arunachal Pradesh	19341	21105	168634	120	115	308	13977.47	86.72
Assam	293999	320108	10416260	3494	3439	25964	9421.36	111.97
Bihar	461307	459699	9984295	8089	7695	40041	4431.41	77.7
Chandigarh	40730	41573	581721	474	468	1746	38590.17	449.1
Chhattisgarh	689201	703661	12440190	9739	9717	42812	26979.67	381.25
Dadra and Nagar Haveli	7047	7415	132289	2	2	9	12030.44	3.41
Delhi	799064	806934	14348458	14125	14016	62005	47597.5	841.38
Goa	113451	116695	1343287	2292	2244	7401	77783.68	1571.43
Gujarat	561769	593952	9133281	5674	5834	23185	9294.7	93.88
Haryana	500735	522462	10517838	6424	6479	31671	19751.72	253.4
Jammu and Kashmir	191410	197500	7943113	2391	2315	20502	15603.61	194.91
Jharkhand	226971	236331	4274772	4040	4079	18394	6880.38	122.47
Karnataka	1907238	1962929	37788085	22914	22533	107790	31217.43	375.05
Kerala	2004396	2083298	23997385	9599	9266	30606	60000.97	287.34
Ladakh	10366	10916	117421	72	72	224	37832.12	262.77
Madhya Pradesh	534581	549186	8512735	5169	5160	20615	7360.66	71.17
Maharashtra	4042252	4073053	59223522	71088	70007	268306	35971.31	632.6
Manipur	41220	46295	481010	791	772	2480	16036.48	307.74
Meghalaya	36326	38828	1512205	698	674	6122	12243.8	235.26
Mizoram	16120	17044	306787	84	86	427	14691.86	76.56
Nagaland	13206	13915	383920	410	423	2782	6674.75	207.23
Odisha	577736	594332	20182943	2157	1989	15246	13764.07	51.39
Punjab	422429	421946	10421537	10456	9990	57838	15226.32	376.88
Rajasthan	634910	633034	16637039	6157	5919	35662	9262.21	89.82
Sikkim	14575	15696	218046	175	182	703	23870.86	286.61
Tamil Nadu	1645335	1726816	40903538	20358	19214	109652	22805.3	282.17
Telangana	329792	333956	8438699	2068	2005	11775	9421.64	59.08
Tripura	32869	35134	1214075	291	271	2236	8946.58	79.21
Uttar Pradesh	1105782	1132551	25351545	13939	13930	69963	5534.1	69.76
Uttarakhand	244199	253662	4885358	5676	5771	27475	24210.98	562.74
West Bengal	931107	958952	24747185	7556	7329	43904	10200.99	82.78
India	19690200	19890297	2.61E+08	245824	236813	850612	14683.22	183.31

Table 13: Summary of the different metrics for the states and the nation for waves 1 and 2

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

combined, on 30th June 2021

<i>Place</i>	<i>Reported Cases (Observed)</i>	<i>Reported Cases (Predicted)</i>	<i>Total (reported + unreported) Cases (Predicted)</i>	<i>Reported Deaths (Observed)</i>	<i>Reported Deaths (Predicted)</i>	<i>Total (reported + unreported) Deaths (Predicted)</i>	<i>Cases per million</i>	<i>Deaths per million</i>
Andaman and Nicobar	6589	7509	442215	88	125	1205	19614.74	336.33
Andhra Pradesh	1435447	1934160	62678653	9372	12529	94741	38188.8	257.03
Arunachal Pradesh	21803	37472	1345763	81	169	1081	26138.83	127.19
Assam	328526	526932	11992629	2184	4489	28614	16376.5	146.8
Bihar	651888	725024	11736876	3831	9210	43607	6935.93	92.12
Chandigarh	55352	62637	952040	635	798	3202	58415.84	765.55
Chhattisgarh	912468	1010026	16398535	11734	13290	55184	38933.66	526.13
Dadra and Nagar Haveli	9515	10768	454789	4	4	47	17795.56	6.82
Delhi	1393747	1441171	32298170	21504	24787	130217	85427.99	1487.86
Goa	135851	170231	2859657	2099	3007	12255	114401.7	2097.98
Gujarat	752544	833680	10679538	9114	9771	32345	13621.97	166.45
Haryana	694384	777555	12730020	6685	9328	39434	30319.04	372.45
Jammu and Kashmir	244553	318175	19729485	3147	4176	56408	25753.25	352.73
Jharkhand	315475	344779	5416772	4479	5052	21376	10477.64	154.97
Karnataka	2203361	2894757	45086526	21841	34645	138979	46593.2	575.13
Kerala	2147727	3056730	30106773	6427	13087	39387	87815.65	399.42
Ladakh	16439	20791	312589	165	203	851	73306.57	737.22
Madhya Pradesh	731319	795440	11105810	6988	8777	31707	10873.3	123.64
Maharashtra	5378150	6012954	70329824	81475	118981	375785	54003.89	1087.16
Manipur	39722	74721	1268097	578	1131	4719	27345.27	452.08
Meghalaya	23284	51570	2008222	320	809	7248	16866.82	284.47
Mizoram	8678	21532	544060	24	95	525	18676.53	84.76
Nagaland	18039	25501	699709	203	506	3288	12768.75	248.68
Odisha	612220	916932	21813270	2366	3871	19119	21746.87	98.06
Punjab	497663	598213	11975025	11891	15660	73530	21472	579.27
Rajasthan	859576	928736	18333372	6777	8471	41231	13893.84	130.17
Sikkim	11424	21832	395174	205	317	1580	33867.96	504.44
Tamil Nadu	1598092	2569474	46870171	17669	31592	139771	34425.18	453.43
Telangana	528216	621635	10064462	2949	3565	15201	17819.59	104.76
Tripura	40813	67185	2015217	428	645	4367	18023.27	184.82
Uttar Pradesh	1619541	1716724	29190121	17546	22348	89694	8538.41	113.09
Uttarakhand	287279	348028	7032861	4811	7380	36130	33741.64	725.73
West Bengal	1133393	1507932	27918472	13281	17064	65296	16445.76	194.23
India	24963227	30403185	3.81E+08	273779	386291	1400992	22706.06	298.47

Table 14: Parameter values and descriptions for the SEIR-fansy model.

Parameter	Value	Description
	<i>Time-varying</i>	Rate of infectious transmission by infected, tested individuals with false negative results.
p	0.5	Ratio of rate of spread of infection by tested positive patients to that by false negatives. $p < 1$ represents the scenario where individuals who test positive are infecting susceptible individuals at a lower rate than infected individuals with false negative test results.
u	0.5	Scaling factor for the rate of spread of infection by untested individuals. u is assumed to be < 1 as U mostly consists of asymptomatic or mildly symptomatic cases who are known to spread the disease at a much lower rate than those with higher levels of symptoms.
De	5.2	Incubation period (in days).
Dr	17.8	Means number of days until recovery for infected individuals.
Dt	0	Mean number of days for the test result to come after a person is tested. Under the assumption of instantaneous test results, this is taken to be zero.
c	0.0562	Death rate attributable to COVID-19 which is equivalent to inverse of the average number of days for death starting from the onset of disease times the probability of death of an infected individual.
λ, μ	3.95×10^{-5}	Natural birth and death rates (assumed to be equal).
r	<i>Time-varying</i>	Probability of being tested for infectious individuals.
f	0.15	Probability of a false negative RT-PCR diagnostic test result.
1, 12	0.6 (1) 0.7 (2)	Scaling factors for rate of recovery for undetected and false negative individuals respectively. Both 1 and 2 are assumed to be less than 1. It is assumed that the recovery rate is slower than the detected ones for the False Negative ones because they are not getting any hospital treatments. The condition of Untested individuals is not so severe as they consist of mostly asymptomatic people. So, they are assumed to recover faster than the Current Positive Ones.
1, 12	0.3 (1) 0.7 (2)	Scaling factors for death rate for undetected and false negative individuals respectively. Both 1 and 2 are assumed to be less than 1. Same as before, the death rate for False Negative ones are assumed to be higher than the Current detected Positive as they are not receiving proper treatment. While, for the Untested ones, the death rate is taken to be lesser because they are mostly asymptomatic. So, their probability of dying is much less.

Table T5: Comparison of 4th nationwide serosurvey to combined estimates across waves 1 and 2.


States	4th Nationwide Serosurvey, 31 May 2021 ¹				Model-Based Estimates, 30 June 2021			Difference (Under Counting factor - Under Reporting factor)
	Seroprevalence (%)	Estimated Cases (in Lakhs)	Reported Cases (in Lakhs)	Under Counting Factor	Estimated Cases	Reported Cases	Under Reporting Factor	
Bihar	75.9	947	7	134	11733035	725024	16	118
Uttar Pradesh	71	1689	17	100	29700720	1716724	17	83
Madhya Pradesh	79	674	8	86	11248345	795440	14	72
Jharkhand	61.2	236	3	70	5494715	344779	16	54
Rajasthan	76.2	617	9	66	18167796	928736	20	46
Gujarat	75.3	481	8	59	11073822	833680	13	46
West Bengal	60.9	607	14	44	28541606	1507932	19	25
Assam	50.3	179	4	44	12843468	526932	24	20
Telangana	63.1	243	6	42	10136279	621635	16	26
Odisha	68.1	316	8	41	22332360	916932	24	17
Punjab	66.5	200	6	35	11989926	598213	20	15
Jammu & Kashmir	63	86	3	30	19619546	318175	62	-32
Tamil Nadu	69.2	539	21	26	48926546	2569474	19	7
Uttarakhand	73.1	82	3	25	7182789	348028	21	4
Himachal Pradesh	62	46	2	24	N/A	N/A	N/A	N/A
Chhattisgarh	74.6	220	10	23	459405	10768	43	-20
Haryana	60.1	169	8	22	13080661	777555	17	5
Andhra Pradesh	70.2	378	17	22	63562840	1934160	33	-11
Karnataka	69.8	472	26	18	46131203	2894757	16	2
Maharashtra	58	714	57	12	70307014	6012954	12	0
Kerala	44.4	159	25	6	31342383	3056730	10	-4
India	67.6	9265	282	33	380801295	30403185	13	20

N/A = Not available.

[1] Press Information Bureau, National Media Center. Briefing on COVID-19. July 20, 2021.

Estimated first-wave (top) and second-wave (bottom) fatality rates associated with SARS-CoV-2 for states in India

Wave 1: April 1, 2020 – January 31, 2021. Wave 2: February 1, 2021 – June 30, 2021.



© COV-IND-19 Study Group

Source: covid19india.org

Note:


- Owing to lack of sufficient data, estimates for only twenty states with highest case counts have been presented.

- Coloured blue for IFR₁, red for IFR₂ and green for CFR values.

Supplementary Figure 2. Forest plot of wave 1 and wave 2 infection fatality rates (IFR) and case fatality ratios (CFR) for SARS-CoV-2 in various states in India, where IFR₁ includes reported deaths and IFR₂ further includes the estimate of unreported deaths.

Estimated first-wave (top) and second-wave (bottom) underreporting factors associated with SARS-CoV-2 for states in India

Wave 1: April 1, 2020 – January 31, 2021. Wave 2: February 1, 2021 – June 30, 2021.



© COV-IND-19 Study Group

Source: covid19india.org

Note:

- Owing to lack of sufficient data, estimates for only twenty states with highest case counts have been presented.

- Coloured blue for URF(C) and red for URF(D) values.

Supplementary Figure 3: Estimated first and second wave underreporting factors for cases and deaths associated with SARS-CoV-2 for states in India.

References

- [1] M. J. Page *et al.*, “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” *Syst. Rev.*, vol. 10, no. 1, p. 89, Mar. 2021, doi: 10.1186/s13643-021-01626-4.
- [2] O. Prakash *et al.*, “Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study,” *BMJ Open*, vol. 11, no. 1, p. e044101, Jan. 2021, doi: 10.1136/bmjopen-2020-044101.
- [3] L. R. Inbaraj, C. E. George, and S. Chandrasingh, “Seroprevalence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study,” *PloS One*, vol. 16, no. 3, p. e0249247, 2021, doi: 10.1371/journal.pone.0249247.
- [4] J. S. Kshatri *et al.*, “Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys,” *Epidemiol. Infect.*, vol. 149, p. e139, Apr. 2021, doi: 10.1017/S0950268821000972.
- [5] J. S. Kshatri *et al.*, “Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India,” *Sci. Rep.*, vol. 11, no. 1, p. 10551, May 2021, doi: 10.1038/s41598-021-89877-y.
- [6] S. Selvaraju *et al.*, “Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India,” *Emerg. Infect. Dis.*, vol. 27, no. 2, pp. 586–589, Feb. 2021, doi: 10.3201/eid2702.203938.
- [7] “Estimates of COVID-19 infection fatality rate in Chennai - Mathematics.” <https://maths.mdx.ac.uk/research/modelling-the-covid-19-pandemic/chennaiifrestimates/> (accessed Aug. 14, 2021).
- [8] “A look at serological surveys conducted in Delhi,” *Hindustan Times*, Feb. 02, 2021. <https://www.hindustantimes.com/cities/delhi-news/a-look-at-serological-surveys-conducted-in-delhi-101612270983224.html> (accessed Aug. 09, 2021).
- [9] P. Sharma *et al.*, “Seroprevalence of antibodies to SARS-CoV-2 and predictors of seropositivity among employees of a teaching hospital in New Delhi, India,” *Osong Public Health Res. Perspect.*, vol. 12, no. 2, pp. 88–95, Apr. 2021, doi: 10.24171/j.phrp.2021.12.2.06.
- [10] N. M. Babu, “Percentage of people with antibodies high, shows Delhi serological survey,” *The Hindu*, New Delhi, Jul. 22, 2020. Accessed: Aug. 09, 2021. [Online]. Available: <https://www.thehindu.com/news/cities/Delhi/percentage-of-people-with-antibodies-high/article32156162.ece>
- [11] R. Bhattacharyya *et al.*, “Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates,” *Sci. Rep.*, vol. 11, no. 1, p. 9748, May 2021, doi: 10.1038/s41598-021-89127-1.
- [12] D. K. Hazra *et al.*, “The INDSCI-SIM model for COVID-19 in India,” *medRxiv*, p. 2021.06.02.21258203, Jun. 2021, doi: 10.1101/2021.06.02.21258203.
- [13] P. Misra, S. Kant, R. Guleria, S. K. Rai, and W. U. S. study team of Aiiims, “Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,” *medRxiv*, p. 2021.06.15.21258880, Jun. 2021, doi: 10.1101/2021.06.15.21258880.
- [14] C. E. George, L. R. Inbaraj, S. Chandrasingh, and L. P. de Witte, “High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond?,” *Epidemiol. Infect.*, vol. 149, p. e39, Feb. 2021, doi: 10.1017/S0950268821000273.

- [15] M. Mohanan, A. Malani, K. Krishnan, and A. Acharya, "Prevalence of COVID-19 In Rural Versus Urban Areas in a Low-Income Country: Findings from a State-Wide Study in Karnataka, India," *medRxiv*, p. 2020.11.02.20224782, Nov. 2020, doi: 10.1101/2020.11.02.20224782.
- [16] G. R. Babu *et al.*, "The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide sentinel-based population survey in Karnataka, India," *Int. J. Infect. Dis.*, vol. 108, pp. 27–36, Jul. 2021, doi: 10.1016/j.ijid.2021.05.043.
- [17] R. Cai, P. Novosad, V. Tandel, S. Asher, and A. Malani, "Representative Estimates of COVID-19 Infection Fatality Rates from Three Locations in India," *medRxiv*, Jan. 2021, doi: 10.1101/2021.01.05.21249264.
- [18] S. M. S. Khan *et al.*, "Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case," Social Science Research Network, Rochester, NY, SSRN Scholarly Paper ID 3820632, Apr. 2021. doi: 10.2139/ssrn.3820632.
- [19] S. Sakalle *et al.*, "Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.," *J. Fam. Med. Prim. Care*, vol. 10, no. 3, pp. 1479–1484, Mar. 2021, doi: 10.4103/jfmpc.jfmpc_2015_20.
- [20] Tata Institute of Fundamental Research, "SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2." https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf (accessed Aug. 09, 2021).
- [21] S. Reporter, "Third sero survey: antibodies in 36.30% samples in Mumbai," *The Hindu*, Mumbai, Apr. 25, 2021. Accessed: Aug. 24, 2021. [Online]. Available: <https://www.thehindu.com/news/cities/mumbai/third-sero-survey-antibodies-in-3630-samples-in-mumbai/article34404107.ece>
- [22] A. Malani *et al.*, "Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India.," *Lancet Glob. Health*, vol. 9, no. 2, pp. e110–e111, Feb. 2021, doi: 10.1016/S2214-109X(20)30467-8.
- [23] M. Banaji, "Estimating COVID-19 infection fatality rate in Mumbai during 2020," *medRxiv*, p. 2021.04.08.21255101, Apr. 2021, doi: 10.1101/2021.04.08.21255101.
- [24] "PIB'S BULLETIN ON COVID-19." <https://pib.gov.in/pib.gov.in/Pressreleaseshare.aspx?PRID=1740000> (accessed Aug. 24, 2021).
- [25] M. V. Murhekar *et al.*, "SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021," *Int. J. Infect. Dis.*, vol. 108, pp. 145–155, Jul. 2021, doi: 10.1016/j.ijid.2021.05.040.
- [26] M. V. Murhekar *et al.*, "SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey," *Lancet Glob. Health*, vol. 9, no. 3, pp. e257–e266, Mar. 2021, doi: 10.1016/S2214-109X(20)30544-1.
- [27] M. V. Murhekar *et al.*, "Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020," *Indian J. Med. Res.*, vol. 152, no. 1, p. 48, Jan. 2020, doi: 10.4103/ijmr.IJMR_3290_20.
- [28] G.-A.-U. G.- Öffentlichkeitsarbeit, "COVID-19 - Georg-August-Universität Göttingen." <https://www.uni-goettingen.de/en/606540.html> (accessed Aug. 24, 2021).

- [29] S. Purkayastha *et al.*, “Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India,” *BMC Res. Notes*, vol. 14, no. 1, p. 262, Jul. 2021, doi: 10.1186/s13104-021-05652-2.
- [30] H. Campbell and P. Gustafson, “Inferring the COVID-19 IFR with a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data,” *medRxiv*, p. 2021.05.12.21256975, May 2021, doi: 10.1101/2021.05.12.21256975.
- [31] R. Bhaduri, R. Kundu, S. Purkayastha, M. Kleinsasser, L. J. Beesley, and B. Mukherjee, “Extending the Susceptible-Exposed-Infected-Removed (SEIR) model to handle the high false negative rate and symptom-based administration of COVID-19 diagnostic tests: SEIR-fansy,” *medRxiv*, p. 2020.09.24.20200238, Sep. 2020, doi: 10.1101/2020.09.24.20200238.
- [32] A. Banerjee *et al.*, “SARS-CoV-2 Seroprevalence Study in Pimpri-Chinchwad, Maharashtra, India Coinciding with Falling Trend – Do the Results Suggest Imminent Herd Immunity?,” Social Science Research Network, Rochester, NY, SSRN Scholarly Paper ID 3729394, Nov. 2020. doi: 10.2139/ssrn.3729394.
- [33] S. Goli and K. S. James, “How much of SARS-CoV-2 Infections is India detecting? A model-based estimation,” *medRxiv*, p. 2020.04.09.20059014, Apr. 2020, doi: 10.1101/2020.04.09.20059014.
- [34] S. S. Kar, S. Sarkar, S. Murali, R. Dhodapkar, N. M. Joseph, and R. Aggarwal, “Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020,” *Emerg. Infect. Dis.*, vol. 27, no. 2, pp. 666–669, Feb. 2021, doi: 10.3201/eid2702.204480.
- [35] A. Malani *et al.*, “SARS-CoV-2 Seroprevalence in Tamil Nadu in October–November 2020,” *medRxiv*, p. 2021.02.03.21250949, Apr. 2021, doi: 10.1101/2021.02.03.21250949.
- [36] A. Joshi *et al.*, “Heterogeneous patterns of COVID-19 transmission in an Urban set up – sero-epidemiological survey data from Ujjain, Madhya Pradesh (a central Indian city),” *Data Brief*, vol. 37, p. 107169, Aug. 2021, doi: 10.1016/j.dib.2021.107169.
- [37] M. I. Nisar *et al.*, “Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan.,” *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.*, vol. 106, pp. 176–182, May 2021, doi: 10.1016/j.ijid.2021.03.040.
- [38] M. Haq *et al.*, “SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?,” *Infection*, pp. 1–6, May 2021, doi: 10.1007/s15010-021-01629-2.
- [39] M. G. Ahamad, F. Tanin, B. Talukder, and M. U. Ahmed, “Officially Confirmed COVID-19 and Unreported COVID-19–Like Illness Death Counts: An Assessment of Reporting Discrepancy in Bangladesh,” *Am. J. Trop. Med. Hyg.*, vol. 104, no. 2, pp. 546–548, Feb. 2021, doi: 10.4269/ajtmh.20-1205.
- [40] M. G. Ahamad and F. Tanin, “Confirmed and Unreported COVID-19 Death Counts: An Assessment of Reporting Discrepancy,” Jul. 2020, doi: 10.1101/2020.07.20.20158139.
- [41] M. A. A. Al-Bari, S. Hossain, and M. K.-E. Zahan, “Exploration of sex-specific and age-dependent COVID-19 fatality rate in Bangladesh population.,” *World J. Radiol.*, vol. 13, no. 1, pp. 1–18, Jan. 2021, doi: 10.4329/wjr.v13.i1.1.
- [42] P. Barnwal *et al.*, “No excess mortality detected in rural Bangladesh in 2020 from repeated surveys of a population of 81,000,” May 2021, doi: 10.1101/2021.05.07.21256865.
- [43] S. K. Dey, M. M. Rahman, U. R. Siddiqi, and A. Howlader, “Exploring Epidemiological Behavior of Novel Coronavirus (COVID-19) Outbreak in Bangladesh.,” *SN Compr. Clin. Med.*, pp. 1–9, Aug. 2020, doi: 10.1007/s42399-020-00477-9.
- [44] M. J. Hasan *et al.*, “Clinico-epidemiological characteristics of asymptomatic and symptomatic COVID-19-positive patients in Bangladesh,” *medRxiv*, p. 2020.08.18.20177089, Aug. 2020, doi: 10.1101/2020.08.18.20177089.

- [45] A. Islam, M. A. Sayeed, M. K. Rahman, J. Ferdous, S. Islam, and M. M. Hassan, "Geospatial dynamics of COVID-19 clusters and hotspots in Bangladesh.," *Transbound. Emerg. Dis.*, Jan. 2021, doi: 10.1111/tbed.13973.
- [46] A. Islam *et al.*, "Spatiotemporal patterns and trends of community transmission of the pandemic COVID-19 in South Asia: Bangladesh as a case study.," *Biosaf. Health*, vol. 3, no. 1, pp. 39–49, Feb. 2021, doi: 10.1016/j.bsheal.2020.09.006.
- [47] A. U. Khan, A. H. M. Musleh Uddin, F. U. Khan, S. Khanom, and A. U. Khan, "COVID-19: Current Status in Bangladesh," Jun. 2020, doi: 10.2139/ssrn.3634891.
- [48] A. M. M. Mukaddes, M. Sannyal, Q. Ali, and M. T. Kuhel, "Transmission Dynamics of COVID-19 in Bangladesh - A Compartmental Modeling Approach," Jun. 2020, doi: 10.2139/ssrn.3644855.
- [49] Md. R. Rahman, A. H. M. H. Islam, and Md. N. Islam, "Geospatial modelling on the spread and dynamics of 154 day outbreak of the novel coronavirus (COVID-19) pandemic in Bangladesh towards vulnerability zoning and management approaches," *Model. Earth Syst. Environ.*, Sep. 2020, doi: 10.1007/s40808-020-00962-z.
- [50] M. H. B. Siam, M. M. Hasan, S. M. Tashrif, M. H. Rahaman Khan, E. Raheem, and M. S. Hossain, "Insights into the first seven-months of COVID-19 pandemic in Bangladesh: lessons learned from a high-risk country.," *Heliyon*, vol. 7, no. 6, p. e07385, Jun. 2021, doi: 10.1016/j.heliyon.2021.e07385.
- [51] T. W. Russell *et al.*, "Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections.," *BMC Med.*, vol. 18, no. 1, p. 332, Oct. 2020, doi: 10.1186/s12916-020-01790-9.
- [52] E. A. Rana *et al.*, "Molecular detection and prevalence of SARS-CoV-2 during the early outbreak in Southern Bangladesh," *Int. J. One Health*, vol. 6, no. 2, pp. 153–159, 2020, doi: 10.14202/IJOH.2020.153-159.
- [53] V. S. B. Adapa, S. S. Adapa, and H. Narni, "Andhra Pradesh's COVID-19 Pandemic Case Fatality Rate," Jan. 2021, doi: 10.2139/ssrn.3776490.
- [54] V. S. B. Adapa, S. S. Adapa, and H. Narni, "COVID-19 Pandemic India's Case Fatality Rate," Oct. 2020, doi: 10.2139/ssrn.3687357.
- [55] M. Al-arydah, H. W. Berhe, K. Dib, and K. Madhu, "Mathematical Modelling of the Spread of the Coronavirus under Social Restrictions," *medRxiv*, p. 2020.09.14.20194068, Sep. 2020, doi: 10.1101/2020.09.14.20194068.
- [56] E. S. Asirvatham, J. Lakshmanan, C. J. Sarman, and M. Joy, "Demystifying the varying case fatality rates (CFR) of COVID-19 in India: Lessons learned and future directions," *J. Infect. Dev. Ctries.*, vol. 14, no. 10, Art. no. 10, Oct. 2020, doi: 10.3855/jidc.13340.
- [57] R. Cai, P. M. Novosad, V. Tandel, S. Asher, and A. Malani, "Representative Estimates of COVID-19 Age-Specific Infection Fatality Rates from Four Locations in India: A Cross-Sectional Observational Study," Feb. 2021, doi: 10.2139/ssrn.3783787.
- [58] P. Chatterjee, "Is India missing COVID-19 deaths?," *Lancet Lond. Engl.*, vol. 396, no. 10252, p. 657, Sep. 2020, doi: 10.1016/S0140-6736(20)31857-2.
- [59] S. Chatterjee, A. Sarkar, M. Karmakar, S. Chatterjee, and R. Paul, "SEIRD model to study the asymptomatic growth during COVID-19 pandemic in India.," *Indian J. Phys. Proc. Indian Assoc. Cultiv. Sci. 2004*, pp. 1–13, Nov. 2020, doi: 10.1007/s12648-020-01928-8.
- [60] I. Frost *et al.*, "Risks to Children under-five in India from COVID-19," *medRxiv*, p. 2020.05.18.20105239, May 2020, doi: 10.1101/2020.05.18.20105239.

- [61] N. Gonzalez Garcia *et al.*, "Título: COVID-19 pediatric mortality rates are heterogeneous between countries," Sep. 2020, doi: 10.1101/2020.09.17.20196832.
- [62] M. K. Gupta, P. Bhardwaj, A. D. Goel, S. Saurabh, and S. Misra, "Trends of Epidemiological and Demographic Indicators of COVID-19 in India.," *J. Infect. Dev. Ctries.*, vol. 15, no. 5, pp. 618–624, May 2021, doi: 10.3855/jidc.13243.
- [63] S. Gupta, "The age and sex distribution of COVID-19 cases and fatalities in India," *medRxiv*, p. 2020.07.14.20153957, Jul. 2020, doi: 10.1101/2020.07.14.20153957.
- [64] N. Jahan *et al.*, "Entry and initial spread of COVID-19 in India: Epidemiological analysis of media surveillance data, India, 2020.," *Clin. Epidemiol. Glob. Health*, vol. 9, pp. 347–354, Mar. 2021, doi: 10.1016/j.cegh.2020.10.008.
- [65] S. Kumar, R. Kumar, S. Momani, and S. Hadid, "A study on fractional COVID-19 disease model by using Hermite wavelets," *Math. Methods Appl. Sci.*, vol. n/a, no. n/a, doi: 10.1002/mma.7065.
- [66] M. S. Kumar *et al.*, "National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance.," *Indian J. Med. Res.*, vol. 151, no. 5, pp. 419–423, May 2020, doi: 10.4103/ijmr.IJMR_1818_20.
- [67] A. Menon, N. K. Rajendran, A. Chandrachud, and G. Setlur, "Modelling and simulation of COVID-19 propagation in a large population with specific reference to India," *medRxiv*, p. 2020.04.30.20086306, May 2020, doi: 10.1101/2020.04.30.20086306.
- [68] S. K. Mohanty, U. Sahoo, U. S. Mishra, and M. Dubey, "Age Pattern of Premature Mortality under varying scenarios of COVID-19 Infection in India," *medRxiv*, p. 2020.06.11.20128587, Jun. 2020, doi: 10.1101/2020.06.11.20128587.
- [69] S. Mukhopadhyay and D. Chakraborty, "Estimation of undetected COVID-19 infections in India," May 2020, doi: 10.1101/2020.04.20.20072892.
- [70] S. Naushin *et al.*, "Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2," *eLife*, vol. 10, p. e66537, Apr. 2021, doi: 10.7554/eLife.66537.
- [71] D. Neve, H. Patel, and H. S. Dhiman, "On Modeling of COVID-19 for the Indian Subcontinent using Polynomial and Supervised Learning Regression," *medRxiv*, p. 2020.10.14.20212563, Oct. 2020, doi: 10.1101/2020.10.14.20212563.
- [72] D. Parai *et al.*, "Seroprevalence of anti-SARS-CoV-2 IgG antibody among health care workers of anaesthesia departments from various hospital settings in India," Mar. 2021, doi: 10.1101/2021.03.20.21253819.
- [73] M. Radha and S. Balamuralitharan, "A study on COVID-19 transmission dynamics: stability analysis of SEIR model with Hopf bifurcation for effect of time delay.," *Adv. Differ. Equ.*, vol. 2020, no. 1, p. 523, 2020, doi: 10.1186/s13662-020-02958-6.
- [74] R. Ranjan, A. Sharma, and M. K. Verma, "Characterization of the Second Wave of COVID-19 in India," *medRxiv*, p. 2021.04.17.21255665, Apr. 2021, doi: 10.1101/2021.04.17.21255665.
- [75] J. S and S. Sreedharan, "Analysing the Covid-19 Cases in Kerala: a Visual Exploratory Data Analysis Approach.," *SN Compr. Clin. Med.*, pp. 1–12, Aug. 2020, doi: 10.1007/s42399-020-00451-5.
- [76] P. P. Singh *et al.*, "Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations," *medRxiv*, p. 2021.02.05.21251118, Apr. 2021, doi: 10.1101/2021.02.05.21251118.
- [77] A. K. Srivastav, M. Ghosh, and S. R. Bandekar, "Modeling of COVID-19 with limited public health resources: a comparative study of three most affected countries.," *Eur. Phys. J. Plus*, vol. 136, no. 4, p. 359, 2021, doi: 10.1140/epjp/s13360-021-01333-y.

- [78] V. Tamrakar *et al.*, “District level correlates of COVID-19 pandemic in India,” Oct. 2020, doi: 10.1101/2020.10.08.20208447.
- [79] J. Unnikrishnan, S. Mangalathu, and R. V. Kutty, “Estimating under-reporting of COVID-19 cases in Indian states: an approach using a delay-adjusted case fatality ratio.,” *BMJ Open*, vol. 11, no. 1, p. e042584, Jan. 2021, doi: 10.1136/bmjopen-2020-042584.
- [80] P. Venkatesan, “Estimate of COVID-19 case prevalence in India based on surveillance data of patients with severe acute respiratory illness,” *medRxiv*, p. 2020.04.14.20065342, Apr. 2020, doi: 10.1101/2020.04.14.20065342.
- [81] Y. Wang *et al.*, “Estimating the Prevalence and Mortality of Coronavirus Disease 2019 (COVID-19) in the USA, the UK, Russia, and India.,” *Infect. Drug Resist.*, vol. 13, pp. 3335–3350, 2020, doi: 10.2147/IDR.S265292.
- [82] A. K. Yadav, S. Ghosh, A. Kotwal, S. Kumar, and S. Bobdey, “Serial antibody response among hospitalized coronavirus disease 2019 cases in India.,” *Med. J. Armed Forces India*, Nov. 2020, doi: 10.1016/j.mjafi.2020.09.010.
- [83] A. A. Z. Ansari *et al.*, “Prevalence and cross states comparison of case fatality rate and recovery rate of COVID 19/SARS-COV-2 in India,” *J. Fam. Med. Prim. Care*, vol. 10, no. 1, pp. 475–480, Jan. 2021, doi: 10.4103/jfmpc.jfmpc_1088_20.
- [84] P. Abraham *et al.*, “Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22 - April 30, 2020,” *Indian J. Med. Res.*, vol. 151, no. 5, pp. 424–437, May 2020, doi: 10.4103/ijmr.IJMR_1896_20.
- [85] R. Giri, A. Kumar, M. Saini, and R. K. Sharma, “Living with the virus: Infection and epidemiology of COVID-19 in hotspot area of India.,” *J. Public Aff.*, p. e2651, Feb. 2021, doi: 10.1002/pa.2651.
- [86] M. R. T. Shah, T. Ahammed, A. Anjum, A. A. Chowdhury, and A. J. Suchana, “Finding the real COVID-19 case-fatality rates for SAARC countries.,” *Biosaf. Health*, vol. 3, no. 3, pp. 164–171, Jun. 2021, doi: 10.1016/j.bsheal.2021.03.002.
- [87] J. J. M. Wong *et al.*, “Comparative Analysis of Pediatric COVID-19 Infection in Southeast Asia, South Asia, Japan, and China.,” *Am. J. Trop. Med. Hyg.*, Jun. 2021, doi: 10.4269/ajtmh.21-0299.
- [88] A. Zaveri and P. Chouhan, “Are child and youth population at lower risk of COVID-19 fatalities? Evidences from South-East Asian and European countries,” *Child. Youth Serv. Rev.*, vol. 119, p. 105360, Dec. 2020, doi: 10.1016/j.childyouth.2020.105360.
- [89] R. Bhattacharyya, R. Bhaduri, R. Kundu, M. Salvatore, and B. Mukherjee, “Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, India,” Aug. 2020, doi: 10.1101/2020.07.31.20166249.
- [90] P. Chauhan, A. Kumar, and P. Jamdagni, “Regression Analysis of COVID-19 Spread in India and its Different States,” *medRxiv*, p. 2020.05.29.20117069, May 2020, doi: 10.1101/2020.05.29.20117069.
- [91] B. S. K. Meghana and V. Kakulapati, “State-wise prevalence of COVID 19 in India by using machine learning approaches,” *Int. J. Pharm. Res.*, vol. 12, no. (Meghana B.S.K., meghanasharma224@gmail.com) Chaitanya Bharathi Institute of Technology, Gandipet, Hyderabad, Telangana, India, pp. 2855–2859, 2020, doi: 10.31838/ijpr/2020.SP2.295.
- [92] B. Mukherjee, S. Purkayashtha, R. Kundu, and R. Bhaduri, “Estimating the Infection Fatality Rate from SARS-CoV-2 in India,” Mar. 2021, doi: 10.2139/ssrn.3798552.
- [93] S. Purkayastha *et al.*, “A comparison of five epidemiological models for transmission of SARS-CoV-2 in India.,” *BMC Infect. Dis.*, vol. 21, no. 1, p. 533, Jun. 2021, doi: 10.1186/s12879-021-06077-9.

- [94] V. Patel, C. McCarthy, R. A. Taylor, R. Moir, L. A. Kelly, and E. L. Snary, "An improved methodology for estimating the prevalence of SARS-CoV-2," *medRxiv*, p. 2020.08.04.20168187, Aug. 2020, doi: 10.1101/2020.08.04.20168187.
- [95] A. Velumani *et al.*, "SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020," *medRxiv*, p. 2021.03.19.21253429, Mar. 2021, doi: 10.1101/2021.03.19.21253429.
- [96] N. Gupta *et al.*, "Severe acute respiratory illness surveillance for coronavirus disease 2019, India, 2020," *Indian J. Med. Res.*, vol. 151, no. 2–3, pp. 236–240, 2020, doi: 10.4103/ijmr.IJMR_1035_20.
- [97] O. Prakash, B. Solanki, J. K. Sheth, M. Kadam, and S. Vyas, "Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases.," *Indian J. Public Health*, vol. 65, no. 1, pp. 5–10, Mar. 2021, doi: 10.4103/ijph.IJPH_1199_20.
- [98] M. Mahto, B. Biswas, A. Banerjee, S. Kumar, N. Agarwal, and P. K. Singh, "Igg seropositivity for sars-cov-2 and its predictors among healthcare workers of Eastern India," *Indian J. Hematol. Blood Transfus.*, vol. 36, no. 1 SUPPL, p. S112, 2020, doi: 10.1007/s12288-020-01384-8.
- [99] A. Malani, M. Mohanan, C. Kumar, J. Kramer, and V. Tandel, "Prevalence of SARS-CoV-2 among workers returning to Bihar gives snapshot of COVID across India," Jun. 2020, doi: 10.1101/2020.06.26.20138545.
- [100] M. Madhusudan, J. Sankar, K. Dhanalakshmi, S. Putlibai, and S. Balasubramanian, "Seroprevalence to SARS-CoV-2 Among Healthcare Workers in an Exclusive Pediatric Hospital.," *Indian Pediatr.*, vol. 58, no. 3, pp. 279–280, Mar. 2021, doi: 10.1007/s13312-021-2170-1.
- [101] M. Pons-Salort *et al.*, "Reconstructing the COVID-19 epidemic in Delhi, India: infection attack rate and reporting of deaths," *medRxiv*, p. 2021.03.23.21254092, Mar. 2021, doi: 10.1101/2021.03.23.21254092.
- [102] S. Siddiqui *et al.*, "SARS-CoV-2 Antibody Seroprevalence and Stability in a Tertiary Care Hospital-Setting," Oct. 2020, doi: 10.2139/ssrn.3696827.
- [103] R. Thiruvengadam *et al.*, "Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study.," *Am. J. Trop. Med. Hyg.*, May 2021, doi: 10.4269/ajtmh.21-0164.
- [104] J. Kaushal and P. Mahajan, "Asia's largest urban slum-Dharavi: A global model for management of COVID-19.," *Cities Lond. Engl.*, vol. 111, p. 103097, Apr. 2021, doi: 10.1016/j.cities.2020.103097.
- [105] M. Mishra, R. Chaudhry, F. Rana, D. S. Nag, and S. Rai, "Serosurveillance of Health Care Workers in a COVID Hospital: Immune Response, and Its Longevity.," *Cureus*, vol. 13, no. 3, p. e14020, Mar. 2021, doi: 10.7759/cureus.14020.
- [106] S. Kataria *et al.*, "Is Covid-19 seroprevalence different in health care workers as per their risk of exposure? A study from a tertiary care hospital in National Capital Region of India," Feb. 2021, doi: 10.1101/2021.02.10.21251543.
- [107] S. Ranjan, A. Kaur, and R. Thakur, "Gendered Differentials in Symptoms, Morbidity, and Case Fatality Rate in COVID-19 Pandemic in India: A Study of Karnataka State," Jun. 2021, doi: 10.2139/ssrn.3865604.
- [108] M. S. Khan *et al.*, "SARS-CoV-2 Seroprevalence Among Healthcare Workers by Workplace Exposure Risk in Kashmir, India.," *J. Hosp. Med.*, vol. 16, no. 5, pp. 274–281, May 2021, doi: 10.12788/jhm.3609.
- [109] A. Kumar, D. Sathyapalan, A. Ramachandran, K. Subhash, L. Biswas, and K. V. Beena, "SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India.," *Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.*, vol. 27, no. 3, pp. 481–483, Mar. 2021, doi: 10.1016/j.cmi.2020.09.013.

- [110] H. Kaur, R. Singh, K. Singh, S. Kaur, M. Jairath, and S. K. Sidhu, "Pervasiveness and epidemiological profile of SARS-CoV-2 infection among the population of Majha Region of Punjab, India," *J. Clin. Diagn. Res.*, vol. 15, no. 6, pp. KC01–KC05, 2021, doi: 10.7860/JCDR/2021/48749.15000.
- [111] M. Goenka *et al.*, "Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India.," *J. Assoc. Physicians India*, vol. 68, no. 11, pp. 14–19, Nov. 2020.
- [112] N. Kumar, S. Bhartiya, S. Desai, A. Mutha, A. Beldar, and T. Singh, "Seroprevalence of Antibodies Against SARS-CoV-2 Among Health Care Workers in Mumbai, India.," *Asia. Pac. J. Public Health*, vol. 33, no. 1, pp. 126–128, Jan. 2021, doi: 10.1177/1010539520977307.
- [113] N. N. Mahajan *et al.*, "Prevalence and Clinical Presentation of COVID-19 among Healthcare Workers at a Dedicated Hospital in India.," *J. Assoc. Physicians India*, vol. 68, no. 12, pp. 16–21, Dec. 2020.
- [114] N. Mahajan *et al.*, "Prevalence, Clinical Characteristics, Virus Clearance and Treatment Outcomes of SARS-CoV-2 Infection in Healthcare Workers in India," Oct. 2020, doi: 10.2139/ssrn.3706581.
- [115] T. Singhal, S. Shah, R. Naik, A. Kazi, and P. Thakkar, "Prevalence of COVID-19 antibodies in healthcare workers at the peak of the pandemic in Mumbai, India: A preliminary study.," *Indian J. Med. Microbiol.*, vol. 38, no. 3 & 4, pp. 461–463, Dec. 2020, doi: 10.4103/ijmm.IJMM_20_308.
- [116] J. Tanna *et al.*, "Incidence and Epidemiological study of COVID-19 in Nagpur urban region (India) using Molecular testing," *medRxiv*, p. 2021.05.11.21256719, May 2021, doi: 10.1101/2021.05.11.21256719.
- [117] N. Sharma *et al.*, "The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population-based seroepidemiological study," *medRxiv*, p. 2020.12.13.20248123, Dec. 2020, doi: 10.1101/2020.12.13.20248123.
- [118] R. Gupta *et al.*, "Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers & implications of infection control practice in India.," *Indian J. Med. Res.*, vol. 153, no. 1 & 2, pp. 207–213, Feb. 2021, doi: 10.4103/ijmr.IJMR_3911_20.
- [119] S. M. S. Khan *et al.*, "Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India - A cross-sectional study.," *PloS One*, vol. 15, no. 11, p. e0239303, 2020, doi: 10.1371/journal.pone.0239303.
- [120] P. S. Satpati *et al.*, "Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur, West Bengal, India," *medRxiv*, p. 2020.09.12.20193219, Sep. 2020, doi: 10.1101/2020.09.12.20193219.
- [121] M. Mahto, A. Banerjee, B. Biswas, S. Kumar, N. Agarwal, and P. K. Singh, "Seroprevalence of IgG against SARS-CoV-2 and its determinants among healthcare workers of a COVID-19 dedicated hospital of India.," *Am. J. Blood Res.*, vol. 11, no. 1, pp. 44–52, 2021.
- [122] P. Bogam *et al.*, "Burden of COVID-19 and Case Fatality Rate in Pune India: An Analysis of First and Second Wave of the Pandemic," *medRxiv*, p. 2021.06.21.21259225, Jun. 2021, doi: 10.1101/2021.06.21.21259225.
- [123] A. Ghose *et al.*, "Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city," *medRxiv*, p. 2020.11.17.20228155, Nov. 2020, doi: 10.1101/2020.11.17.20228155.
- [124] J. Monteiro *et al.*, "Into the thirteenth Month: A Case Study on the Outbreak Analytics and Modeling the spread of SARS-CoV-2 Infection in Pune City, India," *medRxiv*, p. 2021.06.22.21259295, Jun. 2021, doi: 10.1101/2021.06.22.21259295.

- [125] S. Sharma, K. Goel, K. K. Kurup, G. S. Grover, and R. Bhaskar, "COVID-19 in Punjab, India: Epidemiological patterns, laboratory surveillance and contact tracing of COVID-19 cases, March-May 2020.," *Clin. Epidemiol. Glob. Health*, vol. 11, p. 100769, Sep. 2021, doi: 10.1016/j.cegh.2021.100769.
- [126] K. S. Vignesh, V. N. Indhiya Selvan, K. Kosalram, and A. Abarajitha, "A spatial exploratory study on COVID-19 disaster - current outbreak in Tamil Nadu, India," *Turk. J. Physiother. Rehabil.*, vol. 32, no. 3, pp. 5332–5341, 2021.
- [127] R. Laxminarayan *et al.*, "Epidemiology and transmission dynamics of COVID-19 in two Indian states," *Science*, vol. 370, no. 6517, pp. 691–697, Nov. 2020, doi: 10.1126/science.abd7672.
- [128] J. Panchamia, B. Bhagat, V. Bharati, A. Joshi, and D. Mavalankar, "Low COVID-19 mortality in old age homes in western India: an empirical study," *medRxiv*, p. 2020.12.08.20245134, Dec. 2020, doi: 10.1101/2020.12.08.20245134.
- [129] A. Suresh and G. N. Srivastava, "Clinicodemographic profile and outcomes of severe COVID-19 infection in young adults," *Indian J. Crit. Care Med.*, pp. S69–S69, 2021.
- [130] S. Banerjee, A. Guha, A. Das, M. Nandi, and R. Mondal, "A Preliminary Report of COVID-19 in Children in India.," *Indian Pediatr.*, vol. 57, no. 10, pp. 963–964, Oct. 2020, doi: 10.1007/s13312-020-2004-6.
- [131] B. B. Basnet *et al.*, "A Year Trend Analysis and Spatial Distribution of COVID-19 Cases in Nepal.," *Asia. Pac. J. Public Health*, p. 10105395211012232, May 2021, doi: 10.1177/10105395211012233.
- [132] M. L. Dhimal *et al.*, "Age and Gender Differences in COVID 19 Morbidity and Mortality in Nepal.," *Kathmandu Univ. Med. J. KUMJ*, vol. 18, no. 72, pp. 329–332, Dec. 2020.
- [133] K. P. Pathak, "COVID-19 in Nepal: Lower Than Expected Incidence and Mortality.," *Asia. Pac. J. Public Health*, vol. 32, no. 6–7, p. 366, Oct. 2020, doi: 10.1177/1010539520940884.
- [134] A. K. Sharma *et al.*, "Epidemiological and clinical profile of covid-19 in nepali children: An initial experience," *J. Nepal Paediatr. Soc.*, vol. 40, no. 3, pp. 202–209, 2020, doi: 10.3126/jnps.v40i3.32438.
- [135] S. Abbas, A. Raza, A. Iftikhar, A. Khan, S. Khan, and M. A. Yusuf, "Seroprevalence of SARS-CoV-2 Antibodies Among Health Care Personnel at a Health Care System in Pakistan.," *Asia. Pac. J. Public Health*, p. 10105395211011010, Apr. 2021, doi: 10.1177/10105395211011010.
- [136] A. Chaudhry *et al.*, "Mortality Analysis of COVID-19 Confirmed Cases in Pakistan," Jun. 2020, doi: 10.1101/2020.06.07.20121939.
- [137] R. ud Din and E. A. Algehyne, "Mathematical analysis of COVID-19 by using SIR model with convex incidence rate," *Results Phys.*, vol. 23, p. 103970, Apr. 2021, doi: 10.1016/j.rinp.2021.103970.
- [138] O. J. Peter, S. Qureshi, A. Yusuf, M. Al-Shomrani, and A. A. Idowu, "A new mathematical model of COVID-19 using real data from Pakistan," *Results Phys.*, vol. 24, p. 104098, May 2021, doi: 10.1016/j.rinp.2021.104098.
- [139] M. Waqar, B. Wahid, M. Idrees, M. Ali, and Z. Rehman, "Seroprevalence of SARS-CoV-2 in Pakistan: an update on epidemiological trends.," *Z. Naturforschung C J. Biosci.*, Jun. 2021, doi: 10.1515/znc-2020-0291.
- [140] S. Zaidi *et al.*, "Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19.," *J. Public Health Oxf. Engl.*, vol. 43, no. 1, pp. 3–8, Apr. 2021, doi: 10.1093/pubmed/fdaa170.
- [141] I. Naiyar, A. F. Anjum, A. M. Khalid, I. Noor, M. S. Abdullah, and M. Z. Anwar, "Seroprevalence of COVID-19 and associated factors in a medical institution in Pakistan.," *J. Taibah Univ. Med. Sci.*, May 2021, doi: 10.1016/j.jtumed.2021.04.004.

- [142] A. Younas, S. Waheed, S. Khawaja, M. Imam, M. Borhany, and T. Shamsi, "Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan.," *Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapheresis*, vol. 59, no. 6, p. 102923, Dec. 2020, doi: 10.1016/j.transci.2020.102923.
- [143] S. Ali, N. Muhammad, J. Afridi, T. Mehar, N. Mehmood, and Ziauddin, "IgM and IgG antibodies status in suspected patients of Covid-19 in Khyber Pakhtunkhwa, Pakistan," *Med. Forum Mon.*, vol. 32, no. 4, pp. 120–123, 2021.
- [144] M. Haq *et al.*, "Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan," Sep. 2020, doi: 10.1101/2020.09.29.20203125.
- [145] W. Javed, J. B. Baqar, S. H. B. Abidi, and W. Farooq, "Sero-prevalence Findings from Metropolises in Pakistan: Implications for Assessing COVID-19 Prevalence and Case-fatality within a Dense, Urban Working Population," *medRxiv*, p. 2020.08.13.20173914, Aug. 2020, doi: 10.1101/2020.08.13.20173914.
- [146] M. Nisar, Y. Yousafzai, N. Saba, U. Waheed, and M. Khalid, "Seroprevalence of SARS-CoV-2 in blood donors during the second wave of COVID-19 pandemic in Peshawar, Pakistan," *Vox Sang.*, vol. 116, no. SUPPL 1, pp. 146–147, 2021, doi: 10.1111/vox.13117.
- [147] C. Jeewandara *et al.*, "Seroprevalence of SARS-CoV-2 infection in the Colombo Municipality region, Sri Lanka," *medRxiv*, p. 2021.06.18.21259143, Jun. 2021, doi: 10.1101/2021.06.18.21259143.
- [148] A. T. Levin, W. P. Hanage, N. Owusu-Boaitey, K. B. Cochran, S. P. Walsh, and G. Meyerowitz-Katz, "Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications," *Eur. J. Epidemiol.*, vol. 35, no. 12, pp. 1123–1138, 2020, doi: 10.1007/s10654-020-00698-1.